var title_f37_52_38720="Ketoconazole: Patient drug information";
var content_f37_52_38720=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"13\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Ketoconazole: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <div class=\"block note\" id=\"F12804657\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <p>",
"     Information for this drug is presented separately based upon the following methods of administration:",
"    </p>",
"   </div>",
"   <div class=\"sec_xr rmolist\" id=\"F12804658\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <ul xmlns=\"\">",
"     <li>",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?2/30/2533?source=see_link\">",
"       Ketoconazole (systemic): Patient drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?33/51/34612?source=see_link\">",
"       Ketoconazole (topical): Patient drug information",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10781 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.234.146.186-BFC6E11EC2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_52_38720=[""].join("\n");
var outline_f37_52_38720=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   DRUG INFORMATION",
"   <br/>",
"   [by method of administration]",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?2/30/2533?source=related_link\">",
"      Ketoconazole (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?33/51/34612?source=related_link\">",
"      Ketoconazole (topical): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_52_38721="Spinal hemangioblastoma";
var content_f37_52_38721=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F60110&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F60110&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Hemangioblastoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 188px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) The intraoperative photograph of a spinal hemangioblastoma shows enlarged vessels (arrowhead) feeding the strawberry-like exophytic mass (arrow).",
"    <br>",
"     (B) A cross-section from a resected cerebellar hemangioblastoma illustrates the tumor's reddish color due to its vascularity (arrow) compared to the normal cerebellar gray and white matter (arrowhead).",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"      Courtesy of Eric T Wong, MD.",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_52_38721=[""].join("\n");
var outline_f37_52_38721=null;
var title_f37_52_38722="Giant granules in Chediak-Higashi syndrome";
var content_f37_52_38722=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F71313&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F71313&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Giant neutrophil granules in Chediak-Higashi syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 442px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Peripheral blood smear from a patient with Chediak-Higashi syndrome shows giant granules in the cytoplasm of both a neutrophil and a band form. These granules are formed by the inappropriate fusion of lysosomes and endosomes.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert L Baehner, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_52_38722=[""].join("\n");
var outline_f37_52_38722=null;
var title_f37_52_38723="Unified uterine cavity";
var content_f37_52_38723=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F62456&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F62456&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Septum resected and uterine cavity now unified",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 417px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Laufer MR. Structural abnormalities of the female reproductive tract. In: Pediatric and adolescent gynecology, 6th ed, Emans SJ, Laufer MR, Goldstein DP (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_52_38723=[""].join("\n");
var outline_f37_52_38723=null;
var title_f37_52_38724="Mature teratoma Low";
var content_f37_52_38724=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F57501&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F57501&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mediastinal mature teratoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 370px; height: 243px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Adult type squamous epithelium and skin appendages, such as sebaceous glands, are frequent components of mature teratomas in the mediastinum. (Hematoxylin and eosin, magnification 10x).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William Travis, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_52_38724=[""].join("\n");
var outline_f37_52_38724=null;
var title_f37_52_38725="Vitamin D3 (cholecalciferol): Drug information";
var content_f37_52_38725=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Vitamin D3 (cholecalciferol): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?9/30/9701?source=see_link\">",
"    see \"Vitamin D3 (cholecalciferol): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/4/33862?source=see_link\">",
"    see \"Vitamin D3 (cholecalciferol): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F150802\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Bio-D-Mulsion Forte&reg; [OTC];",
"     </li>",
"     <li>",
"      Bio-D-Mulsion&reg; [OTC];",
"     </li>",
"     <li>",
"      D-3 [OTC];",
"     </li>",
"     <li>",
"      D3-50&trade; [OTC];",
"     </li>",
"     <li>",
"      D3-5&trade; [OTC];",
"     </li>",
"     <li>",
"      DDrops&reg; Baby [OTC];",
"     </li>",
"     <li>",
"      DDrops&reg; Kids [OTC];",
"     </li>",
"     <li>",
"      DDrops&reg; [OTC];",
"     </li>",
"     <li>",
"      Delta&reg; D3 [OTC];",
"     </li>",
"     <li>",
"      Enfamil&reg; D-Vi-Sol&trade; [OTC];",
"     </li>",
"     <li>",
"      Maximum D3&reg; [OTC];",
"     </li>",
"     <li>",
"      Vitamin D3 [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F150803\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      D-Vi-Sol&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F150827\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Vitamin D Analog",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F150804\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dietary Reference Intake for Vitamin D:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 19-70 years: RDA: 600 units/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Female: Pregnancy/Lactating: RDA: 600 units/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Osteoporosis prevention (unlabeled):",
"     </b>",
"     Adults &ge;50 years: Oral: 800-1000 units/day (NOF guidelines, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Vitamin D deficiency treatment (unlabeled dose):",
"     </b>",
"     Oral: 1000 units/day (Holick, 2007)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F12888900\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/4/33862?source=see_link\">",
"      see \"Vitamin D3 (cholecalciferol): Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Dietary Reference Intake for Vitamin D:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children 0-12 months: Adequate intake: 400 units/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children 1-18 years: RDA: 600 units/day",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F150805\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dietary Reference Intake for Vitamin D:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &le;70 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &gt;70 years: RDA: 800 units/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Osteoporosis prevention (unlabeled use)",
"     </b>",
"     Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Vitamin D deficiency treatment (unlabeled dose):",
"     </b>",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F150796\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral: 5000 units",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     D-3: 1000 units",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     D3-50&trade;: 50,000 units",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     D3-5&trade;: 5000 units",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Maximum D3&reg;: 10,000 units [contains soybean lecithin]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, softgel, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     D-3: 2000 units",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral [drops]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Bio-D-Mulsion Forte&reg;: 2000 units/drop (30 mL) [contains sesame oil]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Bio-D-Mulsion&reg;: 400 units/drop (30 mL) [contains sesame oil]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     DDrops&reg;: 1000 units/drop (10 mL); 2000 units/drop (10 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     DDrops&reg; Baby: 400 units/drop (10 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     DDrops&reg; Kids: 400 units/drop (10 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Enfamil&reg; D-Vi-Sol&trade;: 400 units/mL (50 mL) [gluten free, sugar free; citrus flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 400 units, 1000 units, 2000 units",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Delta&reg; D3: 400 units [sugar free]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Vitamin D3: 1000 units [sugar free]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F150785\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F150797\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dietary supplement, treatment of vitamin D deficiency, or prophylaxis of deficiency",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F12890979\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Osteoporosis prevention",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F10303065\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Cholecalciferol may be confused with alfacalcidol, ergocalciferol",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Administration issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Liquid vitamin D preparations have the potential for dosing errors when administered to infants. Droppers should be clearly marked to easily provide 400 international units. For products intended for infants, the FDA recommends that accompanying droppers deliver no more than 400 international units per dose.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F150825\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined: Endocrine &amp; metabolic: Hypervitaminosis D (signs and symptoms include hypercalcemia, resulting in headache, nausea, vomiting, lethargy, confusion, sluggishness, abdominal pain, bone pain, polyuria, polydipsia, weakness, cardiac arrhythmias [eg, QT shortening, sinus tachycardia], soft tissue calcification, calciuria, and nephrocalcinosis)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F150799\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypercalcemia; hypersensitivity to cholecalciferol or any component of the formulation; malabsorption syndrome; evidence of vitamin D toxicity",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F150824\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2C19 (weak), CYP2C9 (weak), CYP2D6 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F150791\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aluminum Hydroxide: Vitamin D Analogs may increase the serum concentration of Aluminum Hydroxide. Specifically, the absorption of aluminum may be increased, leading to increased serum aluminum concentrations.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the serum concentration of Vitamin D Analogs. More specifically, bile acid sequestrants may impair absorption of Vitamin D Analogs. Management: Avoid concomitant administration of vitamin D analogs and bile acid sequestrants (e.g., cholestyramine). Separate administration of these agents by several hours to minimize the potential risk of interaction. Monitor plasma calcium concentrations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Salts: May enhance the adverse/toxic effect of Vitamin D Analogs.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Vitamin D Analogs may enhance the arrhythmogenic effect of Cardiac Glycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Danazol: May enhance the hypercalcemic effect of Vitamin D Analogs.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mineral Oil: May decrease the serum concentration of Vitamin D Analogs. More specifically, mineral oil may interfere with the absorption of Vitamin D Analogs. Management: Avoid concomitant, oral administration of mineral oil and vitamin D analogs. Consider separating the administration of these agents by several hours to minimize the risk of interaction. Monitor plasma calcium concentrations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the adverse/toxic effect of Vitamin D Analogs.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Orlistat: May decrease the serum concentration of Vitamin D Analogs. More specifically, orlistat may impair absorption of Vitamin D Analogs. Management: Monitor clinical response (including serum calcium) to oral vitamin D analogs closely if used with orlistat.  If this combination must be used, consider giving the vitamin D analog at least 2 hrs before or after orlistat.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sucralfate: Vitamin D Analogs may increase the serum concentration of Sucralfate. Specifically, the absorption of aluminum from sucralfate may be increased, leading to an increase in the serum aluminum concentration.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: May enhance the hypercalcemic effect of Vitamin D Analogs.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin D Analogs: May enhance the adverse/toxic effect of other Vitamin D Analogs.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F595884\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Food: Olestra may impair the absorption of vitamin D.",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13861968\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in animals when high maternal doses of vitamin D were administered during pregnancy. Vitamin D crosses the placenta but the transfer to the fetus from the mother is low. Maternal supplementation has not been shown to affect pregnancy outcomes. Vitamin D requirements are the same in pregnant and nonpregnant females (IOM, 2011).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F7310084\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F7310085\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Small quantities of vitamin D are found in breast milk following normal maternal exposure via sunlight and diet. The amount in breast milk does not correlate with serum levels in the infant. Therefore, vitamin D supplementation is recommended in all infants who are partially or exclusively breast fed. Hypercalcemia has been noted in a breast-feeding infant following maternal use of large doses of ergocalciferol; high doses should be avoided in lactating women (IOM, 2011).",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323065\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (D3-50 Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50000 unit (100): $30.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Maximum D3 Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10000 unit (5): $4.95",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Pronutrients Vitamin D3 Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1000 unit (120): $8.63",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chewable",
"     </b>",
"     (Healthy Kids Vitamin D3 Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     400 unit (60): $5.66",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Bio-D-Mulsion Forte Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2000 unit/0.03 mL (30 mL): $19.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Bio-D-Mulsion Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     400 unit/0.03 mL (30 mL): $11.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (D-Vi-Sol Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     400 units/mL (50 mL): $8.15",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Wellesse Vitamin D3 Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1000 unit/10 mL (480 mL): $6.89",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Dialyvite Vitamin D3 Max Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50000 unit (12): $12.91",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Thera-D 2000 Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2000 unit (180): $30.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Thera-D 4000 Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4000 unit (90): $30.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Thera-D Rapid Repletion Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2000 unit (180): $30.00",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F7310086\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serum calcium times phosphorus should not exceed 70 mg",
"     <sup>",
"      2",
"     </sup>",
"     /dL",
"     <sup>",
"      2",
"     </sup>",
"     to avoid ectopic calcification",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin D deficiency: There is no clear consensus on a reference range for total serum 25(OH)D concentrations or the validity of this level as it relates clinically to bone health. In addition, there is significant variability in the reporting of serum 25 (OH)D levels as a result of different assay types in use. However, the following ranges have been suggested:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adults (NAS, 2011):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     &lt;30 nmol/L (12 ng/mL): At risk for deficiency",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     30-50 nmol/L (12-20 ng/mL): Potentially at risk for inadequacy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     &ge;50 nmol/L (20 ng/mL): Sufficient levels in practically all persons",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     &gt;125 nmol/L (50 ng/mL): Concern for risk of toxicity",
"    </p>",
"    <p style=\"text-indent:-4em;margin-left:6em;margin-right:4em;\">",
"     Children (Misra, 2008):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     &lt;37.5 nmol/L (15 ng/mL): At risk for deficiency",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     37.5-50 nmol/L (15-20 ng/mL): Potentially at risk for inadequacy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     &ge;50 nmol/L (20 ng/mL): Sufficient levels in practically all children",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     &gt;250 nmol/L (100 ng/mL): Concern for risk of toxicity",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F150800\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Arachitol (IN);",
"     </li>",
"     <li>",
"      D!3-Vicotrat (DE);",
"     </li>",
"     <li>",
"      D-Cure (BE, LU);",
"     </li>",
"     <li>",
"      D-Mulsin (DE);",
"     </li>",
"     <li>",
"      Dedrei (DE);",
"     </li>",
"     <li>",
"      Deetipat (FI);",
"     </li>",
"     <li>",
"      Dekristol (DE);",
"     </li>",
"     <li>",
"      Devaron (NL);",
"     </li>",
"     <li>",
"      Devitre (SE);",
"     </li>",
"     <li>",
"      Duvit D!3 (IT);",
"     </li>",
"     <li>",
"      Iper D3 (IT);",
"     </li>",
"     <li>",
"      Laevovit (AT, HU);",
"     </li>",
"     <li>",
"      Neo-Dohyfral D3 (NL);",
"     </li>",
"     <li>",
"      Oleovit D!3 (AT);",
"     </li>",
"     <li>",
"      Ospur D!3 (DE);",
"     </li>",
"     <li>",
"      Ostelavit (PL);",
"     </li>",
"     <li>",
"      Plivit D3 (HR);",
"     </li>",
"     <li>",
"      Quimpe Vitamin D3 (ES);",
"     </li>",
"     <li>",
"      T-Tracetten (DE);",
"     </li>",
"     <li>",
"      Tridelta (IT);",
"     </li>",
"     <li>",
"      Uvedose (FR, LU);",
"     </li>",
"     <li>",
"      Vi-De 3 (AT, CH);",
"     </li>",
"     <li>",
"      Vigantol (CZ, DE, HU, LU, PL, PT);",
"     </li>",
"     <li>",
"      Vigantoletten (AT, DE, LU, PL);",
"     </li>",
"     <li>",
"      Vigorsan (DE);",
"     </li>",
"     <li>",
"      Vit. D3 Agepha (AT);",
"     </li>",
"     <li>",
"      Vitaendil D3 (ES);",
"     </li>",
"     <li>",
"      Vitamin D!3 (HU, HU);",
"     </li>",
"     <li>",
"      Vitamin D!3 Fresenius (HU);",
"     </li>",
"     <li>",
"      Vitamin D!3 Streuli (CH);",
"     </li>",
"     <li>",
"      Vitamin D3-Hevert (DE);",
"     </li>",
"     <li>",
"      Vitamina D3 Berenguer (ES);",
"     </li>",
"     <li>",
"      Vitamine D!3 BON (FR);",
"     </li>",
"     <li>",
"      Vitaminum D3 (PL);",
"     </li>",
"     <li>",
"      Vitamon D3 (BE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F595885\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Distribution: Primarily hepatic",
"    </p>",
"    <p style=\"text-indent:0em;\">",
"     Protein binding: Extensively to vitamin D-binding protein",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Primary liver and kidney hydroxylation; glucuronidation (minimal)",
"    </p>",
"    <p style=\"text-indent:0em;\">",
"     Half-life elimination: 14 hours",
"    </p>",
"    <p style=\"text-indent:0em;\">",
"     Time to peak, plasma: 11 hours",
"    </p>",
"    <p style=\"text-indent:0em;\">",
"     Excretion: As metabolites, urine (2.4%) and feces (4.9%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Dawson-Hughes B, Heaney RP, Holick MF, et al, &ldquo;Estimates of Optimal Vitamin D Status,&rdquo;",
"      <i>",
"       Osteoporos Int",
"      </i>",
"      , 2005, 16(7):713-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/52/38725/abstract-text/15776217/pubmed\" id=\"15776217\" target=\"_blank\">",
"        15776217",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Goltzman D and Cole DEC. &ldquo;Hypoparathyroidism,&rdquo;",
"      <i>",
"       Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism",
"      </i>",
"      , 6th ed. Washington DC: American Society for Bone and Mineral Research; 2006:216.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Holick MF, &ldquo;Vitamin D Deficiency,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2007, 357(3):266-81.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/52/38725/abstract-text/17634462/pubmed\" id=\"17634462\" target=\"_blank\">",
"        17634462",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      IOM (Institute of Medicine),",
"      <i>",
"       Dietary Reference Intakes for Calcium and Vitamin D",
"      </i>",
"      , Washington, DC: The National Academies Press, 2011.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Misra M, Pacaud D, Petryk A, et al, \"Vitamin D Deficiency in Children and Its Management: Review of Current Knowledge and Recommendations,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2008, 122(2):398-417.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/52/38725/abstract-text/18676559/pubmed\" id=\"18676559\" target=\"_blank\">",
"        18676559",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Osteoporosis Foundation, &ldquo;Clinician&rsquo;s Guide to Prevention and Treatment of Osteoporosis,&rdquo; Washington, DC, 2010. Available at file://www.nof.org/files/nof/public/content/file/344/upload/159.pdf",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10117 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-F7325097AE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_52_38725=[""].join("\n");
var outline_f37_52_38725=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150802\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150803\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150827\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150804\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12888900\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150805\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150796\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150785\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150797\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12890979\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10303065\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150825\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150799\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150824\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150791\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F595884\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13861968\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7310084\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7310085\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323065\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7310086\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150800\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F595885\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10117\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10117|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?9/30/9701?source=related_link\">",
"      Vitamin D3 (cholecalciferol): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/4/33862?source=related_link\">",
"      Vitamin D3 (cholecalciferol): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_52_38726="Small vessel vasculitis Churg Strauss";
var content_f37_52_38726=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F57180&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F57180&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Histopathology of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 235px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Small artery in a patient with&nbsp;eosinophilic granulomatosis with polyangiitis (Churg-Strauss) showing intimal fibrinoid necrosis and mural infiltration by histiocytes consistent with a necrotizing granulomatous vasculitis. There is marked extravascular eosinophilia.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_52_38726=[""].join("\n");
var outline_f37_52_38726=null;
var title_f37_52_38727="Alosetron hydrochloride (Lotronex) for irritable bowel syndrome";
var content_f37_52_38727=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Alosetron hydrochloride (Lotronex) for irritable bowel syndrome",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/52/38727/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/52/38727/contributors\">",
"     Michael Camilleri, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/52/38727/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/52/38727/contributors\">",
"     Nicholas J Talley, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/52/38727/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/52/38727/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/52/38727/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 25, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/61/8149?source=see_link\">",
"     Alosetron",
"    </a>",
"    hydrochloride is a selective 5-HT3 antagonist that has been approved for the treatment of women with severe diarrhea-predominant irritable bowel syndrome (IBS) who failed to respond to conventional treatment. The drug has been reintroduced to the market after being withdrawn due to adverse effects including severe constipation and ischemic colitis. Communications from the Food and Drug Administration suggest that fewer than 5 percent of patients with IBS are considered to have severe disease, have symptoms that last more than six months and curtail daily activities, and that only a fraction of these have diarrhea-predominant symptoms. Thus, the proportion of IBS patients who will be eligible for alosetron is small.",
"   </p>",
"   <p>",
"    Physicians who wish to prescribe",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/61/8149?source=see_link\">",
"     alosetron",
"    </a>",
"    are required to:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Self-attest to their qualifications",
"     </li>",
"     <li>",
"      Agree to educate patients on the risks and benefits of treatment and provide patients a copy of the FDA-approved medication guide",
"     </li>",
"     <li>",
"      Obtain a written agreement from patients before their initial prescription",
"     </li>",
"     <li>",
"      Affix a sticker onto prescriptions indicating that they are enrolled in a program to use",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/61/8149?source=see_link\">",
"       alosetron",
"      </a>",
"     </li>",
"     <li>",
"      Report serious adverse events to Prometheus at 1-888-423-5227 or FDA at 1-800-FDA-1088 or",
"      <a class=\"external\" href=\"file://www.fda.gov/medwatch\">",
"       www.fda.gov/medwatch",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The starting dose is 1 mg once daily, which can be increased to 1 mg twice daily after four weeks if the lower dose is well-tolerated but does not adequately control symptoms. Information regarding certification can be found on the manufacturer's web site (www.lotronex.com) or by telephone (1-888-825-5249).",
"   </p>",
"   <p>",
"    This topic review will summarize the major clinical trials of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/61/8149?source=see_link\">",
"     alosetron",
"    </a>",
"    in IBS. A general approach to IBS is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/14/40169?source=see_link\">",
"     \"Treatment of irritable bowel syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL PHARMACOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/61/8149?source=see_link\">",
"     Alosetron",
"    </a>",
"    selectively blocks 5-HT3 receptors, which are extensively distributed on enteric motor neurons and in peripheral afferents and central locations such as the vomiting center. The receptors are cation channels that modulate visceral pain, colonic transit, and gastrointestinal secretion.",
"   </p>",
"   <p>",
"    In non-constipated patients with IBS,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/61/8149?source=see_link\">",
"     alosetron",
"    </a>",
"    decreases brain activity of central autonomic networks (mostly in the amygdala, ventral striatum, and dorsal pons) that mediate emotional expression in response to aversive rectal stimuli [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/52/38727/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. It is unclear whether this reduction in activation of central structures results from a central effect of the medication or is simply the downstream effect of a reduction in the ability of peripheral visceral afferent nerves that convey sensations of pain and discomfort to the spinal cord and central nervous system [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/52/38727/abstract/3\">",
"     3",
"    </a>",
"    ]. Brain imaging studies suggest that greater symptom improvement on alosetron in IBS patients was predicted by less activity in bilateral orbitofrontal cortex (OFC) and medial temporal gyrus during pre-treatment scans, which may be partially predicted by psychological factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/52/38727/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although effects on peripheral afferents have not been conclusively demonstrated in humans, there are ample experimental animal data to suggest that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/61/8149?source=see_link\">",
"     alosetron",
"    </a>",
"    reduces nociception by blocking peripheral sensory pathways. It increases the number and propagation length of high-amplitude contractions in the left colon, leading to a paradoxical decrease in stool frequency and a firming of stool consistency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/52/38727/abstract/5\">",
"     5",
"    </a>",
"    ]. It also significantly retards small intestinal and colonic transit in women to a much larger degree than in men [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/52/38727/abstract/6\">",
"     6",
"    </a>",
"    ]. The degree of response to alosetron may be due to genetic polymorphism in the promoter region of the serotonin gene [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/52/38727/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is also evidence from animal studies that 5-HT3 antagonists affect intestinal secretion, which may benefit patients with IBS and diarrhea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/52/38727/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Unpublished pharmacokinetic studies performed by the manufacturer have demonstrated that the drug is rapidly absorbed after oral administration and has a bioavailability of approximately 50 to 60 percent. Plasma protein binding is 82 percent. Peak plasma concentrations are achieved after one hour. The absorption is decreased by approximately 25 percent by coadministration with food. However, the drug can be taken with or without food.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/61/8149?source=see_link\">",
"     Alosetron",
"    </a>",
"    is extensively metabolized by cytochrome P450 (CYP) enzymes 2C9 (30 percent), 3A4 (18 percent), and 1A2 (10 percent). It is likely that increased exposure to alosetron occurs in patients with hepatic insufficiency, although no pharmacokinetic data are available. Renal impairment (creatinine clearance 4 to 56",
"    <span class=\"nowrap\">",
"     mL/min)",
"    </span>",
"    has no effect on the renal elimination. However, the effect of renal impairment on the excretion of alosetron metabolites has not been assessed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL TRIALS",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/61/8149?source=see_link\">",
"     Alosetron",
"    </a>",
"    was approved initially by the Food and Drug Administration based upon the results of four placebo controlled trials. The first two were 12-week dose-ranging studies (phase II trials) with a total of 832 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/52/38727/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. The second two (phase III studies) were multicenter trials conducted in the United States that determined the efficacy and safety of a dose of 1 mg twice daily for 12 weeks in a total of 1273 non-constipated women with IBS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/52/38727/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. IBS was diagnosed based upon the Rome criteria. The mean age of the women was 46, and the majority (approximately 90 percent) was white. The first of these phase III trials was published in final form [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/52/38727/abstract/11\">",
"     11",
"    </a>",
"    ]. A third phase III study compared alosetron (1 mg twice daily) to mebeverine, an antispasmodic approved in Europe for the treatment of IBS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/52/38727/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Primary endpoints",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary endpoints of the placebo-controlled trials were adequate relief of pain and discomfort, which was assessed weekly. Secondary endpoints were the percentage of days with urgency and daily assessment of stool frequency and consistency.",
"   </p>",
"   <p>",
"    In both of the phase III placebo-controlled studies,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/61/8149?source=see_link\">",
"     alosetron",
"    </a>",
"    was associated with a significant improvement in the proportion of women with pain relief during treatment (41 versus 29 percent and 41 versus 26 percent in the two studies, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/52/38727/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. The beneficial response for the primary endpoints (pain and discomfort) was observed within one to four weeks after beginning therapy, and was sustained throughout the duration of the trial (",
"    <a class=\"graphic graphic_figure graphicRef70978 \" href=\"mobipreview.htm?5/10/5294\">",
"     figure 1",
"    </a>",
"    ). Bloating was not improved. Within one week after discontinuing the drug, symptoms were comparable to those in women receiving placebo. Secondary endpoints relating to bowel movements were typically improved within one week of starting therapy. Subgroup analysis in one of the two studies revealed that the benefit appeared to be confined to patients with diarrhea-predominant symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Secondary endpoints",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/61/8149?source=see_link\">",
"     Alosetron",
"    </a>",
"    was associated with a significant decrease in the percentage of days with urgency compared to placebo throughout the study. Treatment was associated with firmer stools and a significant decrease in stool frequency. These symptoms improved within one week of beginning therapy, and returned to baseline (pretreatment) levels similar to those of the placebo-treated group within one week of discontinuing therapy.",
"   </p>",
"   <p>",
"    Several issues need to be considered when interpreting the efficacy data discussed above:",
"   </p>",
"   <p>",
"    First, the studies discussed above used a 1 mg twice daily dose in contrast to the 1 mg once daily dose recommended for initiating therapy only in women with severe IBS-D. Randomized trials have also demonstrated that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/61/8149?source=see_link\">",
"     alosetron",
"    </a>",
"    0.5 mg every day results in statistically significant and clinically relevant improvements in health-related quality of life (QOL), restriction of daily activities and treatment satisfaction over placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/52/38727/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Post-marketing studies'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Second, although the women included in the trials were permitted to take fiber, other agents commonly used to treat diarrhea-predominant IBS (such as antidiarrheal, antispasmodic, and anticholinergic) were not permitted. Thus, whether",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/61/8149?source=see_link\">",
"     alosetron",
"    </a>",
"    would have an added benefit compared to standard approaches is uncertain.",
"   </p>",
"   <p>",
"    Third, although the absolute proportion of women who benefited from therapy is clinically significant, nearly 30 percent of women in the placebo arm also achieved the primary endpoint. The placebo response rate of these trials approximated the mean placebo response rate described in the literature [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/52/38727/abstract/15\">",
"     15",
"    </a>",
"    ]. While many previous trials in IBS had flawed experimental designs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/52/38727/abstract/16\">",
"     16",
"    </a>",
"    ], more recent trials show enhanced trial methodology. This opens the question as to how effective comparable agents or approved antispasmodics might be if evaluated by the same methods.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/61/8149?source=see_link\">",
"     Alosetron",
"    </a>",
"    was significantly superior in the only study in which it was directly compared to an active agent (mebeverine) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/52/38727/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A fourth issue is that the trials described above have not necessarily identified the optimal method of administration (eg, intermittent, during exacerbation, or continuous). Thus, further phase IV studies will be needed to evaluate optimal dosing regimens, safety, and effectiveness.",
"   </p>",
"   <p>",
"    Finally, the cost-effectiveness of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/61/8149?source=see_link\">",
"     alosetron",
"    </a>",
"    remains to be defined; its cost per quality-adjusted life-year (QALY) gained may be substantial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/52/38727/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Alosetron versus mebeverine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The study comparing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/61/8149?source=see_link\">",
"     alosetron",
"    </a>",
"    to mebeverine included 623 nonconstipated women with IBS who were randomly assigned to alosetron (1 mg twice daily) or mebeverine (135 mg three times daily) for 12 weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/52/38727/abstract/13\">",
"     13",
"    </a>",
"    ]. Similar to the placebo-controlled trials, the primary endpoint was adequate relief of abdominal pain and discomfort while secondary endpoints included assessments of bowel function. At the end of the study, significantly more patients in the alosetron group achieved the primary outcome. Alosetron was also associated with a significant increase in stool firmness, and a decrease in the proportion of days with urgency and mean stool frequency.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Post-marketing studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several post-marketing studies have been performed since the initial controlled trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/52/38727/abstract/18-24\">",
"     18-24",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A 2008 meta-analysis summarized the efficacy and safety of the 5-HT3 receptor antagonist class of drugs in IBS [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/52/38727/abstract/23\">",
"       23",
"      </a>",
"      ]. The study included 14 randomized controlled trials of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/61/8149?source=see_link\">",
"       alosetron",
"      </a>",
"      (n=3024) or cilansetron (n=1116) versus placebo (n=3043) or mebeverine (n=304). The 5-HT3 antagonists were significantly more effective than the comparators in achieving global improvement in IBS symptoms (pooled relative risk, 1.60; 95% CI 1.49-1.72) and relief of abdominal pain and discomfort (pooled relative risk, 1.30; 95% CI 1.22-1.39). Benefits were apparent for both agents in patients of either sex. These results were confirmed in a meta-analysis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/52/38727/abstract/25\">",
"       25",
"      </a>",
"      ], and another meta-analysis indicated significant differences between alosetron and placebo in both sexes (female: RR=1.34 (95% CI 1.21-1.48); male: RR=1.23 (95% CI 1.02-1.47)) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/52/38727/abstract/26\">",
"       26",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      These agents were more likely to cause constipation (pooled relative risk, 4.28; 95% CI 3.28-5.60); there was less constipation with 5-HT3 antagonists in D-IBS patients than in mixed populations (NC-IBS and D-IBS; relative risk ratio, 0.65; 95% CI 0.41-0.99). Nine patients (0.2 percent) using 5-HT3 antagonists had possible ischemic colitis versus none in control groups. Similar conclusions were reached in a later meta-analysis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/52/38727/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      One study provided follow-up information for up to 12 months in women who had participated in one of the multicenter phase III trials [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/52/38727/abstract/19\">",
"       19",
"      </a>",
"      ]. Overall, 59 percent of the subjects completed the study. Adverse events were reported in a significantly higher proportion of patients who received",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/61/8149?source=see_link\">",
"       alosetron",
"      </a>",
"      (83 versus 76 percent), with the difference mostly attributed to a higher rate of constipation in the alosetron group (32 versus 5 percent). Constipation was mild or moderate in most patients, occurring within a median of 13 days after initiating treatment.",
"     </li>",
"     <li>",
"      Another study also involving previously reported patients, suggested that",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/61/8149?source=see_link\">",
"       alosetron",
"      </a>",
"      was associated with improvement in health-related quality of life [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/52/38727/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A third trial included 492 women who were randomly assigned to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/61/8149?source=see_link\">",
"       alosetron",
"      </a>",
"      (1 mg twice daily) or placebo for 12 weeks [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/52/38727/abstract/21\">",
"       21",
"      </a>",
"      ]. Alosetron was associated with a significantly greater percentage of days with satisfactory control of urgency (69 versus 56 percent). Furthermore, a greater percentage of patients had improvement on a global improvement scale at 4, 8, and 12 weeks. Constipation occurred significantly more often in the alosetron group (28 versus 9 percent). Of patients with constipation in the alosetron group, 11, 75, and 14 percent were rated as mild, moderate, and severe, respectively. No cases of ischemic colitis were observed.",
"     </li>",
"     <li>",
"      Other randomized trials have addressed the efficacy of lower doses of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/61/8149?source=see_link\">",
"       alosetron",
"      </a>",
"      than the original dose evaluated in the registration trials [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/52/38727/abstract/14,22\">",
"       14,22",
"      </a>",
"      ]. In one randomized trial, alosetron 0.5 mg and 1 mg once daily as well as 1 mg twice daily were effective in providing global improvement in IBS symptoms, adequate relief of IBS pain and discomfort, and improvement in bowel symptoms in women with severe d-IBS [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/52/38727/abstract/22\">",
"       22",
"      </a>",
"      ]. These data are important since the prevalence of constipation was 19 percent with the highest dose, 9 percent with the lowest dose of 0.5",
"      <span class=\"nowrap\">",
"       mg/day,",
"      </span>",
"      and 5 percent with placebo. This suggests that it is prudent to start with 0.5 mg alosetron dose and to titrate the dose up if needed. This is a clinically appealing strategy that has been used by the author as a precaution to reduce the risk of constipation and potential for associated adverse events. This strategy is particularly relevant given evidence that genetic variation in the serotonin reuptake transporter influences the response to therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/52/38727/abstract/7\">",
"       7",
"      </a>",
"      ]. Nevertheless, it should be noted that one patient on the lowest dose 0.5 mg alosetron (out of 175 patients) developed ischemic colitis. Hence, caution is always necessary when using this medication in patients with IBS.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Men",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/61/8149?source=see_link\">",
"     alosetron",
"    </a>",
"    has been approved only for women. However, it has also been studied in men. A placebo-controlled trial involving 662 men with diarrhea-predominant IBS found that alosetron was significantly more effective in relieving urgency and abdominal pain (53 versus 40 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/52/38727/abstract/27\">",
"     27",
"    </a>",
"    ]. Side effects were similar to the clinical trials in women. As noted in the meta-analysis described above, benefits of the 5-HT3 class of drugs were observed in men and women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/52/38727/abstract/23\">",
"     23",
"    </a>",
"    ]. The original and subsequent guidance for use of alosetron in women was based upon the original phase III program, which was conducted exclusively in women.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     SAFETY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common adverse event in the above studies was constipation, which was significantly more common among women receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/61/8149?source=see_link\">",
"     alosetron",
"    </a>",
"    compared to placebo (28 to 32 versus 5 percent). The majority of patients reporting constipation had mild to moderate symptoms; only about 10 percent of those patients withdrew from the study due to constipation. In the phase III trials, treatment was interrupted per the protocol in 9 percent of patients who had four consecutive days without a bowel movement. The majority of these patients (88 percent) resumed therapy. The rate of other adverse events was comparable to placebo. Safety beyond 12 months has not been established.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Ischemic colitis and severe constipation",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, the risk of ischemic colitis led to establishment of a risk management strategy for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/61/8149?source=see_link\">",
"     alosetron",
"    </a>",
"    and restricted its use. &nbsp;However, the magnitude of the risk and its pathogenesis are unclear.",
"   </p>",
"   <p>",
"    A systematic review of the published literature and cases reported through the FDA Adverse Events Reporting System estimated that the risk of ischemic colitis associated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/61/8149?source=see_link\">",
"     alosetron",
"    </a>",
"    was significantly higher than with placebo (0.15 versus 0.0 percent) but there was no significant difference in the rate of serious complications of constipation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/52/38727/abstract/28\">",
"     28",
"    </a>",
"    ]. Based upon post-marketing surveillance, the rate of ischemic colitis and serious complications of constipation were estimated to be 1.1 and 0.66 per 1000 patient-years of alosetron, respectively.",
"   </p>",
"   <p>",
"    The pathogenesis of ischemic colitis in patients with IBS taking",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/61/8149?source=see_link\">",
"     alosetron",
"    </a>",
"    is uncertain. It may be due to a drug class effect given that a related drug (cilansetron) has also been associated with ischemic colitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/52/38727/abstract/29\">",
"     29",
"    </a>",
"    ]. However, IBS itself has also been associated with ischemic colitis in epidemiologic studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/52/38727/abstract/30\">",
"     30",
"    </a>",
"    ]. Further complicating matters is the observation that focal active colitis may be seen in asymptomatic patients undergoing screening colonoscopy, and such a finding may be misclassified as being caused by ischemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/52/38727/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In experimental settings, preconstricted arterioles exhibited normal dilatory responses to balloon distension in the presence or absence of 5-HT3 or 5-HT4 antagonists suggesting that these classes of receptors do not change the ability of normal vessels to induce reflex vasodilatation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/52/38727/abstract/32\">",
"     32",
"    </a>",
"    ]. Intravenously-administered",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/61/8149?source=see_link\">",
"     alosetron",
"    </a>",
"    (0.03 to 0.3 mg per kg) and cilansetron caused a small and transient constriction of the rat mesenteric vascular bed, whereas blood flow in the colon remained unaltered; oral administration of alosetron had no effects at any site [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/52/38727/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some authors have speculated that ischemia results from constipation that may result from the slow transit induced by 5-HT3 antagonists. Subtle changes in Doppler mucosal blood flow have been observed in patients with normal or slow transit constipation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/52/38727/abstract/34\">",
"     34",
"    </a>",
"    ]. However, it is unclear whether these subtle differences can overcome the pressure-flow autoregulation intrinsic to colonic blood flow; thus, even with perfusion pressures of 60 mmHg, increased oxygen extraction will maintain normal colonic oxygen uptake [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/52/38727/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Finally, although rise in intraluminal pressure or straining may temporarily reduce mucosal blood flow [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/52/38727/abstract/36\">",
"     36",
"    </a>",
"    ], such changes are not sustained over time, and it is typical for contractile amplitudes and frequency of high amplitude contractions to be reduced rather than increased in patients with constipation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/52/38727/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. A critical appraisal could not find an experimental basis for the development of ischemic colitis with 5-HT3 antagonists [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/52/38727/abstract/39\">",
"     39",
"    </a>",
"    ], and a study in rats [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/52/38727/abstract/40\">",
"     40",
"    </a>",
"    ] showed that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/61/8149?source=see_link\">",
"     alosetron",
"    </a>",
"    did not significantly alter baseline colonic blood flow in the anesthetized rat; nor did it interfere with vascular control mechanisms activated during occlusion and reactive hyperemia.",
"   </p>",
"   <p>",
"    Among 29,072 patients who received 203,939",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/61/8149?source=see_link\">",
"     alosetron",
"    </a>",
"    prescriptions, the incidence rates for ischemic colitis and complications of constipation (0.95 and 0.36 cases per 1000 patient-years, respectively) were similar to rates during the postmarketing cycle before alosetron withdrawal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/52/38727/abstract/41\">",
"     41",
"    </a>",
"    ]. No mesenteric ischemia, surgeries, transfusions, or deaths occurred in patients with ischemic colitis and no cases of complications or constipation were associated with toxic megacolon, perforation, surgeries, transfusions, or deaths. The authors concluded that serious outcomes associated with ischemic colitis and complications of constipation appear to be mitigated since introduction of alosetron under the risk management plan.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?30/34/31265?source=see_link\">",
"       \"Patient information: Irritable bowel syndrome (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?3/53/3926?source=see_link\">",
"       \"Patient information: Irritable bowel syndrome (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/61/8149?source=see_link\">",
"       Alosetron",
"      </a>",
"      hydrochloride is a selective 5-HT3 antagonist that has been approved for the treatment of women with severe diarrhea-predominant irritable bowel syndrome (IBS) who failed to respond to conventional treatment. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/61/8149?source=see_link\">",
"       Alosetron",
"      </a>",
"      selectively blocks 5-HT3 receptors, which are extensively distributed on enteric motor neurons and in peripheral afferents and central locations such as the vomiting center. The receptors are cation channels that modulate visceral pain, colonic transit, and gastrointestinal secretion. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical pharmacology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/61/8149?source=see_link\">",
"       Alosetron",
"      </a>",
"      is more effective than placebo and mebeverine in the treatment of women who have diarrhea-predominant irritable bowel syndrome. However, the lingering safety concerns and the restrictions have limited the role of alosetron in the treatment of IBS. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical trials'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Adverse effects of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/61/8149?source=see_link\">",
"       alosetron",
"      </a>",
"      include constipation and ischemic colitis. A systematic review of the published literature and cases reported through the FDA Adverse Events Reporting System estimated that the risk of ischemic colitis associated with alosetron was significantly higher than with placebo (0.15 versus 0.0 percent) but there was no significant difference in the rate of serious complications of constipation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/52/38727/abstract/28\">",
"       28",
"      </a>",
"      ]. Based upon post-marketing surveillance, the rate of ischemic colitis and serious complications of constipation were estimated to be 1.1 and 0.66 per 1000 patient-years of alosetron, respectively. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Safety'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/52/38727/abstract/1\">",
"      Mayer EA, Berman S, Derbyshire SW, et al. The effect of the 5-HT3 receptor antagonist, alosetron, on brain responses to visceral stimulation in irritable bowel syndrome patients. Aliment Pharmacol Ther 2002; 16:1357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/52/38727/abstract/2\">",
"      Berman SM, Chang L, Suyenobu B, et al. Condition-specific deactivation of brain regions by 5-HT3 receptor antagonist Alosetron. Gastroenterology 2002; 123:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/52/38727/abstract/3\">",
"      Kozlowski CM, Green A, Grundy D, et al. The 5-HT(3) receptor antagonist alosetron inhibits the colorectal distention induced depressor response and spinal c-fos expression in the anaesthetised rat. Gut 2000; 46:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/52/38727/abstract/4\">",
"      Jarcho JM, Chang L, Berman M, et al. Neural and psychological predictors of treatment response in irritable bowel syndrome patients with a 5-HT3 receptor antagonist: a pilot study. Aliment Pharmacol Ther 2008; 28:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/52/38727/abstract/5\">",
"      Clemens CH, Samsom M, Van Berge Henegouwen GP, et al. Effect of alosetron on left colonic motility in non-constipated patients with irritable bowel syndrome and healthy volunteers. Aliment Pharmacol Ther 2002; 16:993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/52/38727/abstract/6\">",
"      Viramontes BE, Camilleri M, McKinzie S, et al. Gender-related differences in slowing colonic transit by a 5-HT3 antagonist in subjects with diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol 2001; 96:2671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/52/38727/abstract/7\">",
"      Camilleri M, Atanasova E, Carlson PJ, et al. Serotonin-transporter polymorphism pharmacogenetics in diarrhea-predominant irritable bowel syndrome. Gastroenterology 2002; 123:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/52/38727/abstract/8\">",
"      Hirata T, Keto Y, Nakata M, et al. Effects of serotonin 5-HT(3) receptor antagonists on CRF-induced abnormal colonic water transport and defecation in rats. Eur J Pharmacol 2008; 587:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/52/38727/abstract/9\">",
"      Bardhan KD, Bodemar G, Geldof H, et al. A double-blind, randomized, placebo-controlled dose-ranging study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2000; 14:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/52/38727/abstract/10\">",
"      Camilleri M, Mayer EA, Drossman DA, et al. Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist. Aliment Pharmacol Ther 1999; 13:1149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/52/38727/abstract/11\">",
"      Camilleri M, Northcutt AR, Kong S, et al. Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial. Lancet 2000; 355:1035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/52/38727/abstract/12\">",
"      Camilleri M, Chey WY, Mayer EA, et al. A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome. Arch Intern Med 2001; 161:1733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/52/38727/abstract/13\">",
"      Jones RH, Holtmann G, Rodrigo L, et al. Alosetron relieves pain and improves bowel function compared with mebeverine in female nonconstipated irritable bowel syndrome patients. Aliment Pharmacol Ther 1999; 13:1419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/52/38727/abstract/14\">",
"      Cremonini F, Nicandro JP, Atkinson V, et al. Randomised clinical trial: alosetron improves quality of life and reduces restriction of daily activities in women with severe diarrhoea-predominant IBS. Aliment Pharmacol Ther 2012; 36:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/52/38727/abstract/15\">",
"      Camilleri M, Choi MG. Review article: irritable bowel syndrome. Aliment Pharmacol Ther 1997; 11:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/52/38727/abstract/16\">",
"      Klein KB. Controlled treatment trials in the irritable bowel syndrome: a critique. Gastroenterology 1988; 95:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/52/38727/abstract/17\">",
"      Ladabaum U. Safety, efficacy and costs of pharmacotherapy for functional gastrointestinal disorders: the case of alosetron and its implications. Aliment Pharmacol Ther 2003; 17:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/52/38727/abstract/18\">",
"      Lembo T, Wright RA, Bagby B, et al. Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol 2001; 96:2662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/52/38727/abstract/19\">",
"      Wolfe SG, Chey WY, Washington MK, et al. Tolerability and safety of alosetron during long-term administration in female and male irritable bowel syndrome patients. Am J Gastroenterol 2001; 96:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/52/38727/abstract/20\">",
"      Watson ME, Lacey L, Kong S, et al. Alosetron improves quality of life in women with diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol 2001; 96:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/52/38727/abstract/21\">",
"      Lembo AJ, Olden KW, Ameen VZ, et al. Effect of alosetron on bowel urgency and global symptoms in women with severe, diarrhea-predominant irritable bowel syndrome: analysis of two controlled trials. Clin Gastroenterol Hepatol 2004; 2:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/52/38727/abstract/22\">",
"      Krause R, Ameen V, Gordon SH, et al. A randomized, double-blind, placebo-controlled study to assess efficacy and safety of 0.5 mg and 1 mg alosetron in women with severe diarrhea-predominant IBS. Am J Gastroenterol 2007; 102:1709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/52/38727/abstract/23\">",
"      Andresen V, Montori VM, Keller J, et al. Effects of 5-hydroxytryptamine (serotonin) type 3 antagonists on symptom relief and constipation in nonconstipated irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials. Clin Gastroenterol Hepatol 2008; 6:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/52/38727/abstract/24\">",
"      Chey WD, Chey WY, Heath AT, et al. Long-term safety and efficacy of alosetron in women with severe diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol 2004; 99:2195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/52/38727/abstract/25\">",
"      Ford AC, Brandt LJ, Young C, et al. Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis. Am J Gastroenterol 2009; 104:1831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/52/38727/abstract/26\">",
"      Rahimi R, Nikfar S, Abdollahi M. Efficacy and tolerability of alosetron for the treatment of irritable bowel syndrome in women and men: a meta-analysis of eight randomized, placebo-controlled, 12-week trials. Clin Ther 2008; 30:884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/52/38727/abstract/27\">",
"      Chang L, Ameen VZ, Dukes GE, et al. A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS. Am J Gastroenterol 2005; 100:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/52/38727/abstract/28\">",
"      Chang L, Chey WD, Harris L, et al. Incidence of ischemic colitis and serious complications of constipation among patients using alosetron: systematic review of clinical trials and post-marketing surveillance data. Am J Gastroenterol 2006; 101:1069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/52/38727/abstract/29\">",
"      Chey WD, Cash BD. Cilansetron: a new serotonergic agent for the irritable bowel syndrome with diarrhoea. Expert Opin Investig Drugs 2005; 14:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/52/38727/abstract/30\">",
"      Higgins PD, Davis KJ, Laine L. Systematic review: the epidemiology of ischaemic colitis. Aliment Pharmacol Ther 2004; 19:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/52/38727/abstract/31\">",
"      Greenson JK, Stern RA, Carpenter SL, Barnett JL. The clinical significance of focal active colitis. Hum Pathol 1997; 28:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/52/38727/abstract/32\">",
"      Reed DE, Vanner SJ. Long vasodilator reflexes projecting through the myenteric plexus in guinea-pig ileum. J Physiol 2003; 553:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/52/38727/abstract/33\">",
"      Painsipp E, Shahbazian A, Holzer P. Alosetron, cilansetron and tegaserod modify mesenteric but not colonic blood flow in rats. Br J Pharmacol 2009; 158:1210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/52/38727/abstract/34\">",
"      Emmanuel AV, Kamm MA. Laser Doppler flowmetry as a measure of extrinsic colonic innervation in functional bowel disease. Gut 2000; 46:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/52/38727/abstract/35\">",
"      Kvietys PR, Miller T, Granger DN. Intrinsic control of colonic blood flow and oxygenation. Am J Physiol 1980; 238:G478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/52/38727/abstract/36\">",
"      Kvietys PR, Barrowman JA, Harper SL, Granger DN. Relations among canine intestinal motility, blood flow, and oxygenation. Am J Physiol 1986; 251:G25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/52/38727/abstract/37\">",
"      Bampton PA, Dinning PG, Kennedy ML, et al. Spatial and temporal organization of pressure patterns throughout the unprepared colon during spontaneous defecation. Am J Gastroenterol 2000; 95:1027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/52/38727/abstract/38\">",
"      Dinning PG, Bampton PA, Andre J, et al. Abnormal predefecatory colonic motor patterns define constipation in obstructed defecation. Gastroenterology 2004; 127:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/52/38727/abstract/39\">",
"      Camilleri M. Is there an experimental basis for the development of ischaemic colitis as a result of 5-HT3 antagonist treatment? Neurogastroenterol Motil 2007; 19:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/52/38727/abstract/40\">",
"      Grundy D, McLean P, Stead R. Impact of 5-HT3 receptor blockade on colonic haemodynamic responses to ischaemia and reperfusion in the rat. Neurogastroenterol Motil 2007; 19:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/52/38727/abstract/41\">",
"      Chang L, Tong K, Ameen V. Ischemic colitis and complications of constipation associated with the use of alosetron under a risk management plan: clinical characteristics, outcomes, and incidences. Am J Gastroenterol 2010; 105:866.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2597 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-9F69235DB9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_52_38727=[""].join("\n");
var outline_f37_52_38727=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL PHARMACOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL TRIALS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Primary endpoints",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Secondary endpoints",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Alosetron versus mebeverine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Post-marketing studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SAFETY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Ischemic colitis and severe constipation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/2597\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2597|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?5/10/5294\" title=\"figure 1\">",
"      Alosetron and IBS",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?3/53/3926?source=related_link\">",
"      Patient information: Irritable bowel syndrome (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?30/34/31265?source=related_link\">",
"      Patient information: Irritable bowel syndrome (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/14/40169?source=related_link\">",
"      Treatment of irritable bowel syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_52_38728="WHO weight for length girls 0 to 24 months";
var content_f37_52_38728=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F73036%7EPEDS%2F53474&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F73036%7EPEDS%2F53474&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 583px\">",
"   <div class=\"ttl\">",
"    Weight-for-length percentiles, girls 0 to 24 months, WHO growth standards",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 563px; height: 508px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     WHO: World Health Organization.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Centers for Disease Control and Prevention based on data from the WHO Child Growth Standards.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 583px\">",
"   <div class=\"ttl\">",
"    Weight-for-length percentiles, boys 0 to 24 months, WHO growth standards",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 563px; height: 508px; background-image: url(data:image/gif;base64,R0lGODlhMwL8AeYAAP///+bm5gAAABEREYiIiMzMzPDw8N3d3URERO7u7iIiIru7uzMzMzAwMJmZmdDQ0NfX16qqqqCgoFVVVWBgYHd3d4CAgGZmZsDAwHBwcEBAQODg4BAQELq6uiAgIFBQUFZWVisrK7CwsI+Pj5CQkHNzc6ysrMnJyRwcHDk5OYGBgWRkZEdHRw4ODp6enr+/v39/f+zs7PLy8vj4+D8/P+/v7zQ0NO3t7W9vb8HBwXZ2dq+vr+fn55aWlomJierq6sfHx76+vqKiot/f37GxsWVlZWpqal9fX0tLS87Ozs/Pz05OTldXVwAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAAAzAvwBAAf/gACCg4SFhoeIiYqLjI2Oj5CRkpOUlZaXmJmam5ydnp+goaKjpKWmp6ipqqusra6vsLGys7S1tre4ubq7vL2+v8DBwsPExcbHyMnKy8zNzs/Q0dLT1NXW19jZ2tvc3d7f4OHi4+Tl5ufo6err7O3u740C8vP09fb3+Pn6+/z9/v8AAwocSLCgwYMIEypcyLChQ4XIHkqcSLGixYsYM2rcyLGjvogCMsmzNJJQgEInTaIsFHJQSpcrVcqEORPAS0E3AbSkyRNnTJ81bf4EOmgnUaFBcyodivSoTqZLa0bt2dSp0apTnWatipUl1K9SwVJNebVSSZJlhZ1FyzapWEFG/7fKfbv16tywbvMWHXp3LF2verUG5lqX71vCfwnZPZy1r+CnItNGWkuMMiXLkCg75hqXsWe/ij/33FwYL+jTj62KPkqa6WLUiAffzPkaduPVSCVLwjxZ9y/evdEGGE68uPHjyAMISM68ufPnyJdDn06duvTq2LMXv669e3Xu3sM3By++PHPfmdHHU88LePpCDgbIc0AIQVnNuDvLXl3atuH9QdUWm3+B0YbbbAcCNlqCBSqY2oNdAUhTWQnYJwADCQyygAAEIOKeIx/2EuJ6hVRAHwEDDHKBZfhJCJeLAz7YH4S3wWigaTTy52CMMbYW4H8EBskZgwva+GIhByCQQP8CCnQIQAHyOWnIiItQqYuVivAWQYoAVMAAAfcJyOONORoJm5iO+UiVgGqWqZqZbkLIJpEy7thmhELmpsiXABwwgANNeshelYNeWWiW88BAyAEKRAAAAQoc4IBRL3hk6aWYZqrpppzuo+ggBDDQZ6CBDlIpPZhgiYuqghoCJX0AKFAPS2gepl+eabpG551kskZnj3bqCOeRReKa2F7D4hmnnodcgCEAk9IjpWKHtnoMZtHKs0ABDMhzwSGUQVqAIZNOWetgty6b64/D8hqssS72OiaQ6r5bb7z23qsvUGUdwMC3hpRqriErzgOtfALASitIhwBKiAMVPCnAuAsTIuv/PAqXS6t523Hscccfh0xeyOGNTLJ3Jp+cXcoqd1dWtgIoYPG01BIMsCAmPsplxcZgO8+0CUw8sFnnnpnsumvu+uucR9MLGbz7DonjvPiG1jTU/GpiWcEKLEDIluBWe0s9L5ArtCAIRCwIDLMSvfTVqM1IdbFRM401sFZj7W7evsLdN7J3I2im2ILOUzYhF+zMqKODsG3wtegJ4HUC/1p7WdFy+o130u2+PfXedD+9L+jE/h11jYCffjXhYSeyoSCvWl4MZhPQF18CC/yZCKvUitxyeSz/Pl3wwjtHfPHjIe+y8uKxPjQhDIx7AQKPKkBx65AfAqYAuhfs7fOTtJhn/7pzxyl3m6SLrmz55cuLvuehpy946uyjfq/zPA8ygTzRx0qPwkXBnyx4B77dYI5H5JMfupSWLLupbmoHtF/98qVACP5qfvfTmgB1skFYEDB/BvQd87BzvBEap4QmHA4KU6gcFg7PhSTUYKo6+IoP1sxtDdScBN0nrLs5cIIN4hsQH0g/DA6xTkIk3d5oaEO40NAVTXRiW3yoQ6fxsGpU/NwF2aU3+JnuiJsrHRiN6CMmbjCKHuygDcW3rARu0Widy6EW/XZFIaXvhxV8U+BWJ8NLoLGGasSfPEQIw+QV0niHNGQik7NCEzbShWacIcMk+TCE0ScBCGPAAUB4JzfSUf9Xccxi/N6ox9F5cX15lNoeV0khCz1rexyS3eUm6cer5AxFhWCA2gLoxVSiMl/tOyUZSalKU8pxlJ9MIgPh1S8lMWlaERBAhgoYvie2Ao30+NQgwDYIJinsVJ0KpzjHSc5ymjObuZwWpAgBzij+EYppgZnXLHSzGyKpUSoSAPU4mZ8qzrGIPaybFYlZR/MJ05+hi+CxMoiIUA3iANqSJQC8FxJ/zQd7PYunzEClgAT4iXH2HETsCjGBenKwl8T8pTKxKNB/ErGYR7zjQJMJ0FAylGDPIkQBBLBJal6gnhOYAACiOc2QViaePwPABNSGAJqdlBDiGoQDhAoABlCVl8f/HONCYfq+rKp0laWM6UHBisSadnFwhvBXPRHgtWhez6gTlUfXADAAxkmOmmqhx+EeNrGmog1gjnvcIC42H27xr6cBJOQiT7hYRjb2OI8cYWSVN1lHmm0eMoOlU51ouEIkTide04nCAmtNVnxIcktFm1PXqFAuajWInDurKL+YyoIG06vDpKkYlcigSCLidXWFS2jhmtdD1O5gCYCUR4MLwuBk1Ze5NatBcYvQL7YWmeObKVlt21Vm9hF60qNeUIcqTbwGAzPb0x0A6InRair2sS2EL8jkG1/61le+lZXsd/XHv3FZNGHtPWpkptjSl4aRqwEFIx4JCkykFZi2DF6p/2xvWktKZnTAOJwtdBdoUwVr96Xc3WonP/zasPIWrRgmsIAtXE2UVvd8CR6xS0uMYJZ6eMYnlq5YUcziWWavx71572PzWzwi/87IR7bvfZXsWxUPA5uCvG4pNwzHCd8YuyBusIj7ieNl7tbLQGxyhmcXSBXL2MA71DJsH/zVLEt4urNtM41DbOMy7tfHFwZyeoTcWCS3zM8nA3Sgmazk7dy5xT+ucCUvWiH+FVWKz01pdL9cZy5jec5qjttY0ew0KR/YzoVo9IUyFJ+LBhjReVb0IG6ZoiQtSWCQ1rCkOWzlM0NYt+rrLpsnjek379i7SHJmoFgtUQPS0hAb6tB/lf9kXm4Ogk9GtTWVM9dhW8s5x5S246ZpfGBPpxlAvoG2IJzdXEGAyWsLuNguiXteyUApll7qk3qpJQ9tjgqkjxKVqc7J7377+98AN4i9HfpQfO4bVZf1mi7Ji1ispnpRfwoUoByAybfGWqTznmhOo21pbn9bxw6+8q23m+my7rq66/M2ibMiAheIUUUbH+mptxRNrzmrAOl+9MWP2tlRdShQah3AVUl7lagKQq2ylPasq2zMOPMa27mOccevDWaVd3kmDxAAC16OdI5anFad3dACIIruf8WycQh/uCBgxqHUrnfdOydswmC20cR+TNB87jOh905fvHMMAi1owQlUeFn/ufoPYwGmqOSCi0l87/zJvgnUBERFObg/Fc8PnjYCwWztp1ed81P3fIetfumoaEAAGCDLoY9+1wFEDEqOvzyZFQH0bulT57I3dqRfDMpahx7lRiQ9txeMa+FTXSUWEIAFmKXnPt01d/KwfO4hn2JUZ37p1PY9jIhPcl+HvPPAd22vbYMBAWgga9XH/IpV7d67873v78dv/A8J+BZA4ISrd67a1a//6/Ne/LomcsdnZcInU1dHgBEGGymAehOSf++RaE72gLL2f7HVdCdHVt0Getu3cp+Ha1mRAconE2LGf8XVfCCCd37nMSmogvM3ZC3IQi6gdYzkgI/wTtdUZmMm/3KaB2OVtoEHaIFR14PZ9YO/lm1AGBUPwAEeAAExMYLWt34RWIPG50ndV4FFKICih4DV9nsYKEHG53kG0AAc8ABR4YS6t39P2H86iH2bt4U+WHodqH1DCIejl4CCQQECIAGxYYZqSH0muB55t0gryDGDCDyFVojNc0gqIAAggBwu0AGEl35pWIKHkGyCsAC2F2ClBmDjlhZsxD5U6GZWGIDg14WdpoFzOHKiaIRXmBMmIAANwBMPkAGqF2quVFTiZl7nZm7ysU/l1m6I8G7KJgAmZVTEtl6Y8YmbEYrjZ2JS94aq2IxBqG3UZYoW5IGEYAAtwAEGQBMGQAEGUIuLIv9sHbIhZ3dq0BJRkwJAvwgMmOEngNIhFeCLYVNvheBsr8NOAbeP/NiP/khO9lZVUuJX+ph221RXd5WL5uWOenV0pNIhCJBJPUV0h7A4GuKJUxh+TNeKXMhp1yiHbcSBdYiNgoCHKrASFiAC6Kc9+qZau9OQYkd2OoEw9Ehax7Z29UAAE+AkldNcMgcA+chP0LiDvXeEHelxp+iGqTiAQPiFeSEBAkABSiECy7eSnrVx67VZO6d4ueM18LiQvxF5HRIqGbJwIGR0FxlgSkeBziiEIUmEAViA20aU3id1WdcA4VgIHUABIphWPVkfWjl9rOc1JSVvsWeDpiWWgrA/t1f/QHJHHxbCiXbHgvaFiIlYmYf4guIRA41wHBAAAvcHWYUXM0CJWcXmfF5pe9KHmKsAZWbWcXQ5is+4lFnYlKj4lnSohWAVLc9SMDl1ExTQAU1Igyd4kyQohS5mjdlnlNDIlFcol9XokQn1RkHjKLq0U2OnXi9hAak3nJJ4hrP3h4wwSO6HmZqZSJZZMufpHTEAUY5CAEriepi0ScUxAiowHsRJIhCYg2q4lsrZhiAJiiKpm8xJmxrZllDjPdRzARMwAMwmFLP4GHwogeHJfuC5hmxZY9TodAeqoXB2gdJpXSmlVBPATWmDEwbwAT0hAcKpPvx5oX5oof0Jm2zIgxsK/6JI+ZEFipvRCHVOyVcL4FZMojYBoAHdSBQY0ABM6KLHSaFQ+KJSGIjomZnmWaXyRzKcCSYD4CSMyWwBsAKQeBwdgAKDF4niqZ9oCKNO6p8haqMfioUdSmeaFp05Op2aowgkMAIrEYYPwHwyqqbAeKaIkpxtWpQc2Zy1+Zy3KaBwmWA/2ggWsBQaoId+GoVOGqPIdo6MQo8O136UCX/rWUjpiTKhqh08EAM5QANGEAOs2qqo2gPJAQIrIJrf+Sh3dYnnyG4MGYxRIgiUo0+aaEnm5mhCmYqxiaBvWoohmnKLuowDaptXUwMfQANDQAicCQA4UANcMQIq2oC2SKz/xf+OnSpVEfUkvQqWvvCOEceTP8WpO0dsOzUuZjmubFqnALqjjJqb0BqgztqoNvaonUkIGBACR2qVR0eOJEpeuDd9NHdX8Ahr4wp5PccoPweRC+qLFHkIYENw8FmsPHqsHnpbHPqfzKqUPOqccblFy8ebGRKZsPISD+ABJ+CdiMAnzHWrYCcPZROTkkOxsTItNrmf6Sgt9eCu6FRw77lP6yQI7fSPTvu0ULuPNFCdVRUxCABABTFw+narktm0nlUPbLdapdWaiqki7jp9I8WxnKqMthKnhkqKRwmy0Dmyyxp8vzICAoAD7vko1GMhvpgSDaCHZYgIzjJNNztc7CaTg7X/WaypCu4Ba9MTYGgZr1Xrsflqr3I2tzgqt83atv56o9MYJyIAi9qqoBjHOCdBASQgoX4JVEJFVOiImjMTu7vaY49pq6O2MeUJqlYKX6O6PL0bHh3QAigAAde6mFeVlTbxpY1oPKMpM+F6mpdKiZaKpv73n24qsptboyX3aXHLvXWZFwbAARzQouQ6dhgCJaE1AucHGhOKnEI7ifA7gdj7trN5somasiZ7uSjrqAkShqj3ElraIaIGMANbsHuYn+M5to6Lg+pXr7Vlv27Jv/nrv/vbr/qqqEbyAXnIFYqwhGDxvsUZv4B6glJ6SL+rHSlMQlTKu94BAgIwq8RxvIoQ/6bQIcLW+6RNmsMQbIch+33fm6GaC6cka7cwsoh8SRQSoKcqEYYYQDU4vMDGKb8jTL+FCoD3S8FuG75zSreYa8RCApWxSBM1MAIyUAhnvAM7UCZRTChTXMKAuLtXGrx6V6qQ5B0dIAAhEJrF0XCJ8BwuUKZtPKgkXJodYljESLs8TKMZKqcmR8R1i8UTjME9GodlkoQcMLMmsQFHMLSv9D2pIQJK+nLHuYubKK6CGaiu0qsQIzFfx1qEaq/ZC8SIusUgt2W1XMSS7BcG4AFjmBMQQAE1QLW6VJ0f9RgPgJfi+KfR4jXH2I5hWZHrSghB88pRdsKi2sJz7MK+mx0QEP8CAuACnpkCxru38BlNLskcY2rDynFoDYu45Bax1OuQFVsfq5kW4talOse2tPbF/XyoBqrLsjnJnpvB+msbp0epN5EB5qugGoMAAKMUfGqw27QT6cY9qJx7PDtcFomuItKQQ5tUlFNPGXuRZ6dcb2e5lAyyjuy9uRzJAw26yurPMe0UMFyVTUEBZGgIQYXOyssVENAAKknRyLgTW1qaC0s2cUUPXvOTABC0aSoIgZI7GS2YBFkBHZVvKl3QNL2cAI2/tsyKtBzQMI2sVYGHSQwUJCC48CE5xsxcOREClErUpemrZ8dcvyiTaOnR7aGYFFWMR+uSfWJ7A9CSTRu1iJ3/2IqtKTRgq0eNu/uUtWk5rNwjACDltRV5V7cLzenqwIDJ08mbez1Mkre8ZpDc1T+My2SN2nQmxkvqEhKQAVSxCC9BAVJJs4UQlCJ1Npydw5j6ogQJKji7c6NdhWY91mAt0Met2sld1qk9usqsl7LNEy8wA4Vg3TKRAXw5uJV4Ff5ytqk8vaqsYuZImv6jAOJKnp+6zeztgnbMQsQzvPYnpjJ8HLI6HSPQvOdxCC47tBOwsOE9vxVavVK8e/W7y8kaxAde2l28vULMFB1Avn3aFBugAa/tE7Y9JhKAl6xbq+Jdu38q4Bi64Mtt2jPNuRfM1f37r0OxAds44UjxjXlp/xIkkMRbMQIc3uGC6saF/OGLPJTgW9Pae9oozq8qXsEsPhMA/MQwIePb2r4x8gAEmxeD/JJv3Id7Jsfd/N4ptMIsTMcB8M0CMALjXKbGMQJ7DB1jysfO6+Ei/ts7XOBWLMsSLNMKfsUM/sgnHuRfBsASoBQ6zRMbfuFI6AE7TeUKzONR7eNyfr14XuINTuR8HrpDvucPrhIczNaEsAIwjhQPYKTDFLN9ehdVLr3R/Ftnx158/ZLYDENe/h1c3uXzB8P1XRwgwM7EMaZmfqqu6qoHsAQ5EAPfkX+7GL2rbii8GkvKdcy9TchzHsEIXul3TudcrOfTDu30A8NpXdt/jv8Sou4UtB3Cq9fMCQu7zb4L6hqPSsVUYvuaQN7I3ftxzc3a8f6s97rioGsUaC0Ta80VHWDoPEEPMtPfUa7JTvjOdGVXiPt48+xzP/vTEH3sasnIJJ7aJn7tPjzEll7xO4GHILASEqDQ2YgCnZ4TjwKR7DgVUFkCpPyEGw1acJHeDJwKSh3S8qCT7L42bZNO/HUhFqfehBjrjiT0krV3K8CIyDECZD7OuD4cx+snLSsP+9QceJvm7ayxFq1uhaOzSz0PuaPwaCdYAx4wY9lRzG5U5ugkW7JJf0ncFP/oFh/pGw/3Go/xxQcAUHl+OTECq+uNQr0VFzAtsCcYYjzjaWH/Ic8WMdHkxwwvu+Nl7rp66ohQKqpebgQJURBJM/zMdCxd75+LrEWOr5SM72+ah7DYjTchAR/fxIEbI1BfCAQ5ladfqZOtcTiX1eYlk8Z+7sg+Q/Y4CMEdVAygSQe32MZ//MhvEY09UU7iLwmgvhw0ENoUlJi4ItOC2QT+0d9JkBzbkm7/7hXf0vKuxcod99b+0vQ+CIVPExiw3YUQ1HM9Fa8PAAXcEw/w4t6aqYPAeHgNCACCAAICg4eIiYmFio2Oj5CRkoKMk4+ViAgEggQDBwAXDIiYggGIpoeog6qUqaevrrGrsKW0rbK1uACsrLu2vrqGuL3Ev8XDo8bKs7rH/8yDws/A0tO51M7TEoUGrg8Z1gAGIRLNltMPHC0PsdGIC9EDFQAFAxGKpOaH+Pn8/ZL7/fC9K6RAEIJCDAqMaletITZC5SJes/WQ4UNsF5dBo6gRnEOO+jp+nCjRo8WSI0lKQ6WtgUVvzww0GCESEip0HDrAYmiwkAAHABYMKCTvHk9+AP0pXUrpKFKnkwoFmEq1qtWrWAMIyMq1q9evWLeCHUuWrNiyaNNWPau2bVm2buNeHSEgBAS4HVZghRBixFgQIMh2aNGiA1eo+ZKaU8y08WLElhhHwpcxGMrKKlPeyqwZs8deJzl77pzsMkjRv0J/Fuk5QEtu7R6sgPWB3P9FChRWp8K57hjkyL8nB3dMvJHkqMONq9ZNrd3o5yiXa64G3TIy09hNsj7NvDvE66izA6DbgNt3AN6KUSA3HURu7x04cFg3Mjmk48KL609s3xF+/3DJpZWABGYVYIEFHoigXAouGFeDDn5Fl11UiZVXViD4BRZgghFmmFf9AdjYf/vtR+IlIeoj3WjObSdeRS6uFKN24HlXHY3hySheQ8vdaKMg2oRgXiswNQQCe8zhxgst6KgTUYpGjQhliUsBRIBPmxzAQCEIJLDIlISsKFKLO7aW2ozUoQkad9P5uGaZcFqnY44/WiBAAxCMUmQ1FNAUEW5pxqJNTsuAqWIiBwn/MMACQSlAVJRURqrcIxEIkEAFohwwAFALVSlmdHHSCWOobY7Jpo+khUQqqm/O+eNlFNxpAGjfMGOABhJkBGigswz6QGWGQgMVpgAwIE+ln3Qq6bKHOkJAQQ4o4EACAyikrD9SLQhhhGhty+1b3xLobbhgjRsuCAKAAMFcB/Kl4VcgqGDVDzPUa++9L7zww1vEKTbBBaAktIACXl7L7LI+FfLCIQcUwqiWFwwwwSAwJAwmZWiSSWepnH2aGaulucqxqCG/KjKqPappS6zvZRPrKTKx99CRuthUaL8JLyyIAwIo8MkCDFwgwCYUJ3zwwYwVIMABExSFQFHNYuuxdxqb/2z1qBsvSep54IBcUqtW8xo22GKPnGS6gubGEAQNIOmMTH4+c2UhAM8N8KvBNuVsQfUAQK09Bh9NJUAIMFppAROIkoCxX3rqoLnkHhY5g5O7BXnlV11eIF/pYjWCXgNS5S5Yo2MVAwAE3O23ABFoao9XfH2Yd5iIaPlJBQMAEM88fQcuuIlHzT00AFpyWXDUhzBANM8+FYS82TxubaacY0tfctleizx1qllfr3X3qcgkgAXUSYBkNHArE3NKczNwQKUGEX1MzKg4Bb8gjvrEaeAJTEAQo0J5VON+F6kTiegQAyHaIf4VOJRZ72tnWpXKVHWyCWrPgtDDWtcwCAC2Cf9AZocYAZK+Qz9jrG86i6sAzwxyt2Ksr36KSFQilJYs3z2FgAXMG+EUKIh31FBvW6taBjuiwSGCrzmn4uD3NlO9I+Jog6R6QAs++Iw+JeOFv2Cb236BOgTcTxOfOSEMFfEORKnOhvzB4eB06BMYHAKMyYMaAF5gsTra8Y54zKMe98jHPvrxj4AMpCAHSchCGvKQiEykH2kAAAQUYHEESADrXBcmQbqxhwyJgCcOQUejMcWAavwHG2PIQwcM4HjC4qAQswdFJEowiEl84BON2ERXVhA7IpCPTlyRgd6MwgP0SckDNGACjVQAIV6aGwKk8QAUBBMYTinjIRTAQzQ+JpT/wHPMDgeRAGpCyolcYyX3ZukmVcYSnEvkGi3XGb0aDVEbwOwFBD5AH1Y8QADPPMYD4lmTR6hin7tkRjTb0QlUWhM42NQPKL+JSYJwgmBGeRzm1KK5iU6lohPFaEYjV4K6rMsqEGDBh6xiAhSMqwMoGCnskAADIMjgpTCNqQyqYoIQqNQqR0nUT/w2gGoeFDkJLc5CByg1c6KTiBF0ojhTJstWMnGdSz2nd9ClAfOoYgMUyBMzJFCeFe2znll0iW2UwVVu+AZnUgoqWtOqFIztaJVKBNUrwcnUo7pzexgx6i1VcisBtAwYw5yVK8qqzl64QAPBxIY4qNgmwtZnrZ5S/6s2g4elHm7pKEMFIl2bOs52KlWvTmVnXilYS9F6L07iK8ErvGHWVJCgPE9lhQSEJBF0MHY6JagqSWa3j0QtihNDWSZRJdtWxFQqAQ0740/vo1HJWRRcz4VudMs1XbNEaDACeFdVRhAYrHCoQlwZAYXAMpgWmIAs3/0Kb4clCp7tb7jEDQhingWACgh3UsUFrThHa8vSRtWd+6UeVEGLPWPkkgMYaIgKSCALCoDgtACwwAcEWw4MyOdXElHSzSbrCAYqD0XxjawiGiYARiFgKAJwH3zTCEu7fiyp/iVwOgPc3wG3eK8eoQswwWFFV8iEBGQzxa4u4qtqnO4QR8YBTf+ABdlD8MxnhEDxfZ8X4sf4RGeHoOEEiBY0QVTMk1KTaHXVO2bqlrkrza1cmq2CrvFWBQIguOlUSofTq6RXQh6typFtYhacXRkR9P2tpvb35cyGmHCGE0ABCMAALzFuuSC+sWkhKOBySrrATQ3yjP6LY2AY4APpGpIvPu3LQ3TAAyJ4ogFSwODMZEBWckNmI/XHHANkYJfrrZ2KcQcABlIS0lVm6CCERzT/CaBLK76mpGncabxKFXp1LW1nnQ3gjD3bFBtwSQaIEVhwNDOxIUtfhgXAAlGr4gIL6OYmEPDekZRQnfk9RP/+R7zLyjGVwb4hW4u67LhWm7Q23uy/Xez/2RhfesansO1YD+GCDAxJFVw9gXWGKYKMfNqvDynWurk0kWwvPNefnF1QDY1vRHxYEAdIFKNUJOYzG8jlaIb5y2UelrjQpTCeK0FWSuDml6NUzlnhHOhMNwgHNHoQ9HgdVn6O00bcD7jHxq+I863skLujEApUwNHh60CCd1bTL5IxZ/kb202L3dV32sAzMpCrVww5GCJoAFh10QGxdsfoP2yk/BDhArkLNIaYcG+kp051oO77jUTTpEFLLm24ZhrGAW/8tTEIdpIdPCIXL7eP6dkQtpEvtLDujhQ5sEVZhKJgWkoAPVYuW9r+nYzROPkBCV/4/EipEJeMH9QVtfI5/yry98APvvCHT/ziG//4yE8YI/N37AQk6m6EzL00o8zxQXTSJ4evPXM5jCiiEUC4FXAe49npeIIX0dIC7zQrK3+1s39G4Q0xgcOfgQEPBLSVuPkUPO8/HZsZAFBnBXuDIGibImzypX2GZ3XdJwj0oBDE8jxdJ23TU2PoJ3kDJ4GVZnaXRw10MR/gQAKqJSgNsAF59WOF9QqvVh4ZUQOTEABidAgGoFUDNQi+1jvANngIiIPxNggD0TOcgBDWMn4ROGkvloFht4EYSGkbMVcW6CopqHbWwHbqMWGdMUzsIR0QECtUSGR+9xB1l2rWMEwyCHiFABTFIwD3Nn4HmIPbl/99/NFyNAdecVhncyiHdXhRpJMC5PZRbyZSe5ECQ+cVTIeHXME53QUW4pV3jVBSQOcCgQhytMeGyUZsg3AACjBlalh1TUiE3XF+Gph+ocVsBRd55McRD+ASFsBtulUNDzAOEjFbUFh2gnCKAtBq3eFgQ6Ipw0Y3goAnr0ACnzdGbuhbvfcOPkU7kjh7inBcfrMlmKhZawiKoohpS/hZSMiJ00Z57rcLB7ZwgzACf6UKImB/y5ABGqBV1ZgLOBE3unEr21Z0lSBJrdM3FLYKbPd6bjgID0gPw5NsyQiNiUBfxXIBF/CMyBhm2nKHhKiQa0YuDemQXaECApBS3qVdVcH/c3zYFXB2iGvhOQKAc2BxAn1BFUfWMILwRZtwFSEFdJCYCDUYLcdIcsSVFCRmYstUkAaoiaXodWQ3ihW4k+qnjQD3k0PoabECW7lAasTwae/xECfQNuT0hG3yVeBgkgCwQo3UQoPwABQgcezQZPDoM5a4Cd7kj/9oMViGdEtjMcJVaIbmVhtTfklINUIJitQ4lz75iZs4ai7xYN2whYhQd6XHTCiQYKqGLlQ4HSPgd1UpDCiZCxjgcAF4ewoDaNJiMQrklv8odW+UaEGIk2YpSvrlb81Wl3uJcI83lHoJlKWgcMQgAbVSDSLgTK/YAPfXKuITjrZgASlgbgwjDPL4/2umAIzgkAEh2JL1dju5MwhleYO1ZyWVNQig6ZxfAodz+JDhgp3cop3baRU3d15XsQIWSRUY+RcskJE1FwDYNZ5BxwIcqWdXSWvKVAoBIJ4qGQICADrIOW8903sA0JxUtpkHGYk6OYTTiJrpSIpFiaB4yX5mw2kAcJRQqAqfxn+mwJRtcivBaBkSIB8YkBEe13+OYAAskE/owQG1KIwKSKCbKZMDqm/SSJqhCGGWZ5cMyokOOoEW2Fcg8HCzWFXcBpXTIZjak4Kldg37ZJgZ5wjneAodimDQBJbRKKCZCKPJk3U+gYnZgiDcaZ3XqZChw5DqaVI6NxfvSRXiBXSeY/9TY3EXApAC6BlebNoVe/ZGtIYVK1AXN2U/0cA8DpOTLEalVRqoDZV17SaE1saTz0ZtQSlXjWqNCUqUGXNgqcYL6yENGaB5KpEBH4COrUSLsakZmeqbNTMI7EYLfZWYUYoogSd+nMlvggqQsIp4zIkQeQeXYSOXOAp5kvpWk8eEJ3iEdCUAOzYNJGqi4dAAqag+ypoqFoarnqYB79gMBjBCplp9gOUBAhCC+Hh18Ih1rzqlguqi2yRvDDAxEJioePl1NNp+13igRlijtfR/ArCKgNWpr1B/lWoM+tqJAEACAjAfYmKF0/GU1pplvWMKT1pxO9EI0wePQRighDqubIT/e7QKaPd1fcm3sRzbsR77sSAbsoTESI4ARtHHg5jVexobLC6qVuSaU0SzAF0CSQ2krtjYkzmKVO8qo2XDqDNqGgq3NvdYDSSqm7LwaT0qERuAny0jHSWAlCnxWp7KMI22euGAn4k5md4qCBMAFKa0eC8qrlT6slfnUGeIbOnqq4p6gcEqr6x5l7uqmsI6NoOSYO2wASX6DKfIjiNxim0XEbl0W22LtOrzAbnRC9z0fIKAorb4WKxahqhTCAUIqDo5tpQFrgVwWcolq4/hpTTXpZ4rc6AbF3kaAiewkCZwnmuqpnORAqx7FR1FkR25dCP5FR1Qu1NRp45gXmOBnLPG/3tXiWKHGrYCyhjH5QDyoDQRy7kI1W9j56gGZ6PPe1emOTIXp6rCQALfwAv/B5i6kIVZm0WgBqSnFXdH6hEuUKwN8Qj1qBu+q4+ioEKos5zUSXWMIZCCIEnLS7zNG6PTS5fAuqD/C3rVWxnZlp+jYGtgyApPaYvY0IqN+8AmVStBZo5WtZu9Wapcy4t4I6U0eEaaRLnJSJN/aqppyL8JuInw2jEFbLNwu37t+qDb4ZqjQAHgJgizaZjMwVUWSgva0AJgWHCrFqrzI63c9nkmdwDK28HchwhPVkOWCDj1m29oOUNL04xn5JYX06WjmyBgGqZ12MVkcXNyZgICEKf1Cf+npAMCqrvGdXG6zqWeIeAC5DXHWOGIishNirYLfTZZf3YIAkkP7aaZscq5hQMAhyMUw8u8KcyaKwzAkHqaA9yzLawLeTqC1gCMFuGOU9kArXYRtEgB7fsmr4VhzVDKxakCkECQ4YGctlNfufMs+zuoI3y5wyM0PrG5b+mzBffI08HLN8oivxrJbeuufAVqqnqhGZBqDGECqOYdKqC+DzEC8gFCzfF/oqwZBuAePhoO9IS4hzCdHLOfxqYAjMJ8OzXFwUa2xRW6MCfG4gKm8MwVIpmfV3ECcbaQAaACpks67onGe9Fmr7sWISAvtlvQWJG6fKi7WJwKfZyPE2u5TSz/rgbKszcKzJwVbTcbr8a8GjR8CCaQzbfAlJ6qT21TGfsUajWiDci6VXJHDBaAxOBMPAmzd0/iwRFdvKO0gyps0dCroC4czNWL0aJRZKwAgsngtwWGyhkBsBzAsNfRvSvSva01CCSqw76gBC24YRBduTo90VbqyD7NwgEc1JOcTkTtHR2FydMghaPAVXPnERAgrRf8vaCGyXl1igwmHQ1Mf/iaChlAspHAZGAttl+dj7LXE9WZkGIqz45dOXD2pui5kmHRxl5RUnQ8FiYwRYHoFWmqz1fhAigAnlZRAmVaFfXMBDGw2qzd2qzNL8vIEMYYrmEt0dmXQOG8D9AqzGtb/5plrbaPGr2y6LaoID5+uQoPEL6CID6nYQEN4JWb+pFY/TYggL2wYGtNGj4foKSDELgOPEE5RQr8eIwo3L+xys6ZoECYciVcZ7O+7Ilz+7ZCDaxp/REf/Y1GW38YkDLZRj4g6hJ/TRKnqMqqqdfxl8zhECvkaFcziHKbAqAS69UtWrECkHt691AHgJWCsLIi2+Ee/uEgHuIi/rHSJwxj+Z88tLJdXcuFfeH/aTE1C9wbzbb1DaEvPNTVK5HFWtzfjAjzJNKqYQArYK+KxQJ3Etdy/QHem47bjOAAsAE9fggqUM0/28oOKwx+Cq6h2ci2vaIXC4/tLePvzaurKcC9Tf/ATHiUPsqVamdPrhips9gABK4Sz0rEtoABb+5Z+zTntSAC2Uyhd33DSdjg00TeMtmyI2fLRKO48NWDrqrhiCrmYw3Jwi3fZ83RMpysaJMKIjB/0xB3/HcScG1xr8YBxSQRzg3d7VTK8pQB3w0AzzobbEvYmUBrzGnoPEGM9Qa5W86Gxmspz4JcNkjLwuHOLjfPlNPYC4JSAmDQVaECp10VK6DGdCg6LGDZgoif2N4VIhntBgIBgBinHZDPpf2RpB057ysIxDIBE8OM6lxl91sQTaN77/6iFT3A8E3cZn3mlLwqC2usGcC3LiitT9SKg+kRHUV6NvJa3N0cz5zJ0zr/CE9Zr1Ud3I7b1QzUOyXW6wczFJwyFHfjKJu7EH+Mcn8KRwhwN1pMe/d+5vne0ZbO72iNQWs9d0oZmELqWa91m7SwARpQr7FY5CLNK7YmALE4ah+wr4NAAlP06havtZ5S8k9MCCuXzgBAyI4wED8DuSS2yJZwEAAzEAXR9W3YCFrmND61y8Z+Zsj+II8tICEl2VbRAdS+XXP6cuCuLmMxAlPk7V0h2pmd7R0V2tse93efUTiNOnwDOBu/XB4fuQIAMMyTx+ZwJQUhPAeg9WXfmYisaMH+axEums7r8mQe32a+rj2J0Qcs66sAm2uX3c3Rr9hzcS+tPhRAvsiAyu1g/wAlEMGwjqIR769x4sq7ljvs3vmLdxxg/7uX74NM8Q65cxAefyUGaUOU+Lsjv8ujie+lr+8yfuP0rSbP+reDsAIjdKEEXxFsXTYuAPwV/xkY4MndcQJ0vRnJzX8QUOoJpqNGBAgCAIOEhYaHhgKChQkTigoLAAcMig6IioiGBAIIAAOfAgcIAgSZppkDAgufmxejpacAmLG0sou1l7eDAYa8hb6EwIO6wgDFx73Jv8vMhLrGysHR0M2709TO08jV2NbcwsXP29KFJQIcD9gGFCa9Dw0S3uQABhrizQYZAh4Y8/L0KzRs8IdNBAoRhRZZyNDtQQgBHwz869Zt3MRtz/9w5dJoatapBQIGgEQwykGqSBwzjaKE4IAABSdpeUyZKCNHRQFy6tzJs6fPAAJ+Ch1KtKjPoEaTKlWKdKnTpzubPoXAQkAKCDw7gDjRc0SIDkVNoHAhVahYASywGhWrwijVtDwFnGBhoqe5FiOg6hVqk6YtvzVrpaJEwIEASgMAH9pUCYACRYll9k05k2ZlixTDfbuG2SLme5urdeacSBvp0ATBlUbt7Z2AFctEZJAoLEMKiakBWGgwELQ1C+dEjNbd4EFnDB7ihZstbUMDARpOnPY3PLcsxYGx/6U1StEBl4o6aR8E0juAC+FrVQa8/qbvi9eITYfP+vP8zKzxc3v/X52+9Ynv4ScBBxxIAI4FJJBTTwaYQaABQ8NM08FzGtDG2TsW+AeQQPJs8IE4JHAgQIL9VXQfRuMNM5lG7S32yCCPkZLiIKkoMIhhMkqWYnsMwJJAKocdUNNeP5VF5JFHIakkX0s2GZVTEIAgwFc8RVlXViHkRZRYLjz5kwoCtNBWUiVQGVYIY/LkAggQSHVCClOC5eSRfUVwC2M5HtKie7WUd8Eg6Kkyo3Z78llIebAUwkAF2f2n4XWO6hepavudaFp+9olmKaaVsuaQABTg5ssDFEj3iwTF+bebqdkss4E9IQz03zslkJaPQOCsgxCkAAwoQIaTXhosMzZ1d4id/wlsROiKgzar7LKIIJDoIAkoYElCAZYoH6fcPprtfCVmSt2mwwI43YAtxCONbAYUExBu+C1IkTgiiGjBaPkUd1wDCXbjwgeyXmfAhw10QO4/4SrTF0iL2fisYoU6K7EzzOLSnrSFoCcetgfP2+2jnsXXMaXlmqvpx5IivFpu6whQcC8Z9AtMPbB9g9yumhFiQFUepHOcB8BaZEBAAfuyjgqJ1CvAbAmfXDI1C+sCHkp6VqzjxFhnErHFiggAQyEYGzLBn4O80PXZaKet9tpst+3223DHLffcdNdt991456333nz37ffcX5OXUQGhEGL22eNtnfWg7ZnU2CThJdso2P+wODDBIAxczjHKOYM8cn7f1vd5QsJ6/nHnE5nDAc6EYPABBMug6nM0A4Mgcj7nuIAaBg0gvdk6uBoCAQUyE6I0c6Y72jQ5UROCQCR2FvDwIBU8Iv0CMTJa9eLcU4xIBZYQkFgFDEgywLWbE1LeSwAUQEmQk6cs/7ZP9ydu8ipzvnL+9YO7PzbOgU7RBmGBDIGDAhGhzzsMFB/XRIRk1rjVBjojAg8Uz3ggGKCH9hG6ki3PG8XqWvi6Nq30EWIC0pvA5RYFADsJKX7dm1ihIpAYB1jrR9KDoXvmZKQ5EamHPtwLEIP4FCCqoAUCSJNOqHKlnZwgBCUoilfkRBRFiCn/KSZAk1tYABeenAAEXeLJEV/TJiLycEZ7qsDlLsCAAmBPciaMYSwClSfJdO0FhjiAAiIgCQZcYACaAwAM0Iady3SMfviTHwQ9pr/+dWpcjVTe/wLwKpcZxxAmSKA3KtgObgwvVP6pJG8gOQgDgIBD/iGBB3S3DBKAEhgbgFMD+sGrRIaskVZTz9nwqL4BCGkBfqzjILumEVE8An2DeoVj6niKFhXgfIOYgPYQoL04UqaD3ook/u6nyNJ185H8s6X/SFcIFdjrHxmo1TJ2065pOKRf9FEaf4znAd/l5lVMM8QJKLAraoToV+R0JCnFWctC2sSGORwAH3/ERx0iolqq/yCcAHI4o/IkS2NcQwQBFEDRCZQvASx0aEa1WcsPfjOb2jQp6kxE0lu2CgCiTEdrPnDJQjgIQuNAlcG+0bKezXNgAOuMBfjxDwusAF7GcM3LAkrQgZ4UhGjMCAIYAMcBMOqZDbVmJjZRvmWWUDt2QltXr2aIGFUCcpyAo/cgNkS9tNWMSXkrXI0i17kOBSljjGJPVFACteyES0VZwVWK0gEUCIBNQCGKC8ayFhTolScmAEETcwKBuyhRJ3W1a1FySdZBgKdrB1iFIqqp1e+ljbTjKc8LDQUtto7upU+N7SJX+kGVTrKl43RGTItxgg/0Exir4mkDgjYN4KwOtupggf8m9XMrVu3CAAWUB3IEaDKBhlO2EdoRZzuSy004DGuU0BwByNZZ15rXuiV9rYa4WVv1FnS27l1k14iLQaTyQl6LNAFR6VMPqwTsvYOoICtzU0ESGeJfA2wZBwbMSPTCl1vbbWaEp2eKH+XoAl8dT/Ugg0wJa9egPNSsW0U8YhIrpQMPSQFXqgRGnyw2jEMp04qH4gIkPhazPXmLX4Xypi46kQUw1skIkIjYu5pYiFFNHGcP4AhFtFGO5WXPhONoUkRiV3TgvHJTq3td22oKdyJKhgheWYihVQiSC2qQPoi60hF4gHXVsEAIaOmNhbSTEA+A037lG1/cFvS8gIaysxT/F2XWbjm9fnYqbQ/mZeQ+2MG/mC7AntHb3+K5nqZ5B0Is8ilNdu5VLIDXNnhnAdhF+gO0NBpwAOpUbD7Vy1OmsGViLehCz9qg7rVyo7t829Pl2pu7Tm5wsjsIEoDAvgTUlzZIkCpJoUtdJlOlcHiaAQ3MTmcggCc0Kggd57LU0eqFdZJbW+tB01qrPaJWd6g6JCdl9sg5eTe8EztvngyZjDgOgFYmqxMU3/gnVCmyUKgSpyr2eMc/Wexlc6ICgefkTQJgrFPkXW+gZMJOhHCcADq8VlyX29wfPpQiYCGKBFSrhIZEma77HClXu/TQ80z0LirpgU5mw84UKUGz9YOc/xFcyANLuzNB9mHpeYAa2a7rx8xWbQFRedPluSVoCG8BPgCIT2vnVtHHTSFRiuoSERq/FjDbc7GvppvKh5R5ytjL6F877dDFMOevhD4Mms6DVqTZzQSvAabjSmpgAkA2OXaDgWJAIAPAoga3UyDT9fbauuJGBMMMQUOsH2LDHB2E+Dgha64rwuvN6rqhCVH1q7uEvFVTROAGETZCEGCsADjc32ZP+9rb/va4z73ud8/7vq1+8oTQY1ZjT0ixpfByhuF4x2sh+q13fhCVr8DGZN3687A7flVW+8sbvOVgxxzSujmHOr0hAQpsQBzIoa8/DFJ0cmBAROO/CFAl4hszN/9+VPwUhgHMMfdXP777o9M8hPBMyqd1maBGAHB2lud8h5AAnzd6hSB8AIAAQMIAq7V8zkNyfrSA6LVyMsd2vkZS3wd3rhE8wbAB/ERsGzJAzHArpgYfxlV41+ACbwZuAFBB9vRciGchAQZ0qOR/TKVlvAZhmQB8GwV6DrUKQhIS6bE9GuGAE4U1UIiEEnZHhUCA0QQLGyhIxac+XWMjOPIi2BJiFVdFZbhZJmZZOVYCK+BXTaFwRlFYC9cTEDdYQxEldhhvdJgCPiZkLDBjDwcnErckFFdvU7dxyyRCuWCFN5J5nhAJBwBNgzBMhEYtDzgxUwiBVueIVsduIVVaI9X/gdoHbP8HhKL4dlpWgiyIARSwU9nwKg/EGbshUxAkAkiUeKPGLyulAg0AZzBFAQwGAIenCE3XXkG4a5GnZIcwVXA0NuYzfAaIC5mIiZcYioVgVojYZAigVtHoFyn3NB4IfigFeW6naJtiXDloDOtgYAkxVKnmTiGQeCyFOyjQePhRbQPROe9wVNIAXflECBKARKhkjDZIjrg0bsGHNt/xPqjVjbQwjRIDkV+njIGWfeLoeFlGkDBHiphSSSZICCoASt2AAaymKh7giirjQC84EROCi6UBXcoWDGNGi4OAAfaAAnQmhIuWUgGIkIEWCxLZLEEZC5XoYWxFhmdYJElp/2RmlFc9sW8+MRdwEoch0IZFcUR4URRlQkVHkUX/FgBzoSVLJCUt8JVIuZR84ZNSxhFDOSNtyV0ht5YiOIqouJMeVI5D+B+At3O+YGeqsRsIkS2z6B87Y0n0gU8r2Q0GQF11VmqGIHfmJ4TfpoKS+Wimk3UY6I3b9ZZbV5RwWZFpd5FrJzI8OZd1eRpKUzPB4Do0SQj61XSUKQwYgALyOGoiAiHwIQFsFg3c1gtJhw3TNUsXaZcAeJBx+ZMMKJfkpplniZb55pxxMScQsAIRx2+VZZZSCYhANJ0qZhTU2QL8lmNchHBVMp5SMZ2XNRdhModmVIjzhpkOqZnJeZzIyf8iUAdOwbZ9xGmKG3ma3DAhEMGDAMCK3sYLgLlouqkc1wCgsVgNGBAC0JYZFbQrt+BKzhUAFnCbdFeZGRluPUmf8jmfy1mf1iiZ4Qh3oOOhpmmO1UACLVAg/RgzFPGaAkqZHaABImkRxnVB81BtBVoIsbRcgkAqm9Y6hmVtKIqK9ylJxkmRHieiJKqJ9omX+cmRBblNeDmZzPUhIWCPASACACMPA5MCLPhS+TBnoRFAZJobGCIpqhSMvwKb0LBB6UKXXMah4Aef2/GkUBqiI3pNzQmd7klig/pXhrUCVVICc6gCg6iUATACKMCee2VjV4kCXLmHDhcAJiAAl1oCSGT/lRVXqCamp575fH1qa9eECArYQjbxjYl0ong6jsV5iiwaDMZVpDVZKu7QAMwhXw+AozVKESdgD6kCQQaQAsiTGcz2jvRAPLowm9BxbaLJZx/4ocfyDKsqUlMKpRFACQrwGA3JgYUQdsGnANOHgYjiPGS3pFxWpf55pfxpolZKD3ByZtCQDwZUZivAl9WwmEiqIUxHSgI2DbGUrLxQfr0xCHQKbe7aaiyXpFPnhcxkTZhHUSCRYZW4ee8DjdphYZZACeEqa6UXGSDFeannNZQjcoYge73Xsi77sjAbszI7szSLsoJjCNVHfIhjfACgQoPwTBO7p7FgJ74EhRyLHZsQ/xkgW6KUp7QX4ArUNy3Ah3YqZ6d5GZttt6JDaFw2NwglgJv3+gEfqTIiMFyLyRlgRgKewTs8ag2wSHcWUAJIxUFIapmxyn13m4yGMLUTmGHxSXqXE4k2hLG55AidYLTNUj1dtbS6xIjlykckcR4bQ4llp7JOSKt3O5odGoKYq6UB0F8VAksf0LXGoJu++A83GpkAVgguICJhOg5mVqa7MKEzJYOl9CEwerV5W4oaeWUCmIHc5bgAoIR6VAoKMC2UiwtLi7iD4l2YIwAhe7mGgIWf1YRaVX1865AWmaRMOnQq2rn5dU7UUH50F6SipgzrkAI56Rs0R2fb8ACY1q/Kdf++BcSD/xR478q9eIuM1rq3z5CzWoVQABCGIye9p+AIf8K8MyJRCwBR0atDR3gIUGvA6+Mw3YGIY+hu0BmdG+wlRgEm4LkTURJkDBcC4ekTZSKWzynC/NdXWmkmCdeomsoCXIliU7KpHbzCORxv0aKIFSyurHd910i4uOBdCVAeR4sdjoMAj+G3BgwjZ4M+E6yt5bW9maufvBt18noygBcCSJVJGvQgG1oMNAibtOUrY0sRLQkf8zcz6aSv59AvI3jFm2uQjkSqz1C9hQMjRIwLG9ZkVOMsQEuFprqtytmf+qu53lua4LsM8Ls0whC3vbCsoaQBLCC7tYQBena66iD/Z/fXC7RLDawJDNwWplg7rU/3sHiKx06qEc7rLO9zGElcyEy7Qxq8w6JqV281ZC0QZHPBb2+SqTm2AiZshmBJlmbZE155hyDQnUtUAjdGcDKcy3BFzZrFyn+aCVAYHheYnKVKy0aJuQ2ru+zquaHpD1LSbLwwZgI6sN+gm20bDtClCBSQmMcgQd/GO+loAqprDP/0j1c6zlpazlhMhCB6a6fqp3yK0OKsyuZ8jFnbyPTwHCIpjDIaQR/QoP6gyQa7HyLCIZhBg/CkGhK0dDkYSy7DrAHt0NQ6nP270ArNgBI1y5+ZzYaMyHScv6t7l1oLDe+XRIXwACDgpaG8DbeC/5Lfppsp/R9HJxps6w2suHcERIx1nNMOW61NatNS6iICwI2DMtMMDdO23CTWTERlbdZ7FSaTNQKgSlmCRZ72hgIqPBQmIIh1VVkocMJLJFiAiJ47YcPOzCS4vMNxoZYxbQqM4dULrAg0DcSHHNZbnMgFDa/2g5em5DIWkg8KWpO9s6BirCHDeg5Nly1lq36bFL+EgGCEMIwcwI6LXKv6u5+92zTYLNYapQiKnSISdQGPsY21DNmpqrUCbbcErXa3EEAUEAyk0pqzCLtylpPbgILEiBvvkWf9fM8ZLdXNmoPQasogKNmpjNV3bNjAvVUjpwiop9sF/BjpXdPjCiSW4P8+6A3O3BWoznnWQYQUJoBEKszWO/ZEyawTWSSpLKwIW+HBLJYCei1kMuwCf7jXYULCxpzD+N2ehl2xAwzf9M0YBSBRBQgYYD0KgUSUNjGyA3xVUahDCsgYQqy952zV5Py9G0kC51BT+eBzhTACwil/YpuP11ACH11T4LYbm210GnBswbCO1qA0r3MfczzOsh3RUndxt4BWBbgeKNSzl2PiT2zeXe0JQasYYO0IIx7OiFB5hOCASFgZ6do+UfiJLl61qKzTxS2aoILZ0LDcM/MBocYNbtZ+8qDUO95mZksf7igMI1DREPAhu5miOs2/EM3IU76MHuGzyPJ8CEgIaE7/xa6H22DuxH4x5gJQ5sGrCLz0uGBTTZRbLLDwepp3rq4aW7AK6a89q1t2fqAik2Q2oPAwDq+C5LnBO/uA49XFO8B+EennDR7CYAEZdK86r7sb6XY86YcAfAo1DIFMMcKrhKhOCMlbC4n96aHH2D076r+NhdSyhSe7en376pr3XSxbs/I+7/Re7/Z+77T3e7cgKLKAPvEOdpyI7l1+21+eCqBOE6JO6o69iRYriVGreV1FALBe57A13I4+7VdG42FWShqAksOKm8fwDr1KOxSgCMgjXxqgASrtDTAZjPz8jhn6K1b80C4t7bbuu0V4C9cuC9ken8zoepw48FydLAYP/6XtgY0OQEcC0N6V6+bSA+dCG9kwTvOnzNP9U/INcLYDqtEGAd2GoHPuqwwxf8lOI91eHzvD1cnxB6B1++JUH+2ULeU4L3m3YOlfbsB6rEdRLPQJbeaB9sNW52TciBO3TOHQCQEPAQJ6yFc88dZC4W9FsVg3bBRfZMJvVdcHvhMjkPkBMJ3rSdaEXeFm3cOP8z5XjpnfnNCpz+l+b8UW33Iy/lQPgETwBCq/1abb0NwECye5axH7lBxVj4KM9wtEuuRAR/YSDd5Kqsp6a9tb3ffuHaVV/OKvL6s6SS4SECZ09gAC8F863prKnfbMpQ/9x18WgAIReg/5wA/6twLyGP/ab+Z90E7rVX/ztE3ewQ39Ny39JA4IAIKCAYOEhgCFhoqDAouIjIePk4ORiZSSjZCbmJeVnJ+TFAINJ4MSGY6CBhQsBqGDJQ0PsIcSHAIapp0BBhYNEpaqgxC/EpkWGbuCFi0CGa+W0qCZgsPV07zUnrXC29m13OLj4JLXiOjphgLn6u7W7e/y8/T16Oz27/j5iOwB/wADChxIMICAgggTKlxI8CDDhxADQgghAAQEgCtGGPzXIYQKhB1LKOyQQgAKEwshlAihsSFAlSg+CnQBAiVAEygEpOgQsafDnkCDbhRKNGg8fvCQ3juqtCkiAgIY8NvnNKlTqtXIbbtWTqv/Nkxdz3UtNxZRBw8CSBAyoIEWAEcSZolTRMIDBnAGUnGwEE6RLw8qOqmqawECIhMUjhHaoEEAh2Bf+26lVjZy1kjeLHvt9q3z26rrmNrDOm+CgAqg30GVmo90U9etxXoOx3X2ZdthbW/eLU5CCw4iBnX48MoaBeLYGEPzKgIXiw3aJHiwYABzv7jUuW2gEHiQgRLsllvXnBus7sqc153HvX6S6NipYbszjTp1ugjs2E0Y/b6efP8/FRVQgAIWOBCBBj60ggAh8PSPCisE1IEAMhGkQgg2FXRCSSi4sNAIIZRwkUIjCCCiQCescCJAKjiTwgkJLoRgjAXOSGOC/QEY/1+OglSQnwAE2IfOalPxKM9/9JCGXla1kdfebeo5aZ42bAnwgWEA5CUCI3HJluUHrnQCngDZgSOCByAUh40g2J1zQgbZXXKmAB6YQNmTTN4ppWRTarInlIAG6omRRxKqDpLo0CdkOkTCh44DA7DjgCAIsHNBOogWiuc4TfLpaaDlfbrbWA80QOYlD1BAiyLHGSDbmVuCggFaGkB3GwYaULBBOcVM98ow24FgqyAmNPbYqJtmlp6oS87VT7J6MsuJoe645qMAChQAwAEMSIopoYou+lRURaZTwaQEDAAAAQokcMAAESxVlZKbdipos+PRBq2oLnBwbCIiUFBcABs0wP/XZ4ZAkEGtWhnwgWMjbHPCB21B6QsKcX62na6M4OpYnGTt6+ey9+KpbMmW4TutkK5NoO0E+8EMAH4JyGtPuOIO0ih/70Sg7gT1IRBkP9SGdqONNwqFdNLgoeBgACVUGIALJwEUYAcxJTSCMxYlBAEIGCoE04pWgwACjACdAAI7ZCcto9s4wn00y0xVsB+81ixgcz045wyAAwIMUDN/+b2AyAEKxCs0pZcCAMOP/ZkmAAKDN+KltFGijDnJnIrsFSs6FeewnYNkkIKaCAPwSweYbFCSXbf5Akw53wGTyQapoH7CKAJwzN6fnfep+fAn87akyu7Rs4ACgU/6beGGLDD/wAFv6f2W847/mM8F5Po9SKUC7KdjOgUM4DzQlA4dmjzs1oxAfZZ7nrrxnoc6vLOPGGAqBYo8QJwiBbOAN5SDP9Xh4mCXwU40OCG7iH0Cd9QBFu90RTz5XY5+wMuXNeSnQQyGIkcDCNICBFC59T0qW4LAW/X2Rg9usUN93ivXkFAoiPa9K15EYwcM1FGBdq2LNQB4AeSGSMQiGvGISEyiEpfIxCY68YlQjKIUp0jFKlrxilik4g7RkQAgpRCHQYQcOhDAgMrJjGYsjKEa44cO5uVnUuBrHNHk4cLAAdEqm8tTHj24JsHUDxEl4gAGCJGYSixsYIZwFXKqUQzHqCUb/9vRAOswUTvFeAIDFBgB6nLBDt/9CXn6Eh4f+Vg8UPZxj4rIEVQCJwAwmnAQB4DcAeqIvVeu8ZaZSpKRZGbLUZ7MlKScTAYxkYoG2MoALHBLllKQAUqU6nIYyAnDyCG74GSjgZCQQCEZIQJjWcBWpgRmKYf5yWeRk3PII1QBBKCtNColl7fckX3gCRXrsRGV5rxfOIWJz1A4TABhAoD/sASAWbmAE794gGzyIoAWBCccLjBYX2R3jEhIAASWLIR0HCMA1O3znBsUpTijFdJ+orM9RuIWAg5VtDnGE5ctdek7mKeAWsLjaHKrUdJOQJEI/WMEPv3HStCGohT4FEE4Af/oiAhCkrMhBCZS+2lNJKKCnMQEAkvL6UOyqlWFcLWrDMkR4MJXwl6+M6YvHR9o4MlSC4I0mH4EaQAegIuKAiADiumFBpo5DhfArqRZWhBwGpaBBtwFFNIpAeogQAIKDPISvsCFByx5QbiaFLAF1OfvRqZZkaKUbvJMqxrZqg+00gt49vLlZvV42UC6BQIfUGYHbJcJVgS0pLOyEiIXIR21aEWBjPAFCx4riN2xQwOk46xqLxu8k761g5X9aD/RalakkFa0Mlyrab8aEe6C9UAxWlAI0NYBFiz1Qk+TUNYEchAILKgFHioISVaw1IGYIAROfUkJVkDUAJhgbQDN0ID/vqs0AgPFuwY+EGi1i90YXretV4mublI7Us9mTrP/DCgq/EIBChD0ECSQizBy+79J5EWSstKAsBKWDHAWtDEVGdY4y/nWC1b4UzO+bIWpe88IN9h7D/7WvCSsGQpzsMjJKtgzFIFXVDXgkYiAwF53uwp2DNZZvdVKJA+7CguseBAj8Oau4qpjt1qYudA9Mpox62MG/zhnQXano5hr5OciGXgdqGsiHOaWAMSlz4YQAQoemgkSqykSJ8gVlQXRq8fS5QNcBsBG97LoHFewxiRdLo7z2VnnYo7HeGzzmxf1HwYMrY6UkzN/cJpgiCB4IFtrgYNIstQVpKC+/3DvrQni/96G2kglYStICVDQEoCMYKrGtuoIcJ2QVyfY2QSGdqtB/ZZ4vMt6y2MH/Ko7alFH74U9ksq7bFrtIZu505cO5eYswCC3XNQ7DSjBJkrFF2kYWjYYMFg2sPPhixIXACNAy2SRdWFNG7y5p0Q3wZV744OncsGGWKX1GIAa/FBPpt0ObToW97eaJmAA7eS2WhVe5zWLisihGIUGsIRXRcwqVosIMaANAZ4rnwO2DLN3rqDjcg1wObJ0ymimUQ6qcyfc4UNXs8IfPs+jCMB6F2BAAZZX1nJnvOnQMwTHuXWBAYgve9qLMKtbHVagTKQiuWbB0y7U37R3bSAd0QlRA1TV+P8ORG07Cch/i60SZxC7KNL+buC7Ovho0y3reRPEAhjAPRg+Lj9Xb7o7OI4+ALxP1YaQnNQxfvCSL/3OojqBqXzbAQoCAAIdpnKpHBgKdnOgO356wF4/7JdfHHQQG2CBbwWhAsnaNWWcNnjD55dZpIuS6JbtbI6yfRoI38N6ePu4K0Md+dcwhfJSSQDFMS8In1GP8ZwHpueNLyiiP8AZihHBCorzgBDs3hMJlcYzayUM2Q3SOtjxBAQJutGBpxuz0kVymTZ8aWZnJpcj22dxQoYp0Ica5TN9Vld93jYII8QOCrAt3TI5VYcosRQkHNdjnWeAm0ZmgHILLeAWJCBAgnD/JpNUCWzBV5ZQc74lDNNRCx2gaGthAQJzCf3Hev9HfAEYgmf2eepGhESYI1E3dT7kTqskAJciPdq2gBJofVgnAFuUDjDDAAxwcWGURV74hWAYhmI4hmRYhmZ4hlh0hYiweI1nCEIUduY2hVSocepAAKxhh+FXLyJYdCSoFaPQANXBFq/1ARRQDRYQAsPiCSSAC/I2CWdCArJRF5CxghSQXLnlf8IXfEEofgOodAhHfsYHQvEifVI4gXLIM3TIKNMDAFGXh6i1hwvHWpcxCshReuwXAkIHAAEkDYxBCg/Aix+AHOdgAg0gHgW1TS/mGLCHbpaWfELoaUb4iQ23Y/Qw/wAOqEKcd1anqI2puHHssHlGQyOFl1NLc3Yg8A//NSJUk17/QDUCBhAu4AwiYSEhYHc/8TV59w8pMo8BQBIN1TZuM47kSHZbRZA+oTyR0nylOIfbOGdxyJACaHIjWITcoD9pwSYZoAi/UB2LcEi19TAeoEyMIHvrFyUhBnO+UJK6yDsg80cFt4l6OISg2IwwKSXUFmci15DO95DcSGewGDJ92D9o4UBN1guEeDshgECXhAsqKQm/EGnWkG9lImmxVQgMFWN7SJOr9YxHR4BB6ZLTBXGmqJOlJXkTyIkSyYcUWQh0BRy9kAGPJXq5eCbJtRZ6AZWJIJXV4CrTBACI8f9QxYALHzBmWamJJmN0xeeVawmWyieWEEmWmtKNsTF2BokQCBKPshYAEKB26Fg1AmFrzIY1SjUQusaOD5ITaaMiyaYT7yh4lfk2r2mZsRlWjtmTkBmZ6WBqFJiBC5ldERmNsfiJriVQGlYKiCB6BxMJrkdoHdMAy3gJ+QYNjuAL0FAIuTVoP/mVNOaTMjmNhilX+3KT1jYA9pQuk9Obt4meFXhqTlgt22V0igmN8yMBpPAKD5ABWNIqkRBNxAVAppICiWiVFEOYxEABFfMWAeMWieZI8Xl0yAeU3Cmf3vmSjLlc4jkk7GA9gENuIJie6Jk+PbJS7jlklDmbA/YgDHL/EceWa0Y1EEMFa84QVe3YIQQxAn+njwLQEl/DNsw2bSZaEAIJN0GqVRfKgIKgmyPqoWWpDhyHAAm5hdw3D6e1R+M3oaH0h4YhAaRHW5C1V+IAW74oDsi0SJ4ge/i5CnCiChaAC18GisH5oJ34it1ZoXAKfORUpM9nDQkpotmopKGBeCAKABMwNOAHdpB3ljEJnBCaJ6MgMAFQSAKFAsqUCKWSV4OAAc6wHNwgHbfngoV1f1QJHQKwUT7XQQ2qlXYaoV3piaiaR9RYhQJgOI0AfXozboPweDg5hf/BcXZYM9vXp6ioqg2amP3QqIKwAo8VF8sgCCMgF5KQCi3wb4XA/xglZggRtXt/KQgYwA7+Z6qs+p2uipjeWpgUCp53WpuJJ6iXckNR6qGwUYHYIgiSk2rAOghjZYFEU6I/ahBoBwH5CJoSAQLmJRBxN7ACcSGtuSEG617zqDY8uq9WA7HsJbERS7HsRQ9u5C1MmB/rmoHb1qF+CrLWtUtyRH1oqahxKgjGygq/CAAdJgkFQwKWMAL+AmW4x0yHxgx2QRccA3SjkLLR2Kpq+ZurSq4MV6HplA/rxIU5OXIh27RO6w4jxLQRSLTDOq4W6Qip8goQ8GSfMCugugoP46yMEGJ1mZc1mJeQxqy0Mkg25onFV6cSOmFAO5PgyozhmQ8IULJQK/+l1JZxuWo5OiQPvyoIb4iGiJu4iru4jNu4jvu4g+sO3ueGYuRmT1uvDukOkLKBciuLV8sLFnkMvWOfHtCCWQICO3gIy4kZIeZop+ABrJcMhgE6HKBY5Yqyx4e0iVq0aSm0zpi09aAAMIS5UXu5gUt96ZAAwruQJ+umi3p6pnIMCrWCs8AIBfOcUpYLPHezmnoJysGRGLC2AbCmvUOgAJiduWuuqkqsRnu+6tuY9JAuVSeymXu5VTuWT7GErkil6EsyBkARx4AKcAGIZbqzhoCppyIJdXG24/tXqOdbgpYLrnu7zpt078uV7Nu7d5uJ5zoPHze8xKtL9hvCIix24jj/m2enEStKISFQXyDSduDRAu+4mQZ7EyjAjxByERvSUMXmEhY7pAFpsUMhxP+Ap/gbssd7v77JlZ/rT6YSMahgHIvQKodQJSuHCH71UH6xMLsQvndxlYXBT7wbtBt8POLavw76rR0smUtsv0mcq1N6P1X6R6HrZ4rxs97BTIuAAQdUkWCSs4+4Z3DCrIK5vdqJu5zTuRksx3Vrpe5bZmtsuUfsp2+8XfpqYCkcACOgEf4KHgDRET0MNQ31jvcVyifAAgZ7bDByXybRmrL5w0QMxJcssUb8mG7MFEgqCIjDp32bpMIKt5HQtaMqaRGjP6IrCA8QksHVGBpwaCdmyABA/wLYKVAUcFC024gn18h0qrtyOrcXrMjPC7ySeW3fBsJKbLzxsJ6DoH3n2a5L+sv9+7/DTALBYMwbFBeGnMwmYhYSdQjKMbsWQB0BsIij2yxvi8a+G867u8h2S8EcHJZmGXEZOgjl40XufJu7qj6MdwG8TL8lDM9p6Qmh67LHkGiUZQHNDGKOAXOCQAIhMKnja1h5qSoFRREyPUoHHdIFCMnrO64a7NA1+WnoukLbYj7Le9GQCTmy+j1DgwArxdG3WrnWN8s5lckgoBFYk15o9xJrM14SYVT11RH0pZkg8BE72gIy2l1CLMtUHZtsHZCHxw5LvUKIEyRHLQi4+rfdlv/R2wI5HX3OwWq1wAwAjSFAhZTMLWiRhrABFFGIhwAr3LA6Le1h0YwLlN3NY9zQR7udRMvQjgyE3CzUEd0PenOv4EbCGH19wwvVSM28u3u1xopRAqXMqwAMw8DHw0wMHulk9ZYqg0SMpBC2/Dun3xzajEzcPP3IeBvJPLkO9iQId93LSZ3O+XGBg8DaqM1SbZ00a3OOV92PTvPJVeMQKtBQ6dURUbUSDrJfEHDWaV1gsLzW8k3ERVybTViy0e3RSlrJ83AA4PPc99u8DWqscOlnKU2pIWkNoAOIZdsAptt+BxO+rHMLAOVRC+3TZAzUW9m8nr3N7Wuh9WCef428Izv/wtL9zu6gAGXk2pgdn6MAAndFC82qJs06LKTQO1VMiBzJDA6eJYN8g3SClxyO4Zqt3L974Wgct2oM0fKwoShuy+hchWpoCD5TdYcLuVie5Vq+5Vze5WA45YOQy5QLh5O836CGKOYZOAAexzidnca6ArQQFwSVAZctabjwbyrgrInQuqerFrkFoCGd04gsjYeJaci93Jud3CAupXu6k1D+tPytGiLaQ/t73IpK4BPO4CpbiBp5497xAWmSx8shAh9wAv/klrAo6BW8mJyNwUT+2eCszV8BQrVqPh9av1HOxhQNcgBQAXcU4K8tP2tTiBnwi40VDQ4Dg6DTzKpQqdzk/wHWTAFqQbPPsECBLuuKHuvXfugPbeRBjTI5MgHrio0n7ui3PNp1+I0hd1MnDDfdHQArwBNm8xIsQe9bfRAg8jRfM7AuwAInsMOeSXjzHd8U+9ZJkyN19LH6/dEmHumPKeAi8+Ix7rIwvgq4OAgPkBOURcWU6rUGAAJqQdDYnNkGje2I7u0bjuQ6bcE/zeSS/OhIfObvaehE2KgBUOwuyz/I3ACWyAEOhXsXGQtyEb4n8EzVa/K8oeqnWsYpj9kdXtwfLs4vb5sjXGpDUwAZyLckvmrtTiPvHu8BMO8cEd4/Zd42/BMbEiEq8REx/N5EOvAFD/drja7k/DcJyaFJfP9173raDuCA7NTaaQTxGdSoecE6L4u2q3JX9UkXxqQKZ3IX4fsA8ydjSG8/T5/txt3m3B6E2u7NfFLL6zLRvY4u6gL4DcnXhtBF6771Tiv4ezTsgoh6CDTjjEaLyH74juCRJcAXrvecCu30r+7hij7kSb7TGe7yzT2riOAzt07JPzLXlje8l4fXUk31rj88hN8W/2tJEhACotPYgyB6u0cKfOE/HTD5ZkzzJC/8J+/qxX/I7S/1QwaoT2cIiONKeW3i9PuB2gcIFwCDhIMCAoWJiouHAY6PkJGSkwEClJeXIAIgECkdECEjjyUpEI4dIQKijiYoJo8uAq8qKxAlAi3/Kpi7vL2Plr7BwrvAw8bHjsXIy73KzM+8iIvT1ACH0wILhAUDDtjS1eHi4+TV19MIBIML3dTn5YnvgwGJ9IX2hPiG9/X9/AAUBFCA8OGBgQYS7FGgAIDeAw4cRhCS0OAEoQwaBBigIGJDAwEaNuTzN7KkyXkkURYCp7Kly4YpYf47qc9azJo4Z77MqdOmTp4nZQYFKnRfT6JFiyJdahTeN2zaABBQUMAdS6dYs5KTR2jBIQEKAFz4KkBQvKtOuTLtyXLtyIAUDIAwcFACzIXzJAjg8EBhXHoeLVijsIEEBwEqbqZ0uzPeYsVHIb+8ylip5MYrH0fePJTt5aREK/NE/6uVq9SvghSQ9XZWq+vXVmEbIl2uETRIzoZB0MSJU4cULhx1KvFIhYAQJ4SHIM7KVYBbnY53uE09WfXr1rFfz619Gffuz2hjNT1evOzzW83XVg9A9SEErTljJtT2soFUFB7E7eDhwaD7dg0SUAMGDNIBQoSU0MAGBnyAwV4CCAbaZaLFRJl8E2KoT00Xaughhh3OJ2KGNDn2YWcopqgSewA4QFZU8b1GHno0ijNjWuwpwJoian3G4YkHCUDCAxoY8AAK/gHgkUQANLgJISKEkGSDKwCAwQcbZCCABxioSOKXYP74k49kBhXiiBuWaaZmXla45okiulkSiw6EZQ6L4f/cWOOePOKZZ46HMHBAjGha+GGQIzzwgZEedDDIA/3RE2QG9ljQAASPIhSABRY88JFGcFoWqpgljkqhiW2yWahnY5oqH6mrqijniuO4eIg6jPgZG5+83nkeWTCEkwADExDyAlnIJqvsssw26+yz0EYr7bTUVmvttdhmq+223HbrrbXBVuNiVYMcS5ZsevbKZ7rplUMAfCudGSaqYT4kgAQSVElRgQFIoEGSJkAkwiAQNEDCPBQseuUJHwiwoE+pthrxm6VOHGtS8jI2K8aqzgsnrB7Lqiat8GSTK7q6qgsbu+OkuwACCQyLK30Zf1ZfTx1A9IAElFpQ5CAjEDiIXnz/PYpCl02GIBinGKAgQAb0jSyqxRxLfHHIVVOdpqtRW4011iBvvLXWTVUzgTcODJDAySunrLJrLNuo3gEMvLd2vNh9N8kIuHSggigggPDICiyYEsAKxxk+gifNubCbCbe0ENwv4FGnd+XBXI65L5pvToznt7FIwCHtsC2j229nFfefp0sNK1AkHKefBBuBQMhCCoGEKQAYGUAPCQt2UFBGGuzeNdnIU+yS2KdmxvXXSJ3J/Kv0Qt+xm6ibDnf2qZcsHgMzI3CIWYSW5zq9PA14Qn51SWpwQ0EyFECDDAEAwUIGkLACBocJFvbI0zve8s5HPeclz3qsqtjVNFa9ACJw/07oIc8BBhAVuh1iR/Hq3tvI4xUB4GoqCZhgBPrUuudBDDROIgwLHkAkuwTAIwHij5AGcQIEKSkEJDBABiRwCw4g7X8fI6AAp7bA5g1xVg48IREfGKcGCpGJMuFe+U5jMgBMoFgREMDdMqhBdd0oHYOYQAUGAcYpei9vmDhBKlbwGwh0AAXTCcAb42iCFkjuFM4JQCtM0AEQmCAFAijFJToHukEW8hiEPKQkEqlIyjUSkRGkTRUHMEJrwIhmXfQiWV6QiDJ60iwwQFYJD3hCfWCgBfcSAdSCliQJSGlouGhlRQZhqQ24IAMiOEwJDPW8JErviV8CosV8eT1gjq1sUP88JgKlGK+vcJI+UamiAHYUyq9ksldfxJUYyTgzTG4PmDcDQOxa8AASCCYDKSgQACy1uwG1c1Hz+wBDMqACC+wFA9F7IjG9lkRl1qyApPylCUPjxF4SkJne5FFUKGmIS87mmrzK5iBAKEISbg+NkdjNcU6wAsexQHCOCJxwAMmJAAznFKGAAAv+GEjDfe6RmYMp52Q6U5q+1KbNiCRUwohFLVoUojXi4FfsJL6yaM98JmyLpwSyARCwEEHzex8AZCihAwVIBEi6Ui4j5KV/iiypxRxoAotISmEm04jIdOD0EPrQRIxufACw4DSPClSU/UqKPQoVS1wAEQmIYCAi6I//gTwwMACIoAUcKKwrk4QRCHDKnhwwAYj0Cc6wlnWsTNynAs/qNa9ebK06bVtdg8rW1R11Y+DQUn8scDAFqXOxtBQAkgbR2CZpIANyEQHxfDdZg4KVn8bELBIrC1yxKo+zZIXgXe062tCK9qLbCYAaBcCCE6y0EysQDggKZ1IWtNSkKWDOG13QARaMAJXMGQYjYbreRrbXvTjFxHvZ69xvNne5zBWH+H6aXENslQQmUBhhAfO+AEDqaQ2BVGFV0IByZgCySFuiWcFG3M32U7gArPAAjbtZz1LYVX7ySje5OMr7lti+4RgLWvJqMQMcoj8Z2GUtGxJYpI1AYINgsH8a/wSCDVDAX4FU54aPO9zfWji4RM6wkYfc32AW9ICgHQc3PPiU55r4xKX5SrgWUQHwscRc3wqzmMdM5jKb+cxoTrOau7XlREywTt0Es2mrfGUUY9mtCjiAi/iLQMgKKS5YRZqndgmApc6l0JoCAEXKuQIt+dDJGA7ikiWM5MlQdtLKvHCSfYs89hxAAeoANZ3tXGekWnka7rEmiRe4AeI9QAAiaNAHdge8voizr79rsP0+gCUKkCAVi2pipIepYUpzOGv91SyTkbtsDzMQxOKw1VdG3NY7l7pd4pArzPhMjT2XrzIq6J8IGoaBAtOvQARxmH8IEuwHhEACV7LAYQ721f9NExvTx4b0EZUcUMs22Z+V5qyuRE1XRSzAPWPk9rWxHY4ux7V0qxbXiufriBMAMgQmWIEKIBDI5ATABSiYXB0FkF09hsIRKghBB0qwAk2oPLrxNWTMJ0HxQtbcczc/5MCpXW1qMGCMWRyUGRcut1rpKAEDIFfEcVQmwwigBBggTLml0SAWFEiHuECapSxigNs+AAQW8IBAeAtQS3O6yQK9bGcv3e/iqt3sbxd4fadxAQYU4OBbTCjR1zMOul1gAMVSON81RCSHYWAFOcTIBhARWBHQAwNinzWi/df4vyIusZ/lJZSLnemAT/jZbT/ysT/Pb7Ky1RrsWQADxsLzOe//HVnPXMQ2AYCAhFdT1VkWhi1wUQIXVNcEIdBFJVjAXQgg7o4BUIFzdlNdEKwgFYLsTs43N/3KVd/6M6d59uUbSWdOg6FIryQAbn/65rJsAgwAwLASvnTvSQbyILkS7UAQElgWFqsCCPYGUoBbKzVABVfiaIkhafaWefgWd/qWVqUHRWn3bx3jbGi1THO3CAMwRtwgfnq3dy3DItqWdz1nao2xAQ3DAS5gAbglAR7AJK0WEE3SMChQWGEnWTr0LyWAEQ6zAUVWgB8WesumaXCXbJyXbwRlQA6odqfHLuxwCOzXfhq4K6cGgqAhb08jAiyAAUTyF+vUAF0iJIeRAZhS/26UZzBRtwL9A4TDZoA8aGxxR3plx4D+xmxseG+dNoFQ2IS+kl+qczmtEEguAAIb93yvoEcoUAKmEAvH8QrGxzgqxQJ9BAIXF0c4t32LJIm4QYmVaImVgImRcIQI5XpE54mCx3AqIYK4IAEmaAASgAL0JoIpIBJYx1WKpoqDQAIe4AISIE97QWibd4Y7iHZvqFZPhoa+6HZF+INweFB0yHR2uIH4lWX9IIUZMAIUgAHl5oW01ACOp2iH0TCFpgED4X8Z8AAskAFiFxLAyIugN4yit4bB2ItuSIzHSITxOIfNSGrLOGr2eEaQAHJ8aF4n4IhxNALLwQqp4Bwkh3Em5f+IkMMCgNQCqwBfmnh90qeJmYiJEok5nIiH94iPzlgNSBcoQpdQrbYlJPBgG1ACXDIIGJAChKEkI0hvsRMgJIAC+MJrXShk56iD6fiO61iMyJZZQYiAQ7hvZyeB4vBWVFZwyriRTmhti/BzrWEA9vR0FkAYKDiAIqgBjvKKhwZ5WmIlHmABLpAw5egoo6d5ZpiGnXeW8piD6tiDnteObmmU5JBFHviBeciUd/iE1JAAOnIWEnAYGiABVQh5FuA7G6GF9iOF5thqWGINGuAg6JQRHuBCcYmOEYhav8h2CkiAb6mGPhmHwkiX4zAVHFmHepmBWXYIbaYIYwEv5bJmsjn/m7RZm7Z5m7iZm8BCDQdwCJckZ51YfqMVN6pHHqszAeQzGxlAAZ1CASmgdR4wgCgoW3YhlSnYJGGnF7x2CIcmlL21i2ophA/ImTwJl2xJlOBpevBQAAIQkkzoVgMgALD5nnrJMr2ZnENHCA4QeMRyFvkRdtlIEYfZL2JXmfNjKXbhWJV5ixBijgEHmko0l5oJjznZmXL4mWvJjm1JntgzDgigDVmkdPQ5CC6CQflZnyxSAfMZioNQAHUjAIJyFsonfCMwiKZQo7IlCraAAjpaAoOoAimQAqiUAoEoiRepHUcKcxYZkRT5C6U5baeZCOCzl6l5Ft6HDvEJo0JHfngV/yEFUm49pmhi1wKCYZ0lQBdhZwEM5gGCGU4+CaEQSKE2s5lFGac9+TUNyGxLZKfCRo8oc6U8kqXzSX5VqpSJMAG4snosWnQY4I04OJ0cYAEQIJUIoqCs1QAocBgp6aZ6mqEWOpoTeqcVGqELGKrmqaHomZbqWY/fpw1vtqgbyTIEwABrA5UnKjca8C+xuBeHuQErgCBSiQKspQFsChIBUkoP6qmk6pnlCaGjyqfOOqdyWqeX6ad8qQjI+XAYiJeFGjcTYDeweievgKMtQIj/yKPS9Xx/kwIhMKRFmh2WmKRKSonyWh31GjpNmgzJWAhytYSq2a2l1aXTWZkQoB8aMP8wHUABBuMzThN/yOaDp/qp7miq0UqtRUmxyvqs1bqqGpmXhXqrolgeW2IXK6kBXdKoKcAzHiB2ApEkD5us36mqzZqx5AmtNBuzFZuey6qzHcqqHvux/4qa6yEKLpACfhQANeqHLIACqNQCK+BxMhevFHmv0EC1Vcuk+ZqR11qloAiyd4KChGEACsIpGsABqFSZ/IKWEAunHCo1eQqxopmAMyuea3eeHLu17ge0QbuUeZgBG+BjDVCDxRpIhTUinAq3aAmUB/imQymxO4mxdNthG0uaTjl4eot6Pus9V3JbFIBKe0EYlXG4kxu3jTu33lm3POu2dKqzNru6mKG1lcv/lF07on8SOIB0CCiwcchgtczAu72LtUsavE0Ku/nItQErLEVFq2fBsvnnAqp7unfaugj4tpMrvW9KvXa7szLbs+GQNhcUpXl7uavzaSvKrfwKM345Yl/BAX5bnmurrNarp9iLqo6bmc8rqjU7umWSot5AAAMAvokgYoaKouQwLPKZK6wpDlMam7rZwA78wBAcwRJcZq2pCBHwv8YiSuIwZa0nnHUVN6t3AeWLuaWZft92v536hvGrbDkrsysclIw7ntnLvdmmANu6t4TwZgTntcvIMggAHyI8wIRQd3fJYlcjujMsl/arV66ruKk6sSjcwk5cv8xKw9XADSY6op8W/2odfLmzAahuhizwwqXh4Hf4aKrvi7MSGsU3y7pty8TT6sZJ/CGiQxV3Asb6iSwzQ6hebFpBvKjSBhZngVFSC7z0OrWGHJHjkGpzFa6DsMO0e49+PMKza8R4GrkRq71QDMf4a7Gpy8mZrLFzHDHEGw6QjMOye7ykhsYw21VvTDXzG5pK3IaQC73Npr90vK+Wq7ezi8p/QsiHnMjb57veIczxqssh+7G9bL4hy8qYnE8Xy8aYvKevfMRNPJfxK8WjgczM2Meq3JE8mMauHM2grM0L+MKLm8KoK8vQlrl8C7TLTMLg/JbibLjVfMlx7ML3HLrXfM64TMrcXHTe7M7pAf/MRorIwlvICj21Ac06A92x4UvPrWzP5AzL/cys6ByetkzNo7wqpfyzvPzNIO2+Ew0mGY2h0wxwFW3N+TzFmrzGuUzQuwzPIl0eBj3MCL3QwazTFtnQVErTMk0IWXRaKFzPJr3P0trJcvzJFt3S2PzPHl0OCyzE3Sy+LOKicAWrRUXUoGzU0MzULK3U+rzS+CzWLp3Nbfy649BBPMfM+pmlWSzPIV0rFigAIvrFAlDBheAViQCcE/zXgB3Ygj3Ys6nXhFBGGXwuDde/GMzDdmhaCWDX4crXfObMtvzV2yvNG63SYF3WoZy/He0xfoLYjgwAF0zVkrxJ+sV+ZCwOlH3/wl1d0pjt0rUcw+tM25pt25Ib2msx2m2NenjsZjZcCHxs1QWsqKj92hFn2bp91GTNz07tz8+d1J/tyexsreFA2l6LxQCcymsNcVr9FSZqG/ZqzNlHzIiU0zvN0K49VN0tFXb83qk9DiqW1ZHclCT9zIkL001t1k893Wqc0phZxfvLzYycxfF8X/FcydmMxPT7k/wd1tW91Jldzml91lAt2j6N38pc01kUeHJz0+et3gdt3jGH3r1LDR+ezEKbmgt+FSte1RKt3wNebyi92TXepzfe3Bz94FZcCDEu0LEbq+IxAP9bAUmJj0Hu0OEs2/tdqrmtzrvd2dDt39Lt4wU+/w1L/tOEYOQAgOS/LddA/X1HnuRH9eGflnQHID5G7lMfyNxS7txUTt3mjNFIHeA4rpNQHtOLgOYKoOZsHp83ELReDuZcDrDUUOhmzmcfzgBJZ0VUFp9bRN6WY+InbunxheLqla+VoOICgH6P/q3qIOiEXuZhnuDmV+RljgDxiZ8fmEWBMgjxWRWSnoFwjrg5Lre1Hec9XuH9PeFjjeV8bsFfYcKzDgCkbr6KzupGVdpNeCOKrg5141BinkW1Z1TiM0K1/uZF7eS5Xrq77tWzbOOmy+Ocfd13mwjWjuSCkO3ILgCDruymDgDT7uwaCO3z/q03zBUrbgPTVAD+bgPbjv96Ij5zmr7pCb3eJT68nl4s/u4AAC8AAu/mYt7l+S4A++7BQIXvX+5BfinZju0VdsLtsU3jek7LUS7uG0rgFi7gJ3+hlEsOIs+E0f7xd13xiE7mHS/eVA3rMCqillzlvA6/dz7OVm7nAG70wI7hvA0ZuuLzdkfzZc7z9v56Nf3Ot57hJ13uQ//tF12AKv/EEa7hQS3jNE3YaJ/2ar/2bN/2s+nFwO32cj/3dF/3dq/2HAD3NMLg1cMjeWIOfw/47hD4gy/42ED4h1/4ip/4i+/3hs/4jID4kd/4jk/5fS+PlQ/5mT/5lj/kep9JfP/5oj/6pF/6e4Lqpj/S75z6rN//+q5v+qj/+mbPt+551yFZAHmXAAWw+4NwALW/+3cjogew+yHpnsNfALdfCLuP+y2qCL4/CLrv/EIX/Ykg/IlA/c2v/Hfz/Nuw/L3/+8jfolt0/NbfosS/DYSg+8Cf/Tlc/O7J/gDA/NuQd+6J/XH1/iIq/9/f/vwKCAcAgweCg4cFCYcAhoiKjocJBZGTkY8LigkLloOYjJUACZePjIOinZecAJ4HoKeln4uys7QAAgK1ubq7vL2+v8DBt4cOCrcMCQIDCAIKBMYTi8ODEQOT1QMEh9WTEwMDEYfe3wcE39oABd8DFQffCo/rDNTWh/IA2Ojq3xUJCgMKGiEYMG/B/7dohwbOc3Bw2zl6oCp8u/aQ0b8LAMyxI7TOmkZ0DNcBYPBt08h16CQOCvkNX0WJB/0BNKSxQsaKof4FPDnA5LhwLisZXDZIYSSdgn4Ogqnt49KHTBcN7AkxYUmLAzC6HBBtKIJBBRA0JcpMW9ixCArccpBO7M2vACp8PfsWALNNdM2lHSCALd0ICjDxNQmg2LEIAhgwECD2FrpB04JJnky5suVZ09QiM6UsowCMxhpNc2ctQb1DpAuoy4gQwITH1lanG7BoklsApxlNtFfJNKjZhwhEu11Bq122gZcaP6Conm/Uu/FtDpV7JNtB1gzKKqAAt2rai4SvYi1LwaSQsv+EP5/1Wvzt7LRjgyfvdpP41eJTD3rtvXj64QTgF407uvm2GoHuSLLKfA58FcE8+hXm4DwMXDdIcgxEwF89gGkTkAIYfIiPMwB8mEQBEThI4ocHGKSihwcoIMR0HZYYow4EpDjiWAs4cIGPYCX2CGJfMePAAc1Ig8tlTDbppJPTECCATZzRJqVNi4EyjD/cFANQOFzWg4BiQLkGUIDg1bPPBI2Yhx1BmCjAjT1weiknWAcxt8x0CpAUTT38legnIt0VplMEYVZywT8MHGBnOO7805QCtx3CAJrYuZJboEt1Jed81BXw6CKAUTfmI8+IJdtppp0qDjpjZpgoPRN81Sf/V5HsqUiskPZk0KoFuLPAr4OItxIDog4wa2HIMhRpNhc6UMCl1dQanDa4IODDV0sSgK1dmwCZ0bcI7OAMXN7aYtcK0aWbbQ8EAZUuuN4ugO6U2wgQzQQCINrZIZE9KfDABNeSmZBVeoalAFriUgRXWRHQbHcXQHzBtAtc0NoCKFqTZiURFDCBVghQiU8Bz1TsjXEhPyOxqIWePDIBF6SIzgDSVgjozTmzFaO8E6uc1X4VFHDBBS8XM9uwAxzAwALPkDoPsIdUYLJci5imiAIKePOY1RlNvEiGGdV829PPUF22zUvBhbHGQms1gQPFqNNzsWYH+LTGxQLkcaY3/SMI/2CNmMmAAnGLQ5B5vjY9IkAOzF13seRuq+646iIQJ03ksktSOO6uizRCoSOQwQQTUDmv5vW6jTA++rrWbzKgBlzw7bg3GZlhQnZ25UgMA4wL1ObkWFB3xGdDwFfadUKdO98RIgjNdpk83gKBeQut89g/uEqhhZTNn7EVHocAciaVf/7P2xyffEoY0ew99s97p6x3lgIlH3SPYL3IBVRygPZMkiDpfI8Y83BNU6KhjuaoI3r7WWBc4JIR5vVEezfbhFjUd53xvcaCi3DAPPaHwBEV7hAAfJ8sAGgaQTgOT6bRIDrS9aEQxYhyNgrI+a6VQyLQzE00vJHZcPghHVRAR/+YA5ePxGWow8SOX/6q3ZJyR8UqSsZ2wpgi/pTCG7t8o0wk2YhTCvOOcqzDJqQBRxd180UzqZGMM4nRTDrxDQviio5EGQfO9tNGwOVkjlysSVz4EZwE3mR7rqGSWr6RwAbWZj6pU9wbSwQUOe5kkGLEiSVboQyCFKWP+NuKHSm4SS++sWI7GSMqXbiONhFljSV6pSAPGQ5s3EsA2isSLj2DS70s4BZWcoxeOvEVKfVyGabpFy9z6Q5lGlM4twjCYCyDRSta85qyqOYvAtaIRMiim6QASyPCRwlEqIYU3kTNdtAZTgUhQhbuDMVv5GkK1fwmnYTYTm3CSU5GFO4V0lv/ROHsOc5ZFHSftdGnQMd5wnSYM1iQUGc56zmLe5Iinv6c6CdUs9BvdhQ1A82aK4alCE9owhQkXUVJORaKlHoin5rwhEl741JFtAKlmGjRJm5KTS1i86fY1KYvhArUohr1qEhNqlKXakWiMvWpQ/VpFrO5C6lSNRdWlUZVdZFVgG2Vq2ANK1bFarCvjvWsaC1rWmnRVciQla1mVatc5wrXtWImrrprK1T3ytVb+PWvgA2sYAdL2MIa9rCITaxiF8vYxjr2sZCNrGQnS9nKWvaymPUrXzcLjMx69rOgDa1oR0va0pr2tKg9LGdXywunVlWLenVrL2Ir29YO9bazxa1t/3PL2936Fq92patwh1vX3741uMU9LnHzytrmGoy2WIVtb4G73KsaF7l3na5yk7vd7F63ulrVLni9Kt7x1pa63DXv5QrmWufutb3Rda9850vf+tp3YPC9r1Hzy1bo6ve/AA6wgJHK3wFXUZu0e20kIgrPhNICn/1cZy/wiU+RarSi/KwFKOwZTgY79MEPbShG5+lgsNRixLXgqSlSDIoIW5iiGs6wQXtjT1pgFKMvbgVHv9nihhLCFSSWaDo6nLUF5+IROBYoaoJ85H/F18BMLXA2cVGOQnGREFHDCjxkEUb74MRSV2nQY8Z2lS7LIiTRCMklyUyVoHzzHZI44yzMnP+PNwMkASwBFRyjIZM1c+TOluywmpmjkw7D5CtVpsWhMTnmlZRx0HZ+45wWsWg9nhDSMCHxoMOISEwWk5CyWDQ2WkNp8IyDMFIZUJZpgYA0N2QWc1q0wKQM5dsJtSWL4dcuhbcKbwDHWJ3wNQCQFhfrjUc8JFyEfaJRARLNYtnHJjUjHMgcuzQ62mwksW0wVYtlr6ei1g6OtKvtEQCBWyzEBptAd+UtjBDbwdkRtkJjsyCDsrvalXpnfqLzTu9w6pvsfhCRCcHuQ7ip3x4rQPPgzZ1NkC2ELaFfg2ahsl7rGYW4Ivc89VOJ6uwC1/pyjJJqvdRb02Yxw3KyLZYkG17/bQc8RytABaQdQbXJIlD/vvljcg6WQtmLguwhwLJmYZ41+ViBo6LFwb9dm+60ajpEN9rFZv5sBHzFg7OQmCIvXiwGmAzYyrY6MYEeiQkEZOiFtIk3nC2Lnw+bUT52e6ey7vWMUOraYbOJAnI25u5ZiYF6Xp6xZJMesbSGO/D8VCW0DgyQp1yKJFeqyYGXCJVnhjZvk7ZsnAYQ41RtLh+bhf8UWIvRj16gd2LEM1D9+WFbjNVUCtnIFF1Msc2iZFUzNiHuJL98JwSNJEGcQVeP9bY/QxGEN/6WCUeLKu909bQQfOKUr4mONdT5qZN686GvtWcfH20xU/bxAQO5RXDN/2v3AZU7xpSc5HOE/TtNPcZX1onj/wLklYd85AncVfwnmNe/BkKPlDUP13qZ4n4TtAg8l4Bt03yp502+x4AqJAu4l1HUE2pwMT/hVxQmU0DflHrFJxXWkwAFCBbsRj3vdgib8BwIOB6+wXwYZm0Q2GjhIxwTqIKhsoIvBAli4R8XiFBuAUDPFir343E6WAmORAwDJHFk126NAhxZRzONwj7GVzwu6HG64H+W51/7x179d3IM83+QgQsscQBTUSZw1DT7YGyL5EljhAidRCGgBoeM1IaGxEff4ACyVhtxCEt9ww+QxoeM5EZoeEgbEUnssQ5HghTpcUZrKHp19Edbxv9mNlGGXEZIHXFCi7aHxFBGfsgTWDKHVROJfdZQi5aElIhJuhdGNqERhYgneMh6xeJq5BB9+6KItFAPrNh4YJh/I9eF+8WFmMFyO1ZhYFGMA0dQAVVRqiEIOkZkyqiMIrVjKrYdzShktXFO9PRg1zhk3OhNRycJO/ZhzOhNxrhkJbYd3TSOtWEIOhZkKlaNL4aNiNBNR1eNTBYL+fRgDKVh3aQL4HRkx5iPmVBjzVePBENrwMhclaGQC/mQEBmRnOWQEnlFwjhl4YVe3qWR1sWRGemR5PVd6aVe0FWSugWS64WSKdldHcmSH4ldLTlrF1mRlEGRAUNbJlleI7mTG+n/kiGpkjkpkj0Jky9JlOflk0dplElJkjo5lE9CkTS5Tak1lVRZlVZ5lViZlVopWVFZRR6wlWAZlmI5lmRZlmbJAV2Zlmq5lmzZlm75lnAZl3I5l3RZl3Z5l3iZl3q5l3zZl375l4AZmII5mIRZmIZ5mIiZmIq5mIzZmI75mJAZmZI5mZRZmZZ5mZiZmZq5mZzZmZ45mHyhe585mqQZeXyBd5ahFgIQD/hSmq75mgZ2mgOjmqwpmrB5m7jZXLIpNbeQFst0C8ZxAcdwC8ngV/GhL8xwcLm5nMz5VLvZCc2QAFLSHcakGmsRF4kBO6tJm9jxREnSnOAZnkX1nHaBL0gizwBQQ5y4sUuyiRjbqZ7r2YoqJ570WZ8FQ56LAVgRYEzNgUvFWUvEyZ3x6RlcZ58GeqCTQZ7M4Hm81J/awBds4Z6SAJ+hSaAIeqEYGgzkiRj1YIYoo56yyS/FRJznqT/4IiUFmqEquqJ88VfakCJ+hQDSCaK7lADMEHLgYUzHKZ8puqI++qOVwS80B6REWqRN4p7AaaRKuqRM2qRO+qRQGqVSOqVUWqVWeqVYmqVauqVc2qVe+qVgGqZiOqZkWqZmeqZomqZquqZs2qZuaqCBAAA7);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     WHO: World Health Organization.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Centers for Disease Control and Prevention based on data from the WHO Child Growth Standards.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_52_38728=[""].join("\n");
var outline_f37_52_38728=null;
var title_f37_52_38729="Ebstein's anomaly of the tricuspid valve";
var content_f37_52_38729=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Ebstein's anomaly of the tricuspid valve",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/52/38729/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/52/38729/contributors\">",
"     Brojendra N Agarwala, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/52/38729/contributors\">",
"     Ziyad M Hijazi, MD, MPH, FAAP, FACC, FSCAI, FAHA",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/52/38729/contributors\">",
"     Joseph Dearani, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/52/38729/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/52/38729/contributors\">",
"     Heidi M Connolly, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/52/38729/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/52/38729/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/52/38729/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ebstein's anomaly is a congenital malformation that is characterized primarily by abnormalities of the tricuspid valve (TV) and right ventricle (RV) (",
"    <a class=\"graphic graphic_figure graphicRef79822 \" href=\"mobipreview.htm?20/36/21061\">",
"     figure 1",
"    </a>",
"    ). The estimated risk of Ebstein&rsquo;s anomaly in the general population is 1 in 20,000 live births with no predilection for either gender [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/52/38729/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. For unknown reasons, it occurs with higher frequency in infants of mothers who take",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    during early pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/52/38729/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/61/11226?source=see_link&amp;anchor=H1561534#H1561534\">",
"     \"Bipolar disorder in adults: Teratogenic and postnatal risks of pharmacotherapy\", section on 'Lithium'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10180283\">",
"    <span class=\"h1\">",
"     MORPHOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Tricuspid valve",
"    </span>",
"    &nbsp;&mdash;&nbsp;The morphology of the tricuspid valve in Ebstein's anomaly, and consequently the clinical presentation, is highly variable. The tricuspid valve leaflets are malformed and partly attached to the fibrous tricuspid valve annulus and partly to the right ventricular endocardium (",
"    <a class=\"graphic graphic_figure graphicRef61728 \" href=\"mobipreview.htm?19/41/20114\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The anterior leaflet is the largest leaflet and is usually attached to the tricuspid valve annulus.",
"     </li>",
"     <li>",
"      The posterior and septal leaflets are vestigial or absent as there is failure of delamination (separation of the layer of valve tissue) from the myocardium. When present, the free edges are generally displaced posteriorly and downward from the atrioventricular junction and progressively toward the right ventricular outflow tract and apex.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The leaflets of the tricuspid valve may have free leading edges with chordae, or be directly attached to papillary muscle(s) or the underlying myocardium. The tricuspid valve is funnel-shaped (\"sail-like\"), incompetent, and sometimes stenotic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Right ventricle",
"    </span>",
"    &nbsp;&mdash;&nbsp;The valve divides the right ventricle (RV) into two chambers:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The proximal portion is called \"atrialized RV\" because of a downward extension of the tricuspid valve",
"     </li>",
"     <li>",
"      The distal chamber, the RV proper, is small and in some cases consist of only the right ventricular outflow tract",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Classification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Accurate classification of Ebstein&rsquo;s anomaly is challenging since there is infinite anatomical variation; ie, no two hearts are alike. However, simplistic classification systems are present and include mild, moderate, or severe based upon the extent of apical displacement of the valve leaflets with resultant tricuspid regurgitation, and the degree of right-sided cardiac chamber dilation and dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/52/38729/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A more detailed classification that includes anatomy of the tricuspid valve leaflets in conjunction with portions of the Carpentier classification (A, B, C, D) is also available and is based upon the anatomic findings at surgery with four grades of Ebstein's anomaly proposed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/52/38729/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Type I - The anterior tricuspid leaflet is larger and mobile but the posterior and septal leaflets are apically displaced, dysplastic, or absent. The atrialized ventricular chamber size varies from relatively small to large.",
"     </li>",
"     <li>",
"      Type II - The anterior, posterior, and often septal leaflets are present, but are relatively small and displaced in a spiral fashion toward the apex. The atrialized ventricular chamber is moderately large.",
"     </li>",
"     <li>",
"      Type III - The anterior leaflet has restricted motion with shortened, fused, and tethered chordae. Direct insertion of papillary muscles into the anterior leaflet is frequently present. The posterior and septal leaflets are displaced, dysplastic, and usually not reconstructable. The atrialized ventricular chamber is large.",
"     </li>",
"     <li>",
"      Type IV - The anterior leaflet is severely deformed and displaced into the right ventricular outflow tract. There may be few or no chordae, and direct insertions of the papillary muscles into the leading edge of the valve are common. The posterior leaflet is typically dysplastic or absent, and the septal leaflet is represented by a ridge of fibrous material descending apically from the membranous septum. Tricuspid valve tissue is displaced into the right ventricular outflow tract and may cause obstruction of blood flow (functional tricuspid stenosis). Nearly all of the right ventricular cavity is atrialized ventricle.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Associated cardiac defects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other cardiac defects are often associated with Ebstein's anomaly. The most common are [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/52/38729/abstract/7-10\">",
"     7-10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patent foramen ovale (PFO) or atrial septal defect (ASD, mostly secundum). Patients with PFO or ASD can develop cyanosis from right to left shunting, particularly with exercise, and are at risk of paradoxical embolism. In one series, 79 percent of patients had either a persistent or previously closed patent foramen ovale or atrial septal defect [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/52/38729/abstract/8\">",
"       8",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/32/3593?source=see_link\">",
"       \"Patent foramen ovale\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/27/16825?source=see_link\">",
"       \"Pathophysiology and clinical features of atrial septal defects in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Ventricular septal defect. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/19/8506?source=see_link\">",
"       \"Pathophysiology and clinical features of isolated ventricular septal defects in infants and children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pulmonary outflow obstruction may be due to anatomic or functional pulmonary atresia, structural pulmonic valve stenosis, or occasionally the displaced tricuspid valve. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/62/39910?source=see_link\">",
"       \"Clinical manifestations and diagnosis of pulmonic stenosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patent ductus arteriosus. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/52/35656?source=see_link\">",
"       \"Clinical manifestations and diagnosis of patent ductus arteriosus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Coarctation of the aorta. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/53/23385?source=see_link\">",
"       \"Clinical manifestations and diagnosis of coarctation of the aorta\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      One or more accessory conduction pathways is present in up to 20 percent of patients with Ebstein's anomaly, predisposing patients to arrhythmias. Arrhythmias may precipitate heart failure. Sudden death has been reported and may be caused by atrial fibrillation with rapid ventricular response due to conduction through an accessory pathway or from ventricular arrhythmias. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/61/17370?source=see_link&amp;anchor=H3#H3\">",
"       \"Epidemiology, clinical manifestations, and diagnosis of the Wolff-Parkinson-White syndrome\", section on 'Associated cardiac abnormalities'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Less frequently, a number of left heart lesions, including diastolic and systolic dysfunction, mitral valve prolapse, bicuspid aortic valve, and myocardial changes resembling left ventricular noncompaction may be present [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/52/38729/abstract/8\">",
"       8",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/51/41784?source=see_link\">",
"       \"Isolated left ventricular noncompaction\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical presentation of Ebstein's anomaly varies widely, ranging from symptomatic neonate to the asymptomatic adult. In general, symptoms vary according to the anatomic variation (ie, the degree of displacement and the functional status of the tricuspid-like leaflets). Patients with mild apical displacement and mild dysfunction of the tricuspid valve may remain asymptomatic until an advanced age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/52/38729/abstract/11\">",
"     11",
"    </a>",
"    ]. In contrast, patients with marked tricuspid leaflet displacement or abnormal leaflet attachment may have severe regurgitation and right-sided heart failure, elevated right atrial pressures, and significant right-to-left interatrial shunting. The anomaly may be fatal shortly after birth if severe cardiomegaly and heart failure are present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/52/38729/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a review of 220 patients with Ebstein's anomaly, the most common presentation varied with age at presentation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/52/38729/abstract/12\">",
"     12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fetuses &mdash; an abnormal routine prenatal scan (86 percent)",
"     </li>",
"     <li>",
"      Neonates &mdash; cyanosis (74 percent)",
"     </li>",
"     <li>",
"      Infants &mdash; heart failure (43 percent)",
"     </li>",
"     <li>",
"      Children &mdash; an incidental murmur (63 percent)",
"     </li>",
"     <li>",
"      Adolescents and adults &mdash; arrhythmia (42 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Early age at presentation was frequently associated with other cardiac lesions, particularly atrial septal defect, causing cyanosis and pulmonary stenosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptoms such as cyanosis and heart failure from severe tricuspid regurgitation may appear soon after birth, because of high pulmonary vascular resistance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/52/38729/abstract/12\">",
"     12",
"    </a>",
"    ]. However, symptoms often improve as pulmonary vascular resistance decreases.",
"   </p>",
"   <p>",
"    At a later age, symptoms such as exertional dyspnea, fatigue, cyanosis, and palpitations may recur; these symptoms may be insidious in onset.",
"   </p>",
"   <p>",
"    Palpitations due to atrial tachyarrhythmia are present in 20 to 30 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/52/38729/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Some of these arrhythmias may be due to Wolff-Parkinson-White syndrome, since up to 20 percent of patients have one or more accessory pathways; the majority of these pathways are located around the orifice of the malformed tricuspid valve [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/52/38729/abstract/8,14,15\">",
"     8,14,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with Ebstein's anomaly who have an interatrial communication are at risk for paradoxical embolization, brain abscesses, and sudden death. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/37/26201?source=see_link&amp;anchor=H25#H25\">",
"     \"Classification and clinical features of isolated atrial septal defects in children\", section on 'Paradoxical embolization'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The physical findings vary with the severity of pathology and the magnitude of right-to-left interatrial shunting. The following observations apply to patients with more severe disease (usually neonates and children); those with less severe disease more often present with a murmur and click commonly mistaken for mitral valve prolapse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/52/38729/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cyanosis may be severe in infants, while common findings in older children include mild cyanosis, prominent \"a\" wave in the distended jugular veins, and hepatomegaly. The last finding represents passive hepatic congestion resulting from tricuspid regurgitation and elevated right atrial pressure. There may also be a palpable prominent diffuse parasternal impulse and a systolic thrill at the left lower sternal border. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/59/33719?source=see_link\">",
"     \"Examination of the jugular venous pulse\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/43/9909?source=see_link\">",
"     \"Examination of the precordial pulsation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    On auscultation, there are widely split first and second heart sounds, resulting from right bundle branch block. A prominent S3",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a loud S4 give the impression of multiple heart sounds (triple or quadruple gallop). A systolic murmur from tricuspid regurgitation is a common finding; this murmur characteristically increases in intensity with inspiration and may be associated with a mid-diastolic murmur due to the high diastolic flow volume across the tricuspid annulus. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/37/26202?source=see_link\">",
"     \"Auscultation of cardiac murmurs\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, the murmur may be very soft or absent in adults because the low velocity of the to-and-fro flow and rapid equalization of pressure across the tricuspid valve do not result in blood flow turbulence. When tricuspid regurgitation is severe, jugular venous distension and a prominent \"v\" wave may be seen. Hepatomegaly becomes pulsatile in this setting due to systolic expansion of the liver.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10180935\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ebstein&rsquo;s anomaly should be distinguished from other causes of tricuspid regurgitation and right-sided chamber enlargement such as Uhl&rsquo;s anomaly, tricuspid valve dysplasia, tricuspid valve prolapse, tricuspid valve endocarditis, carcinoid heart disease, traumatic injury of the tricuspid valve, and arrhythmogenic right ventricular cardiomyopathy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/9/149?source=see_link\">",
"     \"Etiology, clinical features, and evaluation of tricuspid regurgitation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/22/32106?source=see_link\">",
"     \"Clinical manifestations and diagnosis of arrhythmogenic right ventricular cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Ebstein&rsquo;s anomaly should also be distinguished from other causes of cyanosis. In Ebstein&rsquo;s anomaly, the right heart is frequently enlarged but pulmonary artery hypertension is rare, in contrast to cyanotic congenital heart disease associated with Eisenmenger syndrome. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/35/39478?source=see_link\">",
"     \"Medical management of cyanotic congenital heart disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted in the 2008 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association",
"    <span class=\"nowrap\">",
"     (ACC/AHA)",
"    </span>",
"    guidelines for adults with congenital heart disease, diagnostic testing in patients with suspected Ebstein's anomaly includes electrocardiography, chest radiography, and echocardiography, which documents the presence and severity of the structural abnormalities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/52/38729/abstract/16\">",
"     16",
"    </a>",
"    ]. In general, echocardiography is preferred for analysis of tricuspid valve anatomy and cardiovascular magnetic resonance (CMR) imaging is preferred for evaluation of right ventricular size and function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Electrocardiogram",
"    </span>",
"    &nbsp;&mdash;&nbsp;The electrocardiogram (ECG) usually reveals abnormal findings in Ebstein's anomaly. These include (",
"    <a class=\"graphic graphic_figure graphicRef72686 \" href=\"mobipreview.htm?12/4/12359\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/52/38729/abstract/5,17\">",
"     5,17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Right atrial hypertrophy and right bundle branch block",
"     </li>",
"     <li>",
"      Preexcitation with a left bundle branch pattern with predominant S waves in the right precordium due to right-sided accessory pathway (",
"      <a class=\"graphic graphic_waveform graphicRef80258 \" href=\"mobipreview.htm?35/3/35895\">",
"       waveform 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Low-voltage QRS over the right-sided chest leads",
"     </li>",
"     <li>",
"      Supraventricular tachycardia may be present with or without preexcitation; other forms of atrial tachycardia, such as atrial flutter or atrial fibrillation, may be seen in older persons",
"     </li>",
"     <li>",
"      First degree atrioventricular block",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Chest radiograph",
"    </span>",
"    &nbsp;&mdash;&nbsp;In severe cases, the chest radiograph reveals massive cardiomegaly (often termed a \"wall to wall\" heart) with diminished pulmonary vascularity (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef68211 \" href=\"mobipreview.htm?19/49/20255\">",
"     image 1",
"    </a>",
"    ). The right atrium is prominent and the left heart border becomes straight or convex due to dilated and displaced right ventricular outflow. The chest radiograph may be normal in patients with less severe disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Echocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Comprehensive two-dimensional and Doppler echocardiography is the most useful tool for establishing a diagnosis of Ebstein's anomaly (",
"    <a class=\"graphic graphic_figure graphicRef61728 \" href=\"mobipreview.htm?19/41/20114\">",
"     figure 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef74450 \" href=\"mobipreview.htm?16/5/16465\">",
"     image 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef58746 \" href=\"mobipreview.htm?1/11/1202\">",
"     movie 1",
"    </a>",
"    ). Echocardiography can accurately identify the lesion, its severity, and many of the associated cardiac defects. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/2/14378?source=see_link\">",
"     \"Echocardiographic evaluation of the tricuspid valve\"",
"    </a>",
"    .) The four chamber view is particularly helpful, as it demonstrates the degree of failure of delamination of the anterior and posterior leaflets, and the presence of any (often diminutive) septal leaflet. Three-dimensional echocardiography is being used with increasing frequency to supplement standard two-dimensional images for analysis of tricuspid valve anatomy.",
"   </p>",
"   <p>",
"    The most important findings are [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/52/38729/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Apical displacement of the septal tricuspid valve leaflet (by &ge;8 mm per meter squared body surface area compared to the position of the mitral valve) demonstrated in the apical four-chamber view.",
"     </li>",
"     <li>",
"      Degree of failure of delamination of each of the three leaflets.",
"     </li>",
"     <li>",
"      An increase in right heart volume.",
"     </li>",
"     <li>",
"      Paradoxical ventricular septal motion due to right ventricular volume overload from tricuspid regurgitation.",
"     </li>",
"     <li>",
"      Tricuspid regurgitation, which usually is low velocity (since pulmonary pressures are normal) and may be missed unless the laminar retrograde flow across the tricuspid annulus is identified. The tricuspid regurgitant jet may be present at or near the level of the atrioventricular groove with mild degrees of displacement or it may be located up toward the right ventricular outflow tract and pulmonary valve when tricuspid leaflet displacement is severe.",
"     </li>",
"     <li>",
"      ASD or PFO, often with associated bidirectional shunting.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Doppler echocardiography can determine the degree of tricuspid regurgitation. The major criteria for severe tricuspid regurgitation are a vena contracta width &gt;0.7 cm and systolic flow reversal in the hepatic veins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/52/38729/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. However, systolic flow reversal may not be accurate when atrial fibrillation is present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/52/38729/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/9/149?source=see_link&amp;anchor=H19#H19\">",
"     \"Etiology, clinical features, and evaluation of tricuspid regurgitation\", section on 'Echocardiography'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The Great Ormond Street Score (GOSE) is commonly used for echo evaluation of the neonate. This score is defined as the ratio of the size of the right atrium and atrialized right ventricle divided by the combined area of the functional right ventricle, left atrium, and left ventricle. The greater the ratio, the worse the prognosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/52/38729/abstract/23,24\">",
"     23,24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A transesophageal echocardiogram may provide additional information when the transthoracic echocardiographic images are not technically sufficient to identify the structural and functional abnormalities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/52/38729/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Intrauterine diagnosis of Ebstein's anomaly can be made by fetal echocardiography.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10180432\">",
"    <span class=\"h2\">",
"     Arrhythmia evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, the electrocardiogram may reveal evidence of arrhythmias or preexcitation. Holter monitoring may be helpful in identifying arrhythmias. For patients with tachyarrhythmias or electrocardiographic evidence of preexcitation, the role of electrophysiologic study for identification of accessory pathways and radiofrequency catheter ablation is discussed separately. Electrophysiologic study may also help exclude the presence of ventricular arrhythmias. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/61/17370?source=see_link&amp;anchor=H249527#H249527\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of the Wolff-Parkinson-White syndrome\", section on 'Evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10180895\">",
"    <span class=\"h2\">",
"     CMR",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiovascular magnetic resonance (CMR) imaging enables quantification of right ventricular size and function and visualization of the posterior tricuspid valve leaflet [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/52/38729/abstract/25\">",
"     25",
"    </a>",
"    ]. Since this information is complementary to echocardiographic data, combined CMR and echocardiographic imaging may be helpful prior to surgical intervention for tricuspid repair or replacement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10180515\">",
"    <span class=\"h2\">",
"     Other studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other tests may be helpful in selected patients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pulse oximetry at rest and during exercise can be helpful in the evaluation and periodic assessment of patients with Ebstein&rsquo;s anomaly [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/52/38729/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Exercise testing is helpful in revealing functional limitation in patients with cardiomegaly who may report few symptoms.",
"     </li>",
"     <li>",
"      Coronary angiography is suggested when surgical repair is planned in patients with suspected coronary artery disease, in men &ge;35 years old, in premenopausal women &ge;35 years with coronary risk factors, and in postmenopausal women [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/52/38729/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many patients with Ebstein's anomaly have few symptoms, may live a relatively long and active life, and require only medical therapy; others are more symptomatic and require surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Medical therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medical management in a newborn with cyanosis is limited to supportive therapy until the pulmonary vascular resistance drops and normalizes with time. In case of extreme cyanosis, prostaglandin E1 (also known as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40966?source=see_link\">",
"     alprostadil",
"    </a>",
"    ) infusion is indicated to keep the ductus arteriosus open and increase pulmonary blood flow until the pulmonary vascular resistance drops.",
"   </p>",
"   <p>",
"    In the symptomatic newborn, inhaled nitric oxide may be helpful in reducing pulmonary vascular resistance and improve antegrade pulmonary blood flow. Infants and children with heart failure may benefit from inotropic agent(s) as well as long-term therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    and a loop diuretic. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/63/38906?source=see_link\">",
"     \"Overview of the therapy of heart failure due to systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with Ebstein&rsquo;s anomaly are at risk for thromboembolism due to atrial fibrillation or paradoxical embolism (via a PFO or ASD). Although limited evidence is available to guide therapy, we suggest anticoagulation with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    in patients with atrial fibrillation or history of paradoxical embolus with an unrepaired interatrial shunt [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/52/38729/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Endocarditis prophylaxis is suggested in cyanotic patients with Ebstein&rsquo;s anomaly and in patients with prosthetic cardiac valves or with prosthetic material used for cardiac valve repair. Endocarditis prophylaxis is not recommended in acyanotic patients with Ebstein's anomaly who have no history of valve replacement or prior endocarditis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/52/38729/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/36/585?source=see_link&amp;anchor=H2#H2\">",
"     \"Antimicrobial prophylaxis for bacterial endocarditis\", section on 'Theoretical basis for prophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10180600\">",
"    <span class=\"h3\">",
"     Arrhythmia treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of atrial arrhythmias depends on the rhythm and substrate. Radiofrequency catheter ablation or surgical ablation of atrioventricular accessory pathway(s) is suggested in symptomatic patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/52/38729/abstract/15,27,28\">",
"     15,27,28",
"    </a>",
"    ] Since an interatrial shunt is frequently present, paradoxical embolism is a potential risk of catheter ablation. Atrial tachyarrhythmias (fibrillation and flutter) should be treated with maze surgery at the time of surgical repair. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/60/15305?source=see_link\">",
"     \"Pharmacologic therapy of arrhythmias associated with the Wolff-Parkinson-White syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/45/37591?source=see_link\">",
"     \"Surgical approaches to prevent recurrent atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One study evaluated 65 patients with Ebstein&rsquo;s anomaly, aged 4 months to 20 years, who underwent electrophysiologic study because of drug-refractory or life-threatening arrhythmia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/52/38729/abstract/27\">",
"     27",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A single accessory pathway was present in 52 percent, multiple accessory pathways in 29 percent, and arrhythmias unrelated to an accessory pathway in 18 percent.",
"     </li>",
"     <li>",
"      Ablation of a right free wall or right septal pathway was initially successful in 79 and 89 percent, respectively; however, the recurrence rate was 32 and 29 percent.",
"     </li>",
"     <li>",
"      Among those with arrhythmias unassociated with an accessory pathway, ablation was initially successful in 75 percent and 27 percent had recurrence.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Indications for arrhythmia surgery (surgical ablation of accessory pathways or an AV node reentry pathway or a Maze procedure) concomitant with tricuspid valve repair or replacement and ASD closure, are atrial",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ventricular arrhythmias not amenable to percutaneous treatment and ventricular preexcitation not successfully treated in the electrophysiology lab [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/52/38729/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, surgery should be avoided in the newborn period as the risk of surgery continues to be high (10 to 25 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/52/38729/abstract/23,24,29\">",
"     23,24,29",
"    </a>",
"    ]. In some neonates, surgery will be necessary. Indications for surgery in the neonate include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Severe cyanosis",
"     </li>",
"     <li>",
"      GOSE score 3 or 4 with mild cyanosis",
"     </li>",
"     <li>",
"      CT ratio &gt;80 percent",
"     </li>",
"     <li>",
"      Severe tricuspid regurgitation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Cardiac surgery in patients with Ebstein&rsquo;s anomaly should be performed by surgeons with training and expertise in congenital heart disease. As noted in the 2008",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    adult congenital heart disease guidelines, indications for surgical repair of Ebstein&rsquo;s anomaly beyond infancy include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/52/38729/abstract/16\">",
"     16",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Symptoms or deteriorating exercise capacity",
"     </li>",
"     <li>",
"      Cyanosis (oxygen saturation less than 90 percent)",
"     </li>",
"     <li>",
"      Paradoxical embolism",
"     </li>",
"     <li>",
"      Progressive cardiomegaly on chest x-ray",
"     </li>",
"     <li>",
"      Progressive right ventricular (RV) dilation or reduction of RV systolic function",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Surgical repair includes tricuspid valvuloplasty or replacement, selective plication of the atrialized right ventricle, closure of intracardiac shunts, right reduction atrioplasty, and any indicated arrhythmia procedures. Subtotal closure of the atrial septal defect is preferred when biventricular repair is performed in the symptomatic neonate.",
"   </p>",
"   <p>",
"    As noted above, concomitant arrhythmia surgery is indicated for arrhythmias or pre-excitation not amenable to percutaneous treatment.",
"   </p>",
"   <p>",
"    In the series of 220 patients cited above, 86 percent eventually required surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/52/38729/abstract/12\">",
"     12",
"    </a>",
"    ]. The main indications were severe symptoms or less severe symptoms in patients with cardiomegaly, which is associated with a poor prognosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/52/38729/abstract/30\">",
"     30",
"    </a>",
"    ]. Whenever possible, repair of the tricuspid valve is undertaken since it is associated with a lower mortality and fewer long-term complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/52/38729/abstract/31,32\">",
"     31,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The main tricuspid repair techniques that have been used:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Danielson repair consists of a monocusp repair of the tricuspid valve based on the anterior leaflet. This may result in the hinge point of the anterior leaflet being apical to the true annulus. Right ventricular plication (vertical in the more recent experience) is performed selectively and posterior annuloplasty is performed routinely. Annuloplasty bands have been used when there is no concern about additional somatic growth [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/52/38729/abstract/33,34\">",
"       33,34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The Carpentier technique consists of detaching the large sail-like anterior leaflet from the valve annulus, surgical delamination of the anterior and inferior leaflets, and clockwise rotation to the coronary sinus to create a monocusp valve [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/52/38729/abstract/35\">",
"       35",
"      </a>",
"      ]. The hinge point of the monocusp anterior leaflet is at the level of the true annulus. The atrialized portion of the RV is plicated but in a vertical fashion.",
"     </li>",
"     <li>",
"      The cone reconstruction is the most contemporary and the most anatomic repair technique. It is performed by surgically delaminating the anterior, posterior, and septal leaflets from the underlying myocardium. The mobilized anterior and posterior leaflets are rotated in a clockwise manner to meet the mobilized septal leaflet. This results in 360 degrees of leaflet tissue, ie, a cone of leaflet tissue, that is then re-anchored at the level of the true annulus [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/52/38729/abstract/36\">",
"       36",
"      </a>",
"      ]. The atrialized RV is vertically plicated.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Several other repair techniques, involving annuloplasty",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ventricular plication, have also been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/52/38729/abstract/32,37-40\">",
"     32,37-40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If tricuspid repair is not possible and the patient has reached adult size, tricuspid valve replacement becomes necessary [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/52/38729/abstract/41\">",
"     41",
"    </a>",
"    ]. A biologic prosthesis (a porcine valve is preferred rather than a pericardial valve), is usually chosen because of the high incidence of thromboembolism with a mechanical prosthesis placed in the right heart [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/52/38729/abstract/42\">",
"     42",
"    </a>",
"    ]. The prosthesis is usually placed in an intra-atrial position in order to avoid injury to the right coronary artery or the exposed conduction tissue. Complete AV block is a complication of tricuspid valve replacement, particularly in less experienced centers.",
"   </p>",
"   <p>",
"    Surgical repair in the neonate consists of a biventricular repair or the single ventricle repair. Selection is primarily determined by tricuspid anatomy and surgeon experience. In general, a biventricular repair is preferred when there is good delamination of the anterior leaflet and the neonate is hemodynamically stable. Tricuspid valvuloplasty is most often a monocusp repair, and subtotal closure of the ASD is performed. Selective plication of the right ventricle is performed and generous right reduction atrioplasty is routine to allow room for the compressed lungs. The single ventricle pathway is more often preferred when there is a poorly developed or severely dysplastic anterior leaflet, anatomic pulmonary atresia, or hemodynamic instability. This neonatal operation consists of fenestrated patch closure of the tricuspid valve, atrial septectomy, and a systemic-to-pulmonary artery shunt. Subsequent operations then include a bidirectional cavopulmonary anastomosis at four to six months of age and completion Fontan at two to four years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/52/38729/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/27/41401?source=see_link&amp;anchor=H18895239#H18895239\">",
"     \"Hypoplastic left heart syndrome\", section on 'Surgical management'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Occasionally, a 1.5 ventricle repair is used in infants, children, and adults with severe RV dilatation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/52/38729/abstract/45\">",
"     45",
"    </a>",
"    ]. This results in reduction of the systemic venous volume load to the dysfunctional right ventricle by one-third to one-half and provides a guaranteed preload to the left ventricle. This has been shown to reduce early mortality in many series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/52/38729/abstract/45,46\">",
"     45,46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Surgical tricuspid valve re-repair or replacement is recommended in the following settings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/52/38729/abstract/16\">",
"     16",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Symptoms, worsening exercise capacity, or New York Heart Association functional class III or IV.",
"     </li>",
"     <li>",
"      Severe tricuspid regurgitation after repair with progressive RV dilation, reduction of RV systolic function, or",
"      <span class=\"nowrap\">",
"       appearance/progression",
"      </span>",
"      of atrial",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      ventricular arrhythmias.",
"     </li>",
"     <li>",
"      Bioprosthetic tricuspid valve dysfunction with significant mixed regurgitation and stenosis.",
"     </li>",
"     <li>",
"      Bioprosthetic valve stenosis (mean gradient &gt; 12 to 15 mmHg).",
"     </li>",
"     <li>",
"      Symptoms or decreased exercise tolerance and bioprosthetic valve stenosis (not meeting above criterion).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognosis varies with the severity of the disease. In a review of 220 patients seen between 1958 and 1991, the actuarial survival for all liveborn patients was 67 percent at one year and 59 percent at 10 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/52/38729/abstract/12\">",
"     12",
"    </a>",
"    ]. The major causes of death were heart failure, perioperative, and sudden death. The main predictors of death were echocardiographic grade of severity (relative risk 2.7 for each increase in grade; the grade was based upon the location of displaced tricuspid valve, right ventricular size, and clinical presentation), fetal presentation (relative risk 6.9), and right ventricular outflow tract obstruction (relative risk 2.1).",
"   </p>",
"   <p>",
"    The outcome was better in patients with less severe disease who presented in later childhood or adulthood. Among the survivors, 83 percent were New York Heart Association (NYHA) class I (",
"    <a class=\"graphic graphic_table graphicRef52683 \" href=\"mobipreview.htm?3/2/3117\">",
"     table 1",
"    </a>",
"    ) and 67 percent were receiving no medical therapy.",
"   </p>",
"   <p>",
"    Survival is probably increasing as advances in diagnostic and surgical techniques and postoperative care have led to improvements in surgical outcome. This was illustrated in a report of 158 patients who received a primary tricuspid bioprosthesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/52/38729/abstract/42\">",
"     42",
"    </a>",
"    ]. Ten year survival was 93 percent with freedom from bioprosthesis replacement at 10 and 15 years of 98 and 81 percent, respectively; 92 percent were NYHA class I or II and 94 percent were not receiving anticoagulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/52/38729/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similar results were noted in a review of 60 patients who underwent surgical repair of the tricuspid valve [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/52/38729/abstract/31\">",
"     31",
"    </a>",
"    ]. Hospital mortality was 3 percent, actuarial survival was 97 and 83 percent at one and 18 years, respectively, and 94 percent of survivors were NYHA class I or II [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/52/38729/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     PREGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnancy in congenital heart disease (unrepaired or repaired) poses potential risks to the mother and fetus. The general principles of this problem are discussed separately; issues related to pregnancy in Ebstein's anomaly will be reviewed here. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/7/29818?source=see_link\">",
"     \"Pregnancy in women with congenital heart disease: General principles\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Approximately 50 percent of patients with Ebstein's anomaly are female and the majority reach adulthood despite tricuspid regurgitation and abnormal right ventricular function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/52/38729/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. Right ventricular volume overload is augmented by the increase in cardiac output during pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/52/38729/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cyanosis due to an intracardiac right-to-left shunt may first become manifest during pregnancy because of the rise in right ventricular filling pressure. The right-to-left intracardiac shunt increases the risk of paradoxical embolization, and hypoxemia increases the fetal risk. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/48/39689?source=see_link&amp;anchor=H3#H3\">",
"     \"Atrial septal abnormalities (PFO, ASD, and ASA) and risk of cerebral emboli in adults\", section on 'Paradoxical emboli'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Arrhythmia risk is also increased during pregnancy in Ebstein&rsquo;s anomaly due to predisposition, such as accessory conduction pathway as well as the physiologic and hormonal changes that occur during pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/52/38729/abstract/51\">",
"     51",
"    </a>",
"    ]. The presence of an accessory pathway establishes a precondition for rapid ventricular rates in response to atrial fibrillation or atrial flutter with potentially catastrophic consequences. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/47/24311?source=see_link\">",
"     \"Atrioventricular reentrant tachycardia (AVRT) associated with an accessory pathway\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Despite these concerns, acyanotic women with Ebstein's anomaly usually tolerate pregnancy well [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/52/38729/abstract/49,52,53\">",
"     49,52,53",
"    </a>",
"    ]. A literature review of studies published between 1985 and 2007 found the following rates of complications during completed (&gt;20 weeks gestation) pregnancies among women with Ebstein's anomaly (combined repaired and unrepaired): arrhythmias in 5 of 127 pregnancies (3.9 percent); heart failure in 4 of 127 pregnancies (3.1 percent); and no cardiovascular events (myocardial infarction, stroke, and cardiovascular mortality) in the majority (128) of pregnancies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/52/38729/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is significant fetal risk associated with Ebstein's anomaly. These include an increased incidence of prematurity, fetal wastage, and congenital heart disease regardless of the presence or absence of maternal cyanosis. The above cited review reported the rates of fetal complications among completed (&gt;20 weeks gestation) pregnancies: premature delivery occurred in 28 of 127 pregnancies (22 percent), fetal mortality rate in none of 128 pregnancies, and perinatal mortality in 3 of 128 pregnancies (2.3 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/52/38729/abstract/53\">",
"     53",
"    </a>",
"    ]. Birth weights are lower in infants born to cyanotic women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/52/38729/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the presence of maternal Ebstein's anomaly, the rate of recurrence of congenital heart disease (of any type) in offspring was 4 percent (5 of 126) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/52/38729/abstract/53\">",
"     53",
"    </a>",
"    ]. Paternal Ebstein's anomaly may also increase the risk of congenital heart disease in the offspring (observed rate of 1 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/52/38729/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Repaired Ebstein's anomaly",
"    </span>",
"    &nbsp;&mdash;&nbsp;The reported risk of pregnancy is appreciably reduced after surgical repair of Ebstein's anomaly or catheter ablation of accessory pathways. Closure of an interatrial communication eliminates the risk of paradoxical embolization and the fetal risk of maternal cyanosis. However, the risk of congenital heart disease in the fetus remains.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     PARTICIPATION IN ATHLETICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although there is wide variability in the severity of Ebstein's anomaly, important",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    symptomatic arrhythmias, often during exercise, can occur even in mild cases. Severe cases can be associated with physical disability and an increased risk for sudden cardiac death with exercise [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/52/38729/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The 2005 36th Bethesda Conference on Eligibility Recommendations for Competitive Athletes with Cardiovascular Abnormalities recommended the following in patients with Ebstein's anomaly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/52/38729/abstract/22\">",
"     22",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Athletes with mild Ebstein's anomaly defined as no cyanosis, normal right ventricular size, and with no evidence of atrial or ventricular tachyarrhythmias can participate in all sports (",
"      <a class=\"graphic graphic_figure graphicRef64493 \" href=\"mobipreview.htm?28/51/29489\">",
"       figure 4",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Athletes with Ebstein's anomaly and moderate tricuspid regurgitation can participate in low-intensity competitive sports (class IA) (",
"      <a class=\"graphic graphic_figure graphicRef64493 \" href=\"mobipreview.htm?28/51/29489\">",
"       figure 4",
"      </a>",
"      ) if there is no evidence of arrhythmia on ambulatory ECG Holter monitoring other than isolated premature contractions.",
"     </li>",
"     <li>",
"      Athletes with severe Ebstein's anomaly (severe tricuspid regurgitation, right ventricular enlargement,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      evidence of arrhythmias) are precluded from all sports participation. However, after surgical repair, low-intensity competitive sports (class IA) (",
"      <a class=\"graphic graphic_figure graphicRef64493 \" href=\"mobipreview.htm?28/51/29489\">",
"       figure 4",
"      </a>",
"      ) can be permitted if tricuspid regurgitation is absent or mild, cardiac chamber size on chest radiograph or by echocardiography is not substantially increased, and symptomatic atrial or ventricular tachyarrhythmias are not present on ambulatory ECG monitoring and exercise test. Selected athletes with an excellent hemodynamic result after repair may be permitted additional participation on an individual basis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The general issue of the risk of sudden cardiac death in athletes is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/36/13898?source=see_link\">",
"     \"Risk of sudden cardiac death in athletes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10180269\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ebstein&rsquo;s anomaly is a congenital malformation characterized by variably malformed and displaced tricuspid valve leaflets that are partly attached to the tricuspid valve annulus and partly attached to the right ventricular endocardium. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Tricuspid valve'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ebstein's anomaly can be classified as mild, moderate, or severe based upon the extent of apical displacement of the valve leaflets with resultant tricuspid regurgitation, and the degree of right-sided cardiac chamber dilation and dysfunction. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Classification'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cardiac defects associated with Ebstein&rsquo;s anomaly include atrial septal defect, ventricular septal defect, pulmonary outflow obstruction, patent ductus arteriosus, coarctation of the aorta, one or more accessory conduction pathways, mitral valve prolapse, bicuspid aortic valve, and left ventricular noncompaction. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Associated cardiac defects'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical presentation and prognosis of Ebstein&rsquo;s anomaly varies with the severity of the lesion. Severe malformations associated with cyanosis in neonates and heart failure in infants result in a guarded prognosis. Milder disease may be detected as an incidental murmur in children or adults; these patients may remain asymptomatic for decades. Adolescents and adults commonly present with atrial arrhythmias, often associated with one or more accessory pathways. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Clinical presentation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H17\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Echocardiography is the primary test for establishing the diagnosis of Ebstein&rsquo;s anomaly. Findings include apical displacement of the septal tricuspid leaflet (by &ge;8 mm per meter squared body surface area compared to the position of the mitral valve), enlarged right ventricular volume, and low velocity tricuspid regurgitation. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Echocardiography'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment of atrial arrhythmias includes radiofrequency catheter ablation or surgical ablation of atrioventricular accessory pathway(s) and drug therapy, as discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/60/15305?source=see_link\">",
"       \"Pharmacologic therapy of arrhythmias associated with the Wolff-Parkinson-White syndrome\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/45/37591?source=see_link\">",
"       \"Surgical approaches to prevent recurrent atrial fibrillation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Medical management in a newborn with cyanosis is limited to supportive therapy until the pulmonary vascular resistance drops and normalizes with time. In case of extreme cyanosis, prostaglandin E1 (also known as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40966?source=see_link\">",
"       alprostadil",
"      </a>",
"      ) infusion is indicated to keep the patent ductus arteriosus open and increase pulmonary blood flow until the pulmonary vascular resistance drops. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Medical therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Infants and children with heart failure may benefit from inotropic agent(s),",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      and a loop diuretic. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Medical therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although evidence to guide therapy is limited, we suggest anticoagulation with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      in patients with atrial fibrillation or history of paradoxical embolus with an unrepaired interatrial shunt. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Medical therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend surgical tricuspid valve repair or replacement with concomitant ASD closure in patients with Ebstein&rsquo;s anomaly with the following indications (see",
"      <a class=\"local\" href=\"#H16\">",
"       'Surgery'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Symptoms or deteriorating exercise capacity.",
"     </li>",
"     <li>",
"      Cyanosis (oxygen saturation less than 90 percent).",
"     </li>",
"     <li>",
"      Paradoxical embolism.",
"     </li>",
"     <li>",
"      Progressive cardiomegaly on chest x-ray.",
"     </li>",
"     <li>",
"      Progressive right ventricular (RV) dilation or reduction of RV systolic function.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Surgical tricuspid valve re-repair or replacement is recommended for symptoms, severe tricuspid regurgitation with progressive RV dilation or systolic dysfunction or arrhythmias or bioprosthetic dysfunction. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Acyanotic women with Ebstein's anomaly usually tolerate pregnancy, provided that sinus rhythm is maintained. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Pregnancy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1801906\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The UpToDate editorial staff would&nbsp;like to thank Dr. Catherine M. Otto for her contributions as a Section Editor to previous versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/52/38729/abstract/1\">",
"      Lupo PJ, Langlois PH, Mitchell LE. Epidemiology of Ebstein anomaly: prevalence and patterns in Texas, 1999-2005. Am J Med Genet A 2011; 155A:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/52/38729/abstract/2\">",
"      Correa-Villase&ntilde;or A, Ferencz C, Neill CA, et al. Ebstein's malformation of the tricuspid valve: genetic and environmental factors. The Baltimore-Washington Infant Study Group. Teratology 1994; 50:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/52/38729/abstract/3\">",
"      Pradat P, Francannet C, Harris JA, Robert E. The epidemiology of cardiovascular defects, part I: a study based on data from three large registries of congenital malformations. Pediatr Cardiol 2003; 24:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/52/38729/abstract/4\">",
"      Allan LD, Desai G, Tynan MJ. Prenatal echocardiographic screening for Ebstein's anomaly for mothers on lithium therapy. Lancet 1982; 2:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/52/38729/abstract/5\">",
"      Attenhofer Jost CH, Connolly HM, Dearani JA, et al. Ebstein's anomaly. Circulation 2007; 115:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/52/38729/abstract/6\">",
"      Dearani JA, Danielson GK. Congenital Heart Surgery Nomenclature and Database Project: Ebstein's anomaly and tricuspid valve disease. Ann Thorac Surg 2000; 69:S106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/52/38729/abstract/7\">",
"      BURCHELL HB, DUSHANE JW, KILBY RA, WOOD EH. Ebstein's malformation: a clinical and laboratory study. Medicine (Baltimore) 1956; 35:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/52/38729/abstract/8\">",
"      Attenhofer Jost CH, Connolly HM, O'Leary PW, et al. Left heart lesions in patients with Ebstein anomaly. Mayo Clin Proc 2005; 80:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/52/38729/abstract/9\">",
"      Watson H. Electrode catheters and the diagnosis of Ebstein's anomaly of the tricuspid valve. Br Heart J 1966; 28:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/52/38729/abstract/10\">",
"      SUMNER RG, JACOBY WJ Jr, TUCKER DH. EBSTEIN'S ANOMALY ASSOCIATED WITH CARDIOMYOPATHY AND PULMONARY HYPERTENSION. Circulation 1964; 30:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/52/38729/abstract/11\">",
"      Seward JB, Tajik AJ, Feist DJ, Smith HC. Ebstein's anomaly in an 85-year-old man. Mayo Clin Proc 1979; 54:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/52/38729/abstract/12\">",
"      Celermajer DS, Bull C, Till JA, et al. Ebstein's anomaly: presentation and outcome from fetus to adult. J Am Coll Cardiol 1994; 23:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/52/38729/abstract/13\">",
"      Watson H. Natural history of Ebstein's anomaly of tricuspid valve in childhood and adolescence. An international co-operative study of 505 cases. Br Heart J 1974; 36:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/52/38729/abstract/14\">",
"      LEV M, GIBSON S, MILLER RA. Ebstein's disease with Wolff-Parkinson-White syndrome; report of a case with a histopathologic study of possible conduction pathways. Am Heart J 1955; 49:724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/52/38729/abstract/15\">",
"      Cappato R, Schl&uuml;ter M, Weiss C, et al. Radiofrequency current catheter ablation of accessory atrioventricular pathways in Ebstein's anomaly. Circulation 1996; 94:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/52/38729/abstract/16\">",
"      Warnes CA, Williams RG, Bashore TM, et al. ACC/AHA 2008 Guidelines for the Management of Adults with Congenital Heart Disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to develop guidelines on the management of adults with congenital heart disease). Circulation 2008; 118:e714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/52/38729/abstract/17\">",
"      VAN LINGEN B, BAUERSFELD SR. The electrocardiogram in Ebstein's anomaly of the tricuspid valve. Am Heart J 1955; 50:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/52/38729/abstract/18\">",
"      Shiina A, Seward JB, Edwards WD, et al. Two-dimensional echocardiographic spectrum of Ebstein's anomaly: detailed anatomic assessment. J Am Coll Cardiol 1984; 3:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/52/38729/abstract/19\">",
"      Gussenhoven EJ, Stewart PA, Becker AE, et al. \"Offsetting\" of the septal tricuspid leaflet in normal hearts and in hearts with Ebstein's anomaly. Anatomic and echographic correlation. Am J Cardiol 1984; 54:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/52/38729/abstract/20\">",
"      Bonow RO, Carabello BA, Chatterjee K, et al. 2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2008; 118:e523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/52/38729/abstract/21\">",
"      Zoghbi WA, Enriquez-Sarano M, Foster E, et al. Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography. J Am Soc Echocardiogr 2003; 16:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/52/38729/abstract/22\">",
"      Graham TP Jr, Driscoll DJ, Gersony WM, et al. Task Force 2: congenital heart disease. J Am Coll Cardiol 2005; 45:1326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/52/38729/abstract/23\">",
"      Knott-Craig CJ, Goldberg SP, Overholt ED, et al. Repair of neonates and young infants with Ebstein's anomaly and related disorders. Ann Thorac Surg 2007; 84:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/52/38729/abstract/24\">",
"      Knott-Craig CJ, Goldberg SP, Kirklin JK. Surgical strategy to prevent cardiac injury during reoperation in infants. J Cardiothorac Surg 2008; 3:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/52/38729/abstract/25\">",
"      Attenhofer Jost CH, Edmister WD, Julsrud PR, et al. Prospective comparison of echocardiography versus cardiac magnetic resonance imaging in patients with Ebstein's anomaly. Int J Cardiovasc Imaging 2012; 28:1147.",
"     </a>",
"    </li>",
"    <li>",
"     Wilson W, Taubert KA, Gewitz M, et al. Prevention of Infective Endocarditis. Guidelines From the American Heart Association. A Guideline From the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation 2007; 115 published online April 19, 2007. www.circ.ahajournals.org/cgi/reprint/CIRCULATIONAHA.106.183095v1 (Accessed on May 04, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/52/38729/abstract/27\">",
"      Reich JD, Auld D, Hulse E, et al. The Pediatric Radiofrequency Ablation Registry's experience with Ebstein's anomaly. Pediatric Electrophysiology Society. J Cardiovasc Electrophysiol 1998; 9:1370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/52/38729/abstract/28\">",
"      Misaki T, Watanabe G, Iwa T, et al. Surgical treatment of patients with Wolff-Parkinson-White syndrome and associated Ebstein's anomaly. J Thorac Cardiovasc Surg 1995; 110:1702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/52/38729/abstract/29\">",
"      Starnes VA, Pitlick PT, Bernstein D, et al. Ebstein's anomaly appearing in the neonate. A new surgical approach. J Thorac Cardiovasc Surg 1991; 101:1082.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/52/38729/abstract/30\">",
"      Mair DD. Ebstein's anomaly: natural history and management. J Am Coll Cardiol 1992; 19:1047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/52/38729/abstract/31\">",
"      Augustin N, Schmidt-Habelmann P, Wottke M, et al. Results after surgical repair of Ebstein's anomaly. Ann Thorac Surg 1997; 63:1650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/52/38729/abstract/32\">",
"      Vargas FJ, Mengo G, Granja MA, et al. Tricuspid annuloplasty and ventricular plication for Ebstein's malformation. Ann Thorac Surg 1998; 65:1755.",
"     </a>",
"    </li>",
"    <li>",
"     Danielson GK. Ebstein's anomaly of the tricuspid valve. In: Pediatric Cardiac Surgery, Mavroudas C, Backer CL (Eds), Mosby, St. Louis 1994. p.413.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/52/38729/abstract/34\">",
"      Danielson GK, Driscoll DJ, Mair DD, et al. Operative treatment of Ebstein's anomaly. J Thorac Cardiovasc Surg 1992; 104:1195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/52/38729/abstract/35\">",
"      Carpentier A, Chauvaud S, Mac&eacute; L, et al. A new reconstructive operation for Ebstein's anomaly of the tricuspid valve. J Thorac Cardiovasc Surg 1988; 96:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/52/38729/abstract/36\">",
"      da Silva JP, Baumgratz JF, da Fonseca L, et al. The cone reconstruction of the tricuspid valve in Ebstein's anomaly. The operation: early and midterm results. J Thorac Cardiovasc Surg 2007; 133:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/52/38729/abstract/37\">",
"      Quaegebeur JM, Sreeram N, Fraser AG, et al. Surgery for Ebstein's anomaly: the clinical and echocardiographic evaluation of a new technique. J Am Coll Cardiol 1991; 17:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/52/38729/abstract/38\">",
"      Hetzer R, Nagdyman N, Ewert P, et al. A modified repair technique for tricuspid incompetence in Ebstein's anomaly. J Thorac Cardiovasc Surg 1998; 115:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/52/38729/abstract/39\">",
"      Marianeschi SM, McElhinney DB, Reddy VM, et al. Alternative approach to the repair of Ebstein's malformation: intracardiac repair with ventricular unloading. Ann Thorac Surg 1998; 66:1546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/52/38729/abstract/40\">",
"      Wu Q, Huang Z. A new procedure for Ebstein's anomaly. Ann Thorac Surg 2004; 77:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/52/38729/abstract/41\">",
"      Bove EL, Kirsh MM. Valve replacement for Ebstein's anomaly of the tricuspid valve. J Thorac Cardiovasc Surg 1979; 78:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/52/38729/abstract/42\">",
"      Kiziltan HT, Theodoro DA, Warnes CA, et al. Late results of bioprosthetic tricuspid valve replacement in Ebstein's anomaly. Ann Thorac Surg 1998; 66:1539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/52/38729/abstract/43\">",
"      van Son JA, Falk V, Black MD, et al. Conversion of complex neonatal Ebstein's anomaly into functional tricuspid or pulmonary atresia. Eur J Cardiothorac Surg 1998; 13:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/52/38729/abstract/44\">",
"      Kaulitz R, Ziemer G. Modified Fontan procedure for Ebstein's anomaly of the tricuspid valve--an alternative surgical approach preserving Ebstein's anatomy. Thorac Cardiovasc Surg 1995; 43:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/52/38729/abstract/45\">",
"      Quinonez LG, Dearani JA, Puga FJ, et al. Results of the 1.5-ventricle repair for Ebstein anomaly and the failing right ventricle. J Thorac Cardiovasc Surg 2007; 133:1303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/52/38729/abstract/46\">",
"      Malhotra SP, Petrossian E, Reddy VM, et al. Selective right ventricular unloading and novel technical concepts in Ebstein's anomaly. Ann Thorac Surg 2009; 88:1975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/52/38729/abstract/47\">",
"      Dearani JA, Bacha E, da Silva JP. Cone Reconstruction of the Tricuspid Valve for Ebstein's Anomaly: Anatomic Repair. Op Tech Thorac Cardiovasc Surg 2008; :109.",
"     </a>",
"    </li>",
"    <li>",
"     Perloff, JK. The Clinical Recognition of Congenital Heart Disease, 6th ed, Elsevier/Saunders, Philadelphia 2012.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/52/38729/abstract/49\">",
"      Connolly HM, Warnes CA. Ebstein's anomaly: outcome of pregnancy. J Am Coll Cardiol 1994; 23:1194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/52/38729/abstract/50\">",
"      Waickman LA, Skorton DJ, Varner MW, et al. Ebstein's anomaly and pregnancy. Am J Cardiol 1984; 53:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/52/38729/abstract/51\">",
"      Kounis NG, Zavras GM, Papadaki PJ, et al. Pregnancy-induced increase of supraventricular arrhythmias in Wolff-Parkinson-White syndrome. Clin Cardiol 1995; 18:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/52/38729/abstract/52\">",
"      Donnelly JE, Brown JM, Radford DJ. Pregnancy outcome and Ebstein's anomaly. Br Heart J 1991; 66:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/52/38729/abstract/53\">",
"      Drenthen W, Pieper PG, Roos-Hesselink JW, et al. Outcome of pregnancy in women with congenital heart disease: a literature review. J Am Coll Cardiol 2007; 49:2303.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8146 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-50E636C042-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_52_38729=[""].join("\n");
var outline_f37_52_38729=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10180269\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10180283\">",
"      MORPHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Tricuspid valve",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Right ventricle",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Classification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Associated cardiac defects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10180935\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      TESTING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Electrocardiogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Chest radiograph",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Echocardiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10180432\">",
"      Arrhythmia evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10180895\">",
"      CMR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10180515\">",
"      Other studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Medical therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10180600\">",
"      - Arrhythmia treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Repaired Ebstein's anomaly",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      PARTICIPATION IN ATHLETICS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10180269\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1801906\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/8146\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/8146|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?19/49/20255\" title=\"diagnostic image 1\">",
"      Chest radiograph Ebstein",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?16/5/16465\" title=\"diagnostic image 2\">",
"      Echocardiogram Ebstein II",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/8146|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?20/36/21061\" title=\"figure 1\">",
"      Pathophysiology Ebstein anomaly",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?19/41/20114\" title=\"figure 2\">",
"      Echocardiogram Ebstein I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?12/4/12359\" title=\"figure 3\">",
"      ECG Ebstein anomaly",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?28/51/29489\" title=\"figure 4\">",
"      Classification exercise",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/8146|MOV\">",
"      <a href=\"#\" title=\"MOVIES\">",
"       MOVIES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"mobipreview.htm?1/11/1202\" title=\"movie 1\">",
"      Ebsteins anomaly four chamber echocardiogram",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/8146|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?3/2/3117\" title=\"table 1\">",
"      Methods to assess cardiovascular disability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/8146|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?35/3/35895\" title=\"waveform 1\">",
"      ECG Ebstein anomaly WPW",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/36/585?source=related_link\">",
"      Antimicrobial prophylaxis for bacterial endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/48/39689?source=related_link\">",
"      Atrial septal abnormalities (PFO, ASD, and ASA) and risk of cerebral emboli in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/47/24311?source=related_link\">",
"      Atrioventricular reentrant tachycardia (AVRT) associated with an accessory pathway",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/37/26202?source=related_link\">",
"      Auscultation of cardiac murmurs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/61/11226?source=related_link\">",
"      Bipolar disorder in adults: Teratogenic and postnatal risks of pharmacotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/37/26201?source=related_link\">",
"      Classification and clinical features of isolated atrial septal defects in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/22/32106?source=related_link\">",
"      Clinical manifestations and diagnosis of arrhythmogenic right ventricular cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/53/23385?source=related_link\">",
"      Clinical manifestations and diagnosis of coarctation of the aorta",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/52/35656?source=related_link\">",
"      Clinical manifestations and diagnosis of patent ductus arteriosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/62/39910?source=related_link\">",
"      Clinical manifestations and diagnosis of pulmonic stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/2/14378?source=related_link\">",
"      Echocardiographic evaluation of the tricuspid valve",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/61/17370?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of the Wolff-Parkinson-White syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/9/149?source=related_link\">",
"      Etiology, clinical features, and evaluation of tricuspid regurgitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/59/33719?source=related_link\">",
"      Examination of the jugular venous pulse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/43/9909?source=related_link\">",
"      Examination of the precordial pulsation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/27/41401?source=related_link\">",
"      Hypoplastic left heart syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/51/41784?source=related_link\">",
"      Isolated left ventricular noncompaction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/35/39478?source=related_link\">",
"      Medical management of cyanotic congenital heart disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/63/38906?source=related_link\">",
"      Overview of the therapy of heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/32/3593?source=related_link\">",
"      Patent foramen ovale",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/27/16825?source=related_link\">",
"      Pathophysiology and clinical features of atrial septal defects in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/19/8506?source=related_link\">",
"      Pathophysiology and clinical features of isolated ventricular septal defects in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/60/15305?source=related_link\">",
"      Pharmacologic therapy of arrhythmias associated with the Wolff-Parkinson-White syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/7/29818?source=related_link\">",
"      Pregnancy in women with congenital heart disease: General principles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/36/13898?source=related_link\">",
"      Risk of sudden cardiac death in athletes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/45/37591?source=related_link\">",
"      Surgical approaches to prevent recurrent atrial fibrillation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_52_38730="Fentanyl: Drug information";
var content_f37_52_38730=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Fentanyl: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?0/29/472?source=see_link\">",
"    see \"Fentanyl: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/45/35546?source=see_link\">",
"    see \"Fentanyl: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708780\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F170610\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Abstral&reg;;",
"     </li>",
"     <li>",
"      Actiq&reg;;",
"     </li>",
"     <li>",
"      Duragesic&reg;;",
"     </li>",
"     <li>",
"      Fentora&reg;;",
"     </li>",
"     <li>",
"      Lazanda&reg;;",
"     </li>",
"     <li>",
"      Onsolis&reg;;",
"     </li>",
"     <li>",
"      Subsys&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F170611\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Abstral&trade;;",
"     </li>",
"     <li>",
"      Actiq&reg;;",
"     </li>",
"     <li>",
"      Apo-Fentanyl&reg; Matrix;",
"     </li>",
"     <li>",
"      Duragesic&reg;;",
"     </li>",
"     <li>",
"      Duragesic&reg; MAT;",
"     </li>",
"     <li>",
"      Fentanyl Citrate Injection, USP;",
"     </li>",
"     <li>",
"      Novo-Fentanyl;",
"     </li>",
"     <li>",
"      Onsolis&reg;;",
"     </li>",
"     <li>",
"      PMS-Fentanyl MTX;",
"     </li>",
"     <li>",
"      RAN&trade;-Fentanyl Matrix Patch;",
"     </li>",
"     <li>",
"      RAN&trade;-Fentanyl Transdermal System;",
"     </li>",
"     <li>",
"      ratio-Fentanyl;",
"     </li>",
"     <li>",
"      Sandoz Fentanyl Patch;",
"     </li>",
"     <li>",
"      Teva-Fentanyl",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F170659\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Analgesic, Opioid;",
"     </li>",
"     <li>",
"      Anilidopiperidine Opioid;",
"     </li>",
"     <li>",
"      General Anesthetic",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F170615\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Ranges listed may not represent the maximum doses that may be required in all patients. Doses and dosage intervals should be titrated to pain relief/prevention. Monitor vital signs routinely. Single I.M. doses have duration of 1-2 hours, single I.V. doses last 0.5-1 hour.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Surgery:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Premedication: I.M., slow I.V.: 50-100 mcg/dose 30-60 minutes prior to surgery",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Adjunct to regional anesthesia: Slow I.V.: 25-100 mcg/dose over 1-2 minutes.",
"     <b>",
"      Note:",
"     </b>",
"     An I.V. should be in place with regional anesthesia so the I.M. route is rarely used but still maintained as an option in the package labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adjunct to general anesthesia: Slow I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Low dose: 0.5-2 mcg/kg/dose depending on the indication.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Moderate dose: Initial: 2-20 mcg/kg/dose; Maintenance (bolus or infusion): 1-2 mcg/kg/",
"     <b>",
"      hour",
"     </b>",
"     . Discontinuing fentanyl infusion 30-60 minutes prior to the end of surgery will usually allow adequate ventilation upon emergence from anesthesia. For &ldquo;fast-tracking&rdquo; and early extubation following major surgery, total fentanyl doses are limited to 10-15 mcg/kg.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     High dose: 20-50 mcg/kg/dose;",
"     <b>",
"      Note:",
"     </b>",
"     High-dose fentanyl as an adjunct to general anesthesia is rarely used, but is still described in the manufacturer&rsquo;s label.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Pain management:",
"     </b>",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V. (unlabeled use): Bolus at start of infusion: 1-2 mcg/kg",
"     <b>",
"      or",
"     </b>",
"     25-100 mcg/dose; continuous infusion rate: 1-2 mcg/kg/",
"     <b>",
"      hour",
"     </b>",
"     <b>",
"      or",
"     </b>",
"     25-200 mcg/hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Severe (unlabeled use): I.M, I.V.: 50-100 mcg/dose every 1-2 hours as needed; patients with prior opiate exposure may tolerate higher initial doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Patient-controlled analgesia (PCA) (unlabeled use):",
"     </i>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Usual concentration: 10 mcg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Demand dose: Usual: 20 mcg; range: 10-50 mcg",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:4em;text-align:justify;\">",
"     Lockout interval: 5-8 minutes",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:4em;text-align:justify;\">",
"     Usual basal rate: &le;50 mcg/hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Critically-ill patients (unlabeled dose):",
"     </i>",
"     Slow I.V.: 25-35 mcg (based on ~70 kg patient)",
"     <b>",
"      or",
"     </b>",
"     0.35-0.5 mcg/kg every 30-60 minutes as needed (Barr, 2013).",
"     <b>",
"      Note:",
"     </b>",
"     More frequent dosing may be needed (eg, mechanically-ventilated patients).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Continuous infusion: 50-700 mcg/hour (based on ~70 kg patient)",
"     <b>",
"      or",
"     </b>",
"     0.7-10 mcg/kg/",
"     <b>",
"      hour",
"     </b>",
"     (Barr, 2013)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Intrathecal (I.T.) (unlabeled use; American Pain Society, 2008):",
"     <b>",
"      Must be preservative-free.",
"     </b>",
"     Doses must be adjusted for age, injection site, and patient&rsquo;s medical condition and degree of opioid tolerance.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Single dose: 5-25 mcg/dose; may provide adequate relief for up to 6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Continuous infusion: Not recommended in acute pain management due to risk of excessive accumulation. For chronic cancer pain, infusion of very small doses may be practical (American Pain Society, 2008).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Epidural (unlabeled use; American Pain Society, 2008):",
"     <b>",
"      Must be preservative-free.",
"     </b>",
"     Doses must be adjusted for age, injection site, and patient&rsquo;s medical condition and degree of opioid tolerance",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Single dose: 25-100 mcg/dose; may provide adequate relief for up to 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Continuous infusion: 25-100 mcg/hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Breakthrough cancer pain:",
"     </b>",
"     Transmucosal: For patients who are tolerant to and currently receiving opioid therapy for persistent cancer pain; dosing should be individually titrated to provide adequate analgesia with minimal side effects. Dose titration should be done if patient requires more than 1 dose/breakthrough pain episode for several consecutive episodes. Patients experiencing &gt;4 breakthrough pain episodes/day should have the dose of their long-term opioid re-evaluated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Lozenge (Actiq&reg;): Initial dose: 200 mcg; the second dose may be started 15 minutes after completion of the first dose if pain unrelieved. A maximum of 1 additional dose can be given per pain episode; must wait at least 4 hours before treating another episode. Consumption should be limited to &le;4 units/day. Additional requirements suggest need for improved baseline therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Buccal film (Onsolis&reg;): Initial dose: 200 mcg for all patients",
"     <b>",
"      Note:",
"     </b>",
"     Patients previously using another transmucosal product should be initiated at doses of 200 mcg; do",
"     <b>",
"      not",
"     </b>",
"     switch patients using any other fentanyl product on a mcg-per-mcg basis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Dose titration: If titration required, increase dose in 200 mcg increments once per episode using multiples of the 200 mcg film; do not redose within a single episode of breakthrough pain and separate single doses by &ge;2 hours. During titration, do not exceed 4 simultaneous applications of the 200 mcg films (800 mcg). If &gt;800 mcg required, treat next episode with one 1200 mcg film (maximum dose: 1200 mcg). Once maintenance dose is determined, all other unused films should be disposed of and that strength (using a single film) should be used. During any pain episode, if adequate relief is not achieved after 30 minutes following buccal film application, a rescue medication (as determined by healthcare provider) may be used.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Maintenance: Determined dose applied as a single film once per episode and separated by &ge;2 hours (dose range: 200-1200 mcg); limit to 4 applications/day. Consider increasing the around-the-clock opioid therapy in patients experiencing &gt;4 breakthrough pain episodes/day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Buccal tablet (Fentora&reg;): Initial dose: 100 mcg; a second 100 mcg dose, if needed, may be started 30 minutes after the start of the first dose.",
"     <b>",
"      Note:",
"     </b>",
"     For patients previously using the transmucosal lozenge (Actiq&reg;), the initial dose should be selected using the conversions listed below (maximum: 2 doses per breakthrough pain episode every 4 hours).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Dose titration, if required, should be done using multiples of the 100 mcg tablets. Patient can use two 100 mcg tablets (one on each side of mouth). If that dose is not successful, can use four 100 mcg  tablets (two on each side of mouth). If titration requires &gt;400 mcg/dose, then use 200 mcg tablets.",
"     <b>",
"      Note:",
"     </b>",
"     Buccal tablet may be administered sublingually once an effective maintenance dose has been established.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Conversion from lozenge to buccal tablet",
"     </i>",
"     (Fentora&reg;):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Lozenge dose 200-400 mcg, then buccal tablet 100 mcg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Lozenge dose 600-800 mcg, then buccal tablet 200 mcg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Lozenge dose 1200-1600 mcg, then buccal tablet 400 mcg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Four 100 mcg buccal tablets deliver approximately 12% and 13% higher values of C",
"     <sub>",
"      max",
"     </sub>",
"     and AUC, respectively, compared to one 400 mcg buccal tablet. To prevent confusion, patient should only have one strength available at a time. Using more than four buccal tablets at a time has not been studied.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Nasal spray (Lazanda&reg;):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Initial dose: 100 mcg (one 100 mcg spray in one nostril) for all patients.",
"     <b>",
"      Note:",
"     </b>",
"     Patients previously using another fentanyl product should be initiated at a dose of 100 mcg; do not convert patients from other fentanyl products to Lazanda&reg; on a mcg-per-mcg basis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Dose titration: If pain is relieved within 30 minutes, that same dose should be used to treat subsequent episodes. If pain is unrelieved, may increase to a higher dose using the recommended titration steps.",
"     <b>",
"      Must wait at least 2 hours before treating another episode with nasal spray.",
"     </b>",
"     Dose titration steps: If no relief with 100 mcg dose, increase to 200 mcg dose per episode (one 100 mcg spray in each nostril); if no relief with 200 mcg dose, increase to 400 mcg per episode (one 400 mcg spray); if no relief with 400 mcg dose, increase to 800 mcg dose per episode (one 400 mcg spray in each nostril).",
"     <b>",
"      Note:",
"     </b>",
"     Single doses &gt;800 mcg have not been evaluated. There are no data supporting the use of a combination of dose strengths.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Maintenance dose: Once maintenance dose for breakthrough pain episode has been determined, use that dose for subsequent episodes. For pain that is not relieved after 30 minutes of Lazanda&reg; administration or if a separate breakthrough pain episode occurs within the 2 hour window before the next Lazanda&reg; dose is permitted, a rescue medication may be used. Limit Lazanda&reg; use to &le;4 episodes of breakthrough pain per day. If response to maintenance dose changes (increase in adverse reactions or alterations in pain relief), dose readjustment may be necessary. If patient is experiencing &gt;4 breakthrough pain episodes/day, consider increasing the around-the-clock, long-acting opioid therapy; if long-acting opioid therapy dose is altered, re-evaluate and retitrate Lazanda&reg; dose as needed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Sublingual spray (Subsys&reg;):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Initial dose: 100 mcg for all patients. If pain is unrelieved, 1 additional 100 mcg dose may be given 30 minutes after administration of the first dose. A maximum of 2 doses can be given per breakthrough pain episode; must wait at least 4 hours before treating another episode.",
"     <b>",
"      Note:",
"     </b>",
"     Patients must remain on around-the-clock opioids during use. Patients previously using other fentanyl products should be initiated at a dose of 100 mcg; do not convert patients from any other fentanyl product (transmucosal, transdermal, or parenteral) to Subsys&reg; on a mcg-per-mcg basis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Dose titration: If pain is relieved within 30 minutes, that same dose should be used to treat subsequent episodes and no titration is necessary. If pain is unrelieved, may increase to a higher dose using the recommended titration steps. Goal is to determine the dose that provides adequate analgesia (with tolerable side effects) using a single dose per breakthrough pain episode.  For each breakthrough pain episode, if pain unrelieved after 30 minutes only 1 additional dose using the same strength may be given (maximum: 2 doses per breakthrough pain episode).",
"     <b>",
"      Must wait at least 4 hours before treating another episode with Subsys&reg;.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Dose titration steps: If no relief with 100 mcg dose, increase to 200 mcg dose per episode (one 200 mcg unit); if no relief with 200 mcg dose, increase to 400 mcg per episode (one 400 mcg unit); if no relief with 400 mcg dose, increase to 600 mcg dose per episode (one 600 mcg unit); if no relief with 600 mcg dose, increase to 800 mcg dose per episode (one 800 mcg unit); if no relief with 800 mcg dose, increase to 1200 mcg dose per episode (two 600 mcg units); if no relief with 1200 mcg dose, increase to 1600 mcg per episode (two 800 mcg units).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Maintenance dose: Once maintenance dose for breakthrough pain episode has been determined, use that dose for subsequent episodes. If occasional episodes of unrelieved breakthrough pain occur following 30 minutes of Subsys&reg; administration, 1 additional dose using the same strength may be administered (maximum: 2 doses per breakthrough pain episode); patient must wait 4 hours before treating another breakthrough pain episode with Subsys&reg;. Once maintenance dose is determined, limit Susbsys&trade; use to &le;4 episodes of breakthrough pain per day. If response to maintenance dose changes (increase in adverse reactions or alterations in pain relief), dose readjustment may be necessary. If patient is experiencing &gt;4 breakthrough pain episodes/day, consider increasing the around-the-clock, long-acting opioid therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Sublingual tablet (Abstral&reg;):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Initial dose:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     U.S. labeling: 100 mcg for all patients; if pain is unrelieved, a second dose may be given 30 minutes after administration of the first dose. A maximum of 2 doses can be given per breakthrough pain episode; must wait at least 2 hours before treating another episode.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Canadian labeling: 100 mcg for all patients; if pain is unrelieved 30 minutes after administration of Abstral&trade;, an alternative rescue medication (other than Abstral&trade;) may be given. Administer only 1 dose of Abstral&trade; per breakthrough pain episode; must wait at least 2 hours before treating another episode.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Patients previously using another fentanyl product should be initiated at a dose of 100 mcg; do not convert patients from other fentanyl products to Abstral&reg; on a mcg-per-mcg basis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Dose titration: If titration required, increase in 100 mcg increments (up to 400 mcg) over consecutive breakthrough episodes. If titration requires &gt;400 mcg/dose, increase in increments of 200 mcg, starting with 600 mcg dose. During titration, patients may use multiples of 100 mcg and/or 200 mcg tablets for any single dose; do not exceed 4 tablets at one time; safety and efficacy of doses &gt;800 mcg have not been evaluated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Maintenance dose: Once maintenance dose for breakthrough pain episode has been determined, use only 1 tablet in the appropriate strength per episode; if pain is unrelieved with maintenance dose:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     U.S. labeling recommendations: A second dose may be given after 30 minutes; maximum of 2 doses/episode of breakthrough pain; separate treatment of subsequent episodes by &ge;2 hours; limit treatment to &le;4 breakthrough episodes/day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Canadian labeling recommendations:  Administer alternative rescue medication after 30 minutes; maximum of 1 Abstral&trade; dose/episode of breakthrough pain; separate treatment of subsequent episodes by &ge;2 hours; limit treatment to &le;4 breakthrough episodes/day.",
"    </p>",
"    <p style=\"text-indent:-4em;margin-left:10em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Consider increasing the around-the-clock long-acting opioid therapy in patients experiencing &gt;4 breakthrough pain episodes/day; if long-acting opioid therapy dose altered, re-evaluate and retitrate Abstral&reg; dose as needed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Chronic pain management:",
"     </b>",
"     Children &ge;2 years and Adults (opioid-tolerant patients): Transdermal patch (Duragesic&reg;):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Initial:",
"     </i>",
"     To convert patients from oral or parenteral opioids to transdermal patch, a 24-hour analgesic requirement should be calculated (based on prior opiate use). Using the tables, the appropriate initial dose can be determined. The initial fentanyl dosage may be approximated from the 24-hour morphine dosage equivalent and titrated to minimize adverse effects and provide analgesia. With the initial application, the absorption of transdermal fentanyl requires several hours to reach plateau; therefore transdermal fentanyl is inappropriate for management of acute pain. Change patch every 72 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Conversion from continuous infusion of fentanyl:",
"     </i>",
"     In patients who have adequate pain relief with a fentanyl infusion, fentanyl may be converted to transdermal dosing at a rate equivalent to the intravenous rate.  A two-step taper of the infusion to be completed over 12 hours has been recommended (Kornick, 2001) after the patch is applied. The infusion is decreased to 50% of the original rate six hours after the application of the first patch, and subsequently discontinued twelve hours after application.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Titration:",
"     </i>",
"     Short-acting agents may be required until analgesic efficacy is established and/or as supplements for &ldquo;breakthrough&rdquo; pain. The amount of supplemental doses should be closely monitored. Appropriate dosage increases may be based on daily supplemental dosage using the ratio of 45 mg/24 hours of oral morphine to a 12.5 mcg/hour increase in fentanyl dosage.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Frequency of adjustment:",
"     </i>",
"     The dosage should not be titrated more frequently than every 3 days after the initial dose or every 6 days thereafter. Patients should wear a consistent fentanyl dosage through two applications (6 days) before dosage increase based on supplemental opiate dosages can be estimated.",
"     <b>",
"      Note:",
"     </b>",
"     Upon discontinuation, ~17 hours are required for a 50% decrease in fentanyl levels.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Frequency of application:",
"     </i>",
"     The majority of patients may be controlled on every 72-hour administration; however, a small number of patients require every 48-hour administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Dose conversion guidelines for transdermal fentanyl (see tables).",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     U.S. and Canadian dose conversion guidelines differ. Consult appropriate table.",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <caption style=\"text-align:center;\">",
"      U.S. Labeling: Dose Conversion Guidelines: Recommended Initial Duragesic&reg; Dose Based Upon Daily Oral Morphine Dose",
"      <sup>",
"       1,2",
"      </sup>",
"     </caption>",
"     <col align=\"center\" width=\"200\">",
"     </col>",
"     <col align=\"center\" width=\"200\">",
"     </col>",
"     <thead valign=\"middle\">",
"      <tr>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Oral 24-Hour Morphine",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (mg/day)",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Duragesic&reg; Dose",
"         <sup>",
"          3",
"         </sup>",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (mcg/h)",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tfoot valign=\"middle\">",
"      <tr>",
"       <td align=\"left\" colspan=\"2\">",
"        <p style=\"text-indent:0em;text-align:left;\">",
"         <sup>",
"          1",
"         </sup>",
"         The table should NOT be used to convert from transdermal fentanyl (Duragesic&reg;) to other opioid analgesics. Rather, following removal of the patch, titrate the dose of the new opioid until adequate analgesia is achieved.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"2\">",
"        <p style=\"text-indent:0em;text-align:left;\">",
"         <sup>",
"          2",
"         </sup>",
"         Recommendations are based on U.S. product labeling for Duragesic&reg;.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"2\">",
"        <p style=\"text-indent:0em;text-align:left;\">",
"         <sup>",
"          3",
"         </sup>",
"         Pediatric patients initiating therapy on a 25 mcg/hour Duragesic&reg; system should be opioid-tolerant and receiving at least 60 mg oral morphine equivalents per day.",
"        </p>",
"       </td>",
"      </tr>",
"     </tfoot>",
"     <tbody valign=\"middle\">",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         60-134",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         25",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         135-224",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         50",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         225-314",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         75",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         315-404",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         100",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         405-494",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         125",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         495-584",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         150",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         585-674",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         175",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         675-764",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         200",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         765-854",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         225",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         855-944",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         250",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         945-1034",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         275",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1035-1124",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         300",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <caption style=\"text-align:center;\">",
"      U.S. Labeling: Dose Conversion Guidelines",
"      <sup>",
"       1,2",
"      </sup>",
"     </caption>",
"     <col align=\"left\" width=\"100\">",
"     </col>",
"     <col align=\"center\" width=\"100\">",
"     </col>",
"     <col align=\"center\" width=\"100\">",
"     </col>",
"     <col align=\"center\" width=\"100\">",
"     </col>",
"     <col align=\"center\" width=\"100\">",
"     </col>",
"     <thead valign=\"middle\">",
"      <tr>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Current Analgesic",
"        </p>",
"       </th>",
"       <th align=\"center\" colspan=\"4\">",
"        <p style=\"text-indent:0em;\">",
"         Daily Dosage",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (mg/day)",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tfoot valign=\"middle\">",
"      <tr>",
"       <td align=\"left\" colspan=\"5\">",
"        <p style=\"text-indent:0em;\">",
"         <sup>",
"          1",
"         </sup>",
"         The table should NOT be used to convert from transdermal fentanyl (Duragesic&reg;) to other opioid analgesics. Rather, following removal of the patch, titrate the dose of the new opioid until adequate analgesia is achieved.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"5\">",
"        <p style=\"text-indent:0em;\">",
"         <sup>",
"          2",
"         </sup>",
"         Recommendations are based on U.S. product labeling for Duragesic&reg;.",
"        </p>",
"       </td>",
"      </tr>",
"     </tfoot>",
"     <tbody valign=\"middle\">",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Morphine (I.M./I.V.)",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         10-22",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         23-37",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         38-52",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         53-67",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Oxycodone (oral)",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         30-67",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         67.5-112",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         112.5-157",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         157.5-202",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Codeine (oral)",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         150-447",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         -",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         -",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         -",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Hydromorphone (oral)",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         8-17",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         17.1-28",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         28.1-39",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         39.1-51",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Hydromorphone (I.V.)",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1.5-3.4",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         3.5-5.6",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         5.7-7.9",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         8-10",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Meperidine (I.M.)",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         75-165",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         166-278",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         279-390",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         391-503",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Methadone (oral)",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         20-44",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         45-74",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         75-104",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         105-134",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"       </td>",
"       <td align=\"center\">",
"       </td>",
"       <td align=\"center\">",
"       </td>",
"       <td align=\"center\">",
"       </td>",
"       <td align=\"center\">",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         <b>",
"          Fentanyl transdermal recommended dose (mcg/h)",
"         </b>",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         <b>",
"          25 mcg/h",
"         </b>",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         <b>",
"          50 mcg/h",
"         </b>",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         <b>",
"          75 mcg/h",
"         </b>",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         <b>",
"          100 mcg/h",
"         </b>",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Transdermal patch (Duragesic&reg; MAT [Canada; not available in U.S.]): Adults:",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <caption style=\"text-align:center;\">",
"      Canadian Labeling: Dose Conversion Guidelines (Adults): Recommended Initial Duragesic&reg; MAT Dose Based Upon Daily Oral Morphine Dose",
"      <sup>",
"       1,2",
"      </sup>",
"     </caption>",
"     <col align=\"center\" width=\"200\">",
"     </col>",
"     <col align=\"center\" width=\"200\">",
"     </col>",
"     <thead valign=\"middle\">",
"      <tr>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Oral 24-Hour Morphine",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (Current Dose in mg/day)",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Duragesic&reg; MAT  Dose",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (Initial Dose in mcg/h)",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tfoot>",
"      <tr>",
"       <td align=\"left\" colspan=\"2\" valign=\"top\">",
"        <p style=\"text-indent:-2em;margin-left:2em;\">",
"         <sup>",
"          1",
"         </sup>",
"         The table should NOT be used to convert from transdermal fentanyl (Duragesic&reg; MAT) to other opioid analgesics. Rather, following removal of the patch, titrate the dose of the new opioid until adequate analgesia is achieved.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"2\" valign=\"top\">",
"        <p style=\"text-indent:-2em;margin-left:2em;\">",
"         <sup>",
"          2",
"         </sup>",
"         Recommendations are based on Canadian product labeling for Duragesic&reg; MAT.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"2\" valign=\"top\">",
"        <p style=\"text-indent:-2em;margin-left:2em;\">",
"         <b>",
"          Note:",
"         </b>",
"         The 12 mcg/hour dose included in this table is to be used for incremental dose adjustment and is generally not recommended for initial dosing, except for patients in whom lower starting doses are deemed clinically appropriate.",
"        </p>",
"       </td>",
"      </tr>",
"     </tfoot>",
"     <tbody valign=\"middle\">",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         45-59",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         12",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         60-134",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         25",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         135-179",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         37",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         180-224",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         50",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         225-269",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         62",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         270-314",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         75",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         315-359",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         87",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         360-404",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         100",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         405-494",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         125",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         495-584",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         150",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         585-674",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         175",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         675-764",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         200",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         765-854",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         225",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         855-944",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         250",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         945-1034",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         275",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1035-1124",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         300",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <caption style=\"text-align:center;\">",
"      Canadian Labeling: Dosing Conversion Guidelines (Adults)",
"      <sup>",
"       1,2",
"      </sup>",
"     </caption>",
"     <col align=\"left\" width=\"140\">",
"     </col>",
"     <col align=\"center\" width=\"50\">",
"     </col>",
"     <col align=\"center\" width=\"50\">",
"     </col>",
"     <col align=\"center\" width=\"50\">",
"     </col>",
"     <col align=\"center\" width=\"50\">",
"     </col>",
"     <col align=\"center\" width=\"50\">",
"     </col>",
"     <col align=\"center\" width=\"50\">",
"     </col>",
"     <col align=\"center\" width=\"50\">",
"     </col>",
"     <thead valign=\"middle\">",
"      <tr>",
"       <th align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         Current Analgesic",
"        </p>",
"       </th>",
"       <th align=\"center\" colspan=\"7\">",
"        <p style=\"text-indent:0em;\">",
"         Daily Dosage",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (mg/day)",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tfoot valign=\"middle\">",
"      <tr>",
"       <td align=\"left\" colspan=\"8\">",
"        <p style=\"text-indent:0em;\">",
"         <sup>",
"          1",
"         </sup>",
"         The table should NOT be used to convert from transdermal fentanyl (Duragesic&reg; MAT) to other opioid analgesics. Rather, following removal of the patch, titrate the dose of the new opioid until adequate analgesia is achieved.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"8\">",
"        <p style=\"text-indent:0em;\">",
"         <sup>",
"          2",
"         </sup>",
"         Recommendations are based on Canadian product labeling for Duragesic&reg; MAT.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"8\">",
"        <p style=\"text-indent:0em;\">",
"         <sup>",
"          3",
"         </sup>",
"         Morphine dose conversion based upon I.M to oral dose ratio of 1:3.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"8\">",
"        <p style=\"text-indent:0em;\">",
"         <sup>",
"          4",
"         </sup>",
"         Insufficient data available to provide specific dosing recommendations. Use caution; adjust dose conservatively.",
"        </p>",
"       </td>",
"      </tr>",
"     </tfoot>",
"     <tbody valign=\"middle\">",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Morphine",
"         <sup>",
"          3",
"         </sup>",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (I.M./I.V.)",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         20-44",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         45-60",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         61-75",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         76-90",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         n/a",
"         <sup>",
"          4",
"         </sup>",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         n/a",
"         <sup>",
"          4",
"         </sup>",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         n/a",
"         <sup>",
"          4",
"         </sup>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Oxycodone",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (oral)",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         30-66",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         67-90",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         91-112",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         113-134",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         135-157",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         158-179",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         180-202",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Codeine",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (oral)",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         150-447",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         448-597",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         598-747",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         748-897",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         898-1047",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1048-1197",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1198-1347",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Hydromorphone",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (oral)",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         8-16",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         17-22",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         23-28",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         29-33",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         34-39",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         40-45",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         46-51",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Hydromorphone",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (I.V.)",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         4-8.4",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         8.5-11.4",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         11.5-14.4",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         14.5-16.5",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         16.6-19.5",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         19.6-22.5",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         22.6-25.5",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"       </td>",
"       <td align=\"center\">",
"       </td>",
"       <td align=\"center\">",
"       </td>",
"       <td align=\"center\">",
"       </td>",
"       <td align=\"center\">",
"       </td>",
"       <td align=\"center\">",
"       </td>",
"       <td align=\"center\">",
"       </td>",
"       <td align=\"center\">",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         <b>",
"          Fentanyl transdermal recommended dose",
"         </b>",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         <b>",
"          (mcg/h)",
"         </b>",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         <b>",
"          25 mcg/h",
"         </b>",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         <b>",
"          37 mcg/h",
"         </b>",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         <b>",
"          50 mcg/h",
"         </b>",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         <b>",
"          62 mcg/h",
"         </b>",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         <b>",
"          75 mcg/h",
"         </b>",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         <b>",
"          87 mcg/h",
"         </b>",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         <b>",
"          100 mcg/h",
"         </b>",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F170639\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/45/35546?source=see_link\">",
"      see \"Fentanyl: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Ranges listed may not represent the maximum doses that may be required in all patients. Doses and dosage intervals should be titrated to pain relief/prevention. Monitor vital signs routinely. Single I.M. doses have duration of 1-2 hours, single I.V. doses last 0.5-1 hour.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Adjunct to anesthesia (induction and maintenance):",
"     </b>",
"     Children &ge;2 years: I.V.: 2-3 mcg/kg/dose every 1-2 hours as needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Pain management (unlabeled use):",
"     </b>",
"     I.V.: 0.5-2 mcg/kg/dose given every 1-2 hours as needed; continuous infusion: 0.5-2 mcg/kg/",
"     <b>",
"      hour",
"     </b>",
"     ; titrate to desired effects",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Patient-controlled analgesia (PCA) (unlabeled use; American Pain Society, 2008):",
"     </i>",
"     Children &lt;50 kg:",
"     <b>",
"      Note:",
"     </b>",
"     Opiate-naive: Consider lower end of dosing range:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Usual concentration: 10 mcg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Demand dose: 0.5-1 mcg/kg/dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Lockout interval: 6-8 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Usual basal rate: 0-0.5 mcg/kg/",
"     <b>",
"      hour",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Chronic pain management:",
"     </b>",
"     Children &ge;2 years (opioid-tolerant patients): Transdermal patch (Duragesic&reg;): Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Minor procedures/analgesia (unlabeled use):",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Children 1-12 years: 0.5-2 mcg/kg/dose given 3 minutes prior to procedure; may repeat every 1-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Children &gt;12 years: 0.5-2 mcg/kg/dose (maximum: 50 mcg/dose) given 3 minutes prior to procedure; may repeat in 5 minutes if necessary; if more than 2 doses are needed, repeat with a maximum of 25 mcg/dose up to 5 times",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Continuous sedation/analgesia:",
"     </b>",
"     0.5-2 mcg/kg/",
"     <b>",
"      hour",
"     </b>",
"     ; titrate to desired effect",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Breakthrough cancer pain:",
"     </b>",
"     Children &ge;16 years: Transmucosal lozenge (Actiq&reg;): Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F170616\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Elderly have been found to be twice as sensitive as younger patients to the effects of fentanyl. A wide range of doses may be used. When choosing a dose, take into consideration the following patient factors: age, weight, physical status, underlying disease states, other drugs used, type of anesthesia used, and the surgical procedure to be performed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Transmucosal lozenge (eg, Actiq&reg;): In clinical trials, patients who were &gt;65 years of age were titrated to a mean dose that was 200 mcg less than that of younger patients.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F14936198\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection: No dosage adjustment provided in manufacturer&rsquo;s labeling; use with caution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Transdermal (patch): Degree of impairment (ie, Cl",
"     <sub>",
"      cr",
"     </sub>",
"     ) not defined in manufacturer&rsquo;s labeling.",
"    </p>",
"    <p style=\"text-indent:2em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Mild-to-moderate impairment: Initial: Reduce dose by 50%.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Severe impairment: Use not recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Transmucosal (buccal film/tablet, sublingual spray/tablet, lozenge) and nasal spray: Although fentanyl pharmacokinetics may be altered in renal disease, fentanyl can be used successfully in the management of breakthrough cancer pain. Doses should be titrated to reach clinical effect with careful monitoring of patients with severe renal disease.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F170617\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection: No dosage adjustment provided in manufacturer&rsquo;s labeling; use with caution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Transdermal (patch):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mild-to-moderate impairment: Initial: Reduce dose by 50%.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Severe impairment: Use not recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Transmucosal (buccal film/tablet, sublingual spray/tablet, lozenge) and nasal spray: Although fentanyl pharmacokinetics may be altered in hepatic disease, fentanyl can be used successfully in the management of breakthrough cancer pain. Doses should be titrated to reach clinical effect with careful monitoring of patients with severe hepatic disease.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F170583\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Film, for buccal application, as citrate [strength expressed as base]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Onsolis&reg;: 200 mcg (30s); 400 mcg (30s); 600 mcg (30s); 800 mcg (30s); 1200 mcg (30s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as citrate [strength expressed as base, preservative free]: 0.05 mg/mL (2 mL, 5 mL, 10 mL, 20 mL, 50 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liquid, sublingual, as base [spray]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Subsys&reg;: 100 mcg (30s); 200 mcg (30s); 400 mcg (30s); 600 mcg (30s); 800 mcg (30s) [contains dehydrated ethanol 63.6%, propylene glycol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Lozenge, oral, as citrate [strength expressed as base, transmucosal]: 200 mcg (30s); 400 mcg (30s); 600 mcg (30s); 800 mcg (30s); 1200 mcg (30s); 1600 mcg (30s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Actiq&reg;: 200 mcg (30s); 400 mcg (30s); 600 mcg (30s); 800 mcg (30s); 1200 mcg (30s); 1600 mcg (30s) [contains sugar 2 g/lozenge; berry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Patch, transdermal, as base: 12 [delivers 12.5 mcg/hr] (5s); 25 [delivers 25 mcg/hr] (5s); 50 [delivers 50 mcg/hr] (5s); 75 [delivers 75 mcg/hr] (5s); 100 [delivers 100 mcg/hr] (5s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Duragesic&reg;: 12 [delivers 12.5 mcg/hr] (5s) [contains ethanol 0.1mL/10 cm",
"     <sup>",
"      2",
"     </sup>",
"     ; 5 cm",
"     <sup>",
"      2",
"     </sup>",
"     ]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Duragesic&reg;: 25 [delivers 25 mcg/hr] (5s) [contains ethanol 0.1 mL/10 cm",
"     <sup>",
"      2",
"     </sup>",
"     ; 10 cm",
"     <sup>",
"      2",
"     </sup>",
"     ]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Duragesic&reg;: 50 [delivers 50 mcg/hr] (5s) [contains ethanol 0.1 mL/10 cm",
"     <sup>",
"      2",
"     </sup>",
"     ; 20 cm",
"     <sup>",
"      2",
"     </sup>",
"     ]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Duragesic&reg;: 75 [delivers 75 mcg/hr]  (5s) [contains ethanol 0.1 mL/10 cm",
"     <sup>",
"      2",
"     </sup>",
"     ; 30 cm",
"     <sup>",
"      2",
"     </sup>",
"     ]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Duragesic&reg;: 100 [delivers 100 mcg/hr]  (5s) [contains ethanol 0.1 mL/10 cm",
"     <sup>",
"      2;",
"     </sup>",
"     40 cm",
"     <sup>",
"      2",
"     </sup>",
"     ]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder, for prescription compounding, as citrate: USP: 100% (1 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, intranasal, as citrate [strength expressed as base, spray]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lazanda&reg;: 100 mcg/spray (5 mL); 400 mcg/spray (5 mL) [delivers 8 metered sprays]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, for buccal application, as citrate [strength expressed as base]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Fentora&reg;: 100 mcg (28s); 200 mcg (28s); 400 mcg (28s); 600 mcg (28s); 800 mcg (28s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, sublingual, as citrate [strength expressed as base]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Abstral&reg;: 100 mcg (12s, 32s); 200 mcg (12s, 32s); 300 mcg (12s, 32s); 400 mcg (12s, 32s); 600 mcg (32s); 800 mcg (32s)",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F10461326\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Patch, transdermal, as base: 12 mcg/hr (5s); 25 mcg/hr (5s); 50 mcg/hr (5s); 75 mcg/hr (5s); 100 mcg/hr (5s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Duragesic&reg; MAT: 12 mcg/hr (5s) [contains ethanol 0.1 mL/10 cm",
"     <sup>",
"      2",
"     </sup>",
"     ; 5 cm",
"     <sup>",
"      2",
"     </sup>",
"     ]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Duragesic&reg; MAT: 25 mcg/hr (5s) [contains ethanol 0.1 mL/10 cm",
"     <sup>",
"      2",
"     </sup>",
"     ; 10 cm",
"     <sup>",
"      2",
"     </sup>",
"     ]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Duragesic&reg; MAT: 50 mcg/hr (5s) [contains ethanol 0.1 mL/10 cm",
"     <sup>",
"      2",
"     </sup>",
"     ; 20 cm",
"     <sup>",
"      2",
"     </sup>",
"     ]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Duragesic&reg; MAT: 75 mcg/hr (5s) [contains ethanol 0.1 mL/10 cm",
"     <sup>",
"      2",
"     </sup>",
"     ; 30 cm",
"     <sup>",
"      2",
"     </sup>",
"     ]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Duragesic&reg; MAT: 100 mcg/hr (5s) [contains ethanol 0.1 mL/10 cm",
"     <sup>",
"      2",
"     </sup>",
"     ; 40 cm",
"     <sup>",
"      2",
"     </sup>",
"     ]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F170567\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Injection, lozenge, patch",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F170661\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C-II",
"    </p>",
"   </div>",
"   <div class=\"block accres drugH1Div\" id=\"F11233769\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Prescribing and Access Restrictions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     As a requirement of the REMS program, access is restricted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Transmucosal immediate-release fentanyl  products (eg, sublingual tablets and spray, oral lozenges, buccal tablets and soluble film, nasal spray) are only available through the Transmucosal Immediate-Release Fentanyl (TIRF) REMS ACCESS program. Enrollment in the program is required for outpatients, prescribers for outpatient use, pharmacies (inpatient and outpatient), and distributors. Enrollment is not required for inpatient administration (eg, hospitals, hospices, long-term care facilities), inpatients, and prescribers who prescribe to inpatients. Further information is available at 1-866-822-1483 or at www.TIRFREMSaccess.com",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Effective December, 2011, individual REMs programs for TIRF products were combined into a single access program (TIRF REMS Access). Prescribers and pharmacies that were enrolled in at least one individual REMS program for these products will automatically be transitioned to the single access program.",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874432\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Abstral&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM239930.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM239930.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Actiq&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm085817.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm085817.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Duragesic&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088584.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088584.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Fentora&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088597.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088597.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Lazanda&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM263032.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM263032.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Onsolis&reg;:",
"     <a href=\"file://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022266s000MedGuide.pdf\" target=\"_blank\">",
"      file://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022266s000MedGuide.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Subsys&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM287863.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM287863.pdf",
"     </a>",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F170587\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.V.: Administer as slow I.V. infusion over 1-2 minutes. May also be administered as continuous infusion or PCA (unlabeled use) routes. Muscular rigidity may occur with rapid I.V. administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Transdermal patch (eg, Duragesic&reg;): Apply to nonirritated and nonirradiated skin, such as chest, back, flank, or upper arm. Do not shave skin; hair at application site should be clipped. Prior to application, clean site with clear water and allow to dry completely. Do not use damaged, cut or leaking patches; patch may be less effective. Skin exposure from fentanyl gel leaking from patch may lead to serious adverse effects; thoroughly wash affected skin surfaces with water (do not use soap).  Firmly press in place and hold for 30 seconds. Change patch every 72 hours. Do",
"     <b>",
"      not",
"     </b>",
"     use soap, alcohol, or other solvents to remove transdermal gel if it accidentally touches skin; use copious amounts of water. Avoid exposing application site to external heat sources (eg, heating pad, electric blanket, heat lamp, hot tub). If there is difficulty with patch adhesion, the edges of the system may be taped in place with first-aid tape. If there is continued difficulty with adhesion, an adhesive film dressing (eg, Bioclusive&reg;, Tegaderm&reg;) may be applied over the system.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Lozenge: Foil overwrap should be removed just prior to administration. Place the unit in mouth between the cheek and gum and allow it to dissolve. Do not chew. Lozenge may be moved from one side of the mouth to the other. The unit should be consumed over a period of 15 minutes. Handle should be removed after the lozenge is consumed; early removal should be considered if the patient has achieved an adequate response and/or shows signs of respiratory depression.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Buccal film: Foil overwrap should be removed just prior to administration. Prior to placing film, wet inside of cheek using tongue or by rinsing with water. Place film inside mouth with the pink side of the unit against the inside of the moistened cheek. With finger, press the film against cheek and hold for 5 seconds. The film should stick to the inside of cheek after 5 seconds. The film should be left in place until it dissolves (usually within 15-30 minutes after application). Liquids may be consumed after 5 minutes of application. Food can be eaten after film dissolves. If using more than 1 film simultaneously (during titration period), apply films on either side of mouth (do not apply on top of each other). Do not chew or swallow film. Do not cut or tear the film. All patients must initiate therapy using the 200 mcg film.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Buccal tablet: Patient should not open blister until ready to administer. The blister backing should be peeled back to expose the tablet; tablet should not be pushed out through the blister. Immediately use tablet once removed from blister.  Place entire tablet in the buccal cavity (above a rear molar, between the upper cheek and gum) or under the tongue (maintenance dosing only); should dissolve in about 14-25 minutes. If remnants remain after 30 minutes, they may be swallowed with water. Tablet should not be split, crushed, sucked, chewed, or swallowed whole. When possible, alternate sides of mouth with each dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Nasal spray: Prior to initial use, prime device by spraying 4 sprays into the provided pouch (the counting window will show a green bar when the bottle is ready for use). Insert nozzle a short distance into the nose (~",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     inch or 1 cm) and point towards the bridge of the nose (while closing off the other nostril using 1 finger). Press on finger grips until a &ldquo;click&rdquo; sound is heard and the number in the counting window advances by one. The &ldquo;click&rdquo; sound and dose counter are the only reliable methods for ensuring a dose has been administered (spray is not always felt on the nasal mucosa). Patient should remain seated for at least 1 minute following administration. Do not blow nose for &ge;30 minutes after administration. Wash hands before and after use. There are 8 full therapeutic sprays in each bottle; do not continue to use bottle after &ldquo;8&rdquo; sprays have been used. Dispose of bottle and contents if &ge;5 days have passed since last use or if it has been &ge;4 days since bottle was primed. Spray the remaining contents into the provided pouch, seal in the child-resistant container, and dispose of in the trash.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Sublingual spray: Open sealed blister unit with scissors immediately prior to administration. Contents of unit should be sprayed into mouth under the tongue.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Sublingual tablet: Remove from the blister unit immediately prior to administration. Place tablet directly under the tongue on the floor of the mouth and allow to completely dissolve; do not chew, suck, or swallow. Do not eat or drink anything until tablet is completely dissolved. In patients with a dry mouth, water may be used to moisten the buccal mucosa just before administration. All patients must initiate therapy using the 100 mcg tablet.",
"    </p>",
"   </div>",
"   <div class=\"block uica drugH1Div\" id=\"F14472636\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Usual Infusion Concentrations: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      I.V. infusion:",
"     </b>",
"     10",
"     <b>",
"      mcg",
"     </b>",
"     /mL",
"    </p>",
"   </div>",
"   <div class=\"block uicp drugH1Div\" id=\"F14472637\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Usual Infusion Concentrations: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      I.V. infusion:",
"     </b>",
"     10",
"     <b>",
"      mcg",
"     </b>",
"     /mL",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F170668\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Abciximab, acetaminophen, acyclovir, alprostadil, amiodarone, amphotericin B cholesteryl sulfate complex, ampicillin, anidulafungin, argatroban, atracurium, atropine, bivalirudin, caffeine citrate, calcium gluconate, caspofungin, cefazolin, cefotaxime, cefuroxime, cimetidine, cisatracurium, clindamycin, clonidine, dexamethasone sodium phosphate, diazepam, digoxin, diltiazem, diphenhydramine, dobutamine, dopamine, doripenem, enalaprilat, epinephrine, esmolol, etomidate, fenoldopam, furosemide, gentamicin, haloperidol, heparin, hetastarch in lactate electrolyte injection (Hextend&reg;), hydrocortisone sodium succinate, hydromorphone, hydroxyzine, ketorolac, labetalol, levofloxacin, linezolid, lorazepam, methotrimeprazine, metoclopramide, metronidazole, midazolam, milrinone, morphine, nafcillin, nesiritide, nicardipine, nitroglycerin, norepinephrine, oxaliplatin, palonosetron, pancuronium, phenobarbital, potassium chloride, propofol, ranitidine, remifentanil, sargramostim, scopolamine, sodium bicarbonate, theophylline, thiopental, vancomycin, vecuronium, vitamin B complex with C.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Azithromycin, phenytoin.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Doxapram, pantoprazole.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Atracurium, atropine, bupivacaine, bupivacaine with clonidine, bupivacaine with ketamine, butorphanol, caffeine citrate, chlorpromazine, cimetidine, clonidine, clonidine with lidocaine, dimenhydrinate, diphenhydramine, droperidol, heparin, hydromorphone, hydroxyzine, ketamine, meperidine, metoclopramide, metoclopramide with midazolam, midazolam, morphine, ondansetron, pentazocine, prochlorperazine edisylate, promethazine, ranitidine, scopolamine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Pantoprazole, pentobarbital.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Lidocaine.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F170586\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection: Relief of pain, preoperative medication, adjunct to general or regional anesthesia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Transdermal patch (eg, Duragesic&reg;): Management of persistent moderate-to-severe chronic pain in opioid-tolerant patients when around-the-clock analgesia is needed for an extended period of time",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Transmucosal lozenge (eg, Actiq&reg;), buccal tablet (Fentora&reg;), buccal film (Onsolis&reg;), nasal spray (Lazanda&reg;), sublingual tablet (Abstral&reg;), sublingual spray (Subsys&reg;): Management of breakthrough cancer pain in opioid-tolerant patients",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     \"Opioid-tolerant\" patients are defined as patients who are taking at least:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral morphine 60 mg/day,",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Transdermal fentanyl 25 mcg/hour,",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral oxycodone 30 mg/day,",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral hydromorphone 8 mg/day,",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral oxymorphone 25 mg/day,",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Equianalgesic dose of another opioid for at least 1 week",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F170670\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       FentaNYL may be confused with alfentanil, SUFentanil",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Administration issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Fentanyl transdermal system patches: Leakage of fentanyl gel from the patch has been reported; patch may be less effective; do not use. Thoroughly wash any skin surfaces coming into direct contact with gel with water (do not use soap). May contain conducting metal (eg, aluminum); remove patch prior to MRI.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Fentanyl transdermal system patches:",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:6em;\">",
"       Dosing of transdermal fentanyl patches may be confusing. Transdermal fentanyl patches should always be prescribed in mcg/hour, not size. Patch dosage form of Duragesic&reg;-12 actually delivers 12.5 mcg/hour of fentanyl. Use caution, as orders may be written as &ldquo;Duragesic 12.5&rdquo; which can be erroneously interpreted as a 125 mcg dose.",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:6em;\">",
"       Patches should be stored and disposed of with care to avoid accidental exposure to children. The FDA has issued numerous safety advisories to warn users of the possible consequences (including hospitalization and death) of inappropriate storage or disposal of patches.",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Abstral&reg;, Actiq&reg;, Fentora&reg;, Onsolis&reg;, and Subsys&reg; are not interchangeable; do not substitute doses on a mcg-per-mcg basis.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F170657\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Bradycardia, edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: CNS depression, confusion, dizziness, drowsiness, fatigue, headache, sedation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Dehydration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Constipation, nausea, vomiting,  xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Application-site reaction erythema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Chest wall rigidity (high dose I.V.), muscle rigidity, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Miosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Dyspnea, respiratory depression",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Cardiac arrhythmia, cardiorespiratory arrest, chest pain, DVT, flushing, hyper-/hypotension, orthostatic hypotension, pallor, palpitation, peripheral edema, sinus tachycardia, syncope, tachycardia, vasodilation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Abnormal dreams, abnormal thinking, agitation, amnesia, anxiety, attention disturbance, chills, depression, disorientation, dysphoria, euphoria, fever, hallucinations, hypoesthesia, insomnia, irritability, lethargy, malaise, mental status change, migraine, nervousness, paranoid reaction, restlessness, somnolence, stupor, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Alopecia, bruising, cellulitis, decubitus ulcer, erythema, hyperhidrosis, papules, pruritus, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Breast pain, dehydration, hot flashes, hyper-/hypocalcemia, hyper-/hypoglycemia, hypoalbuminemia, hypokalemia, hypomagnesemia, hyponatremia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdominal distension, abdominal pain, abnormal taste, anorexia, appetite decreased, biliary tract spasm, diarrhea, dyspepsia, dysphagia (buccal tablet/film/sublingual spray), flatulence, gastritis, gastroenteritis, gastroesophageal reflux, GI hemorrhage, gingival pain (buccal tablet), gingivitis (lozenge), glossitis (lozenge), hematemesis, ileus, intestinal obstruction (buccal film),  periodontal abscess (lozenge/buccal tablet), proctalgia, stomatitis (lozenge/buccal tablet/sublingual tablet/sublingual spray), tongue disorder (sublingual tablet), ulceration (gingival, lip, mouth; transmucosal use/nasal spray), weight loss",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Dysuria, erectile dysfunction, urinary incontinence, urinary retention, urinary tract infection,  vaginitis, vaginal hemorrhage",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Anemia, leukopenia, neutropenia, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Alkaline phosphatase increased, ascites, AST increased, jaundice",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local:  Application site pain, application site irritation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Abnormal coordination, abnormal gait, arthralgia, back pain, limb pain, myalgia, neuropathy, paresthesia, rigors, tremor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Blurred vision, diplopia, dry eye, swelling, ptosis, strabismus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Renal failure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Apnea, asthma, bronchitis, cough, dyspnea (exertional), epistaxis, hemoptysis, hypoventilation, hypoxia, laryngitis, nasal congestion (nasal spray), nasal discomfort (nasal spray), nasopharyngitis, pharyngolaryngeal pain, pharyngitis, pneumonia, postnasal drip (nasal spray), pulmonary embolism (nasal spray), rhinitis, rhinorrhea (nasal spray), sinusitis, upper respiratory infection, wheezing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Flu-like syndrome, hiccups, hypersensitivity,  lymphadenopathy, night sweats, parosmia, speech disorder, withdrawal syndrome",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Amblyopia, allergic reaction, anaphylaxis, angina, aphasia, bladder pain, bronchospasm, CNS excitation or delirium, depersonalization, dysesthesia, emotional lability, esophageal stenosis, exfoliative dermatitis, fecal impaction, gum line erosion (lozenge), gum hemorrhage (lozenge), hematuria, hostility, hyper-/hypotonia, laryngospasm, myasthenia, nocturia, oliguria, pancytopenia, paradoxical dizziness, physical and psychological dependence with prolonged use, pleural effusion, polyuria, pustules, speech disorder, stertorous breathing, seizure, tooth loss (lozenge), urinary tract spasm, urticaria, vertigo",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F170590\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to fentanyl or any component of the formulation",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Additional contraindications for transdermal patches (eg, Duragesic&reg;): Severe respiratory disease or depression including acute asthma (unless patient is mechanically ventilated); paralytic ileus; patients requiring short-term therapy, management of acute or intermittent pain, postoperative or mild pain, and in patients who are",
"     <b>",
"      not",
"     </b>",
"     opioid tolerant",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Additional contraindications for transmucosal buccal tablets (Fentora&reg;), buccal films (Onsolis&trade;), lozenges (eg, Actiq&reg;), sublingual tablets (Abstral&reg;), sublingual spray (Subsys&reg;), nasal spray (Lazanda&reg;): Contraindicated in the management of acute or postoperative pain (including headache, migraine, or dental pain), and in patients who are",
"     <b>",
"      not",
"     </b>",
"     opioid tolerant. Abstral&reg; and Onsolis&trade; also are contraindicated for acute pain management in the emergency room.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Canadian labeling: Additional contraindication (not in U.S. labeling): Sublingual tablets (Abstral&trade;): Severe respiratory depression or severe obstructive lung disease",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F170571\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Opioid agonist toxicities: Shares the toxic potentials of opiate agonists, and precautions of opiate agonist therapy should be observed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory depression:",
"     <b>",
"      [U.S. Boxed Warning] Abstral&reg;, Actiq&reg;, Duragesic&reg;, Fentora&reg;, Lazanda&reg;, Onsolis&reg;, Subsys&reg;: May cause potentially life-threatening hypoventilation, respiratory depression, and/or death;",
"     </b>",
"     Abstral&reg;, Actiq&reg;, Duragesic&reg;, Fentora&reg;, Lazanda&reg;, Onsolis&reg;, or Subsys&reg; should only be prescribed for opioid-tolerant patients. Risk of respiratory depression increased in elderly patients, debilitated patients, and patients with conditions associated with hypoxia or hypercapnia; usually occurs after administration of initial dose in nontolerant patients or when given with other drugs that depress respiratory function.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Allergic rhinitis: Nasal spray: Allergic rhinitis is not expected to alter fentanyl absorption following nasal administration; however, use of nasal decongestants (eg, oxymetazoline) during episodes of rhinitis may result in lower peak concentrations and delayed T",
"     <sub>",
"      max",
"     </sub>",
"     , therefore, titration of the nasal spray is not recommended during use of nasal decongestants.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bradycardia: Use with caution when administering to patients with bradycardia or bradyarrhythmias (may produce further bradycardia).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Drug abuse: Use with caution in patients with a history of drug abuse or acute alcoholism; potential for drug dependency exists. Tolerance, psychological and physical dependence may occur with prolonged use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Head trauma: Use with extreme caution in patients with head injury, intracranial lesions, or elevated intracranial pressure; exaggerated elevation of ICP may occur. Opioids may obscure the clinical course of head injury.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Oral mucositis: Sublingual spray (Subsys&reg;): Cancer patients with oral mucositis experienced increased fentanyl exposure following sublingual spray administration; avoid use in patients with grade 2 or higher mucositis; use with caution in patients with grade 1 mucositis, and closely monitor for respiratory and CNS depression.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory disease: Use with caution in patients with pre-existing respiratory compromise (hypoxia and/or hypercapnia), COPD or other obstructive pulmonary disease, and kyphoscoliosis or other skeletal disorder which may alter respiratory function; critical respiratory depression may occur, even at therapeutic dosages.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depressants: When using with other CNS depressants, reduce dose of one or both agents.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CYP3A4 inhibitors:",
"     <b>",
"      [U.S. Boxed Warning]: Use with strong or moderate CYP3A4 inhibitors may result in increased effects and potentially fatal respiratory depression.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; MAO inhibitors: Use is not recommended with MAO inhibitors or within 14 days of MAO inhibitor use; severe and unpredictable adverse effects may result.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly; may be more sensitive to adverse effects. Decrease initial dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull;	Pediatrics:",
"     <b>",
"      [U.S. Boxed Warning]: Buccal film, buccal tablet, nasal spray, sublingual tablet, sublingual spray, transdermal patch, and lozenge preparations contain an amount of medication that can be fatal to children. Keep all used and unused products out of the reach of children at all times and discard products properly.",
"     </b>",
"     Patients and caregivers should be counseled on the dangers to children including the risk of exposure to partially-consumed products.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Injection: May cause muscle rigidity; usually occurs following high doses; respiratory depression may persist beyond analgesic effect; monitor closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     &bull; Transmucosal (buccal film/tablet, sublingual spray/tablet, lozenge) and nasal spray:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     -",
"     <b>",
"      [U.S. Boxed Warning]: Transmucosal and nasal fentanyl formulations are contraindicated in the management of acute or postoperative pain and in opioid nontolerant patients.",
"     </b>",
"     Should be used only for the care of opioid-tolerant cancer patients with breakthrough pain and is intended for use by specialists who are knowledgeable in treating cancer pain.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     -",
"     <b>",
"      [U.S. Boxed Warning]:  Substantial differences exist in the pharmacokinetic profile of fentanyl products. Do not convert patients on a mcg-per-mcg basis from one fentanyl product to another fentanyl product; the substitution of one fentanyl product for another fentanyl product may result in a fatal overdose.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     -",
"     <b>",
"      [U.S. Boxed Warning]: Available only through the TIRF REMS ACCESS program, a restricted distribution program with outpatients, prescribers who prescribe to outpatients, pharmacies (inpatient and outpatient), and distributor-required enrollment.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull;	 Transdermal patch:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     -",
"     <b>",
"      [U.S. Boxed Warning]: Transdermal patch is contraindicated in the management of short-term analgesia, or in the management of postoperative pain, and in patients who are opioid nontolerant. Should only be prescribed by healthcare professionals who are knowledgeable in the use of potent opioids in the management of chronic pain. Monitor closely for respiratory depression during use, particularly during first two applications after initiation of therapy or after dose increases.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     -",
"     <b>",
"      [U.S. Boxed Warning]: Avoid exposure of application site and surrounding area to direct external heat sources. Patients who experience fever or increase in core body temperature should be monitored closely.",
"     </b>",
"     Serum fentanyl concentrations may increase by approximately one-third for patients with a body temperature of 40&deg;C (104&deg;F) secondary to a temperature-dependent increase in fentanyl release from the patch and increased skin permeability.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     -",
"     <b>",
"      [U.S. Boxed Warning]: Accidental exposure may lead to severe respiratory depression, including death, in children and adults; proper procedures for handling and disposal of patches should be followed.",
"     </b>",
"     Avoid unclothed/unwashed application site exposure, inadvertent person-to-person patch transfer (eg, while hugging), incidental exposure (eg, sharing same bed, sitting on patch), intentional exposure (eg, chewing), or accidental exposure by caregivers when applying/removing patch.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     - Should be applied only to intact skin. Use of a patch that has been cut, damaged, or altered in any way may result in overdosage. Patients who experience adverse reactions should be monitored for at least 24 hours after removal of the patch. May contain conducting metal (eg, aluminum); remove patch prior to MRI.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Abuse/misuse/diversion:",
"     <b>",
"      [U.S. Boxed Warning]: Healthcare provider should be alert to problems of abuse, misuse, and diversion.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Optimal regimen: An opioid-containing analgesic regimen should be tailored to each patient's needs and based upon the type of pain being treated (acute versus chronic), the route of administration, degree of tolerance for opioids (naive versus chronic user), age, weight, and medical condition. The optimal analgesic dose varies widely among patients; doses should be titrated to pain relief/prevention.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Rapid infusion: Inject slowly over 3-5 minutes; rapid I.V. infusion may result in skeletal muscle and chest wall rigidity, impaired ventilation, or respiratory distress/arrest; nondepolarizing skeletal muscle relaxant may be required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Withdrawal: Concurrent use of agonist/antagonist analgesics may precipitate withdrawal symptoms and/or reduced analgesic efficacy in patients following prolonged therapy with mu opioid agonists. Abrupt discontinuation following prolonged use may also lead to withdrawal symptoms.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F170653\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP3A4 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F170576\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists (Indirect-Acting): May decrease the serum concentration of FentaNYL. Specifically, fentanyl nasal spray serum concentrations may decrease and onset of effect may be delayed.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Agonists: May decrease the serum concentration of FentaNYL. Specifically, fentanyl nasal spray serum concentrations may decrease and onset of effect may be delayed.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Midodrine; Naphazoline (Ophthalmic); Phenylephrine (Ophthalmic); Phenylephrine (Topical).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alvimopan: Analgesics (Opioid) may enhance the adverse/toxic effect of Alvimopan. This is most notable for patients receiving long-term (i.e., more than 7 days) opiates prior to alvimopan initiation.  Management: Alvimopan is contraindicated in patients receiving therapeutic doses of opioids for more than 7 consecutive days immediately prior to alvimopan initiation.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ammonium Chloride: May increase the excretion of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: May enhance the analgesic effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotic Agents (Phenothiazines): May enhance the hypotensive effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Anilidopiperidine Opioids may enhance the bradycardic effect of Beta-Blockers. Anilidopiperidine Opioids may enhance the hypotensive effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): Anilidopiperidine Opioids may enhance the bradycardic effect of Calcium Channel Blockers (Nondihydropyridine). Anilidopiperidine Opioids may enhance the hypotensive effect of Calcium Channel Blockers (Nondihydropyridine).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Crizotinib: May increase the serum concentration of FentaNYL.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May increase the serum concentration of FentaNYL. Management: Monitor patients extra closely for several days following initiation of the combination, and fentanyl dosage reductions should be made as appropriate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May increase the serum concentration of FentaNYL. Management: Monitor patients extra closely for several days following initiation of the combination, and fentanyl dosage reductions should be made as appropriate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desmopressin: Analgesics (Opioid) may enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Enzalutamide: May decrease the serum concentration of FentaNYL.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ioflupane I 123: FentaNYL may diminish the diagnostic effect of Ioflupane I 123.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: Anilidopiperidine Opioids may enhance the serotonergic effect of MAO Inhibitors. This could result in serotonin syndrome.  Management: Avoid use of fentanyl (and other anilidopiperidine opioids when possible) in patients who have used a monoamine oxidase inhibitor within the past 14 days due to reports of unpredictable but severe adverse effects.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of FentaNYL. Management: Avoid fentanyl during and 2 weeks following mifepristone for treatment of hyperglycemia in Cushing's syndrome. The interaction magnitude could be lower with single doses used to terminate pregnancy, but neither effect has been studied clinically.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mixed Agonist / Antagonist Opioids: May diminish the analgesic effect of Analgesics (Opioid). Management: Seek alternatives to mixed agonist/antagonist opioids in patients receiving pure opioid agonists, and monitor for symptoms of therapeutic failure/high dose requirements (or withdrawal in opioid-dependent patients) if patients receive these combinations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pegvisomant: Analgesics (Opioid) may diminish the therapeutic effect of Pegvisomant.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May decrease the serum concentration of FentaNYL.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: Analgesics (Opioid) may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Succinylcholine: May enhance the bradycardic effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Analgesics (Opioid) may enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F170606\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Ethanol may increase CNS depression. Management: Monitor for increased effects with coadministration. Caution patients about effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Fentanyl concentrations may be increased by grapefruit juice. Management: Avoid concurrent intake of large quantities (&gt;1 quart/day) of grapefruit juice.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: St John's wort may decrease fentanyl levels; gotu kola, valerian, and kava kava may increase CNS depression. Management: Avoid St John's wort, gotu kola, valerian, and kava kava.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F170578\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F170593\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in animal reproduction studies. Fentanyl crosses the placenta and the injectable formulation has been used safely during labor (Gomar, 2000). Chronic use during pregnancy has shown detectable serum concentrations in the newborn with transient respiratory depression, behavioral changes, or seizures in the newborn infant characteristic of neonatal abstinence syndrome; transient neonatal muscular rigidity has also been observed. Transdermal patch, transmucosal lozenge, nasal spray (Lazanda&reg;), sublingual tablet, sublingual spray (Subsys&reg;), buccal tablet (Fentora&reg;), and buccal film (Onsolis&reg;) are not recommended for analgesia during labor and delivery.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F170621\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended (AAP rates &ldquo;compatible&rdquo;; AAP 2001 update pending)",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F170594\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Fentanyl is excreted in low concentrations into breast milk. Breast-feeding is considered acceptable following single doses to the mother; however, limited information is available when used long-term (Spigset, 2000).",
"     <b>",
"      Note:",
"     </b>",
"     Transdermal patch, transmucosal lozenge, sublingual tablet, sublingual spray (Subsys&reg;), buccal tablet (Fentora&reg;), and buccal film (Onsolis&reg;) are not recommended in nursing women due to potential for sedation and/or respiratory depression. Symptoms of opioid withdrawal may occur in infants following the cessation of breast-feeding.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F170595\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Transmucosal lozenge contains 2 g sugar per unit.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F5989383\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Film",
"     </b>",
"     (Onsolis Buccal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mcg (30): $771.75",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     400 mcg (30): $1132.82",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     600 mcg (30): $1495.27",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     800 mcg (30): $1856.33",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1200 mcg (30): $2218.78",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Subsys Sublingual)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mcg (10): $335.06",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mcg (1): $42.32",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     400 mcg (10): $614.42",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     600 mcg (1): $79.78",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     800 mcg (1): $98.28",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1200 (600 X 2) mcg (30): $2030.33",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1600 (800 X 2) mcg (30): $2591.06",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Lozenge",
"     </b>",
"     (Actiq Buccal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mcg (30): $1634.40",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     400 mcg (30): $2070.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     600 mcg (30): $2534.40",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     800 mcg (30): $3001.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1200 mcg (30): $3901.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1600 mcg (30): $4812.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Lozenge",
"     </b>",
"     (FentaNYL Citrate Buccal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mcg (30): $564.12",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     400 mcg (30): $714.71",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     600 mcg (30): $875.40",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     800 mcg (30): $1037.22",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1200 mcg (30): $1348.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1600 mcg (30): $1663.15",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Patch, 72-hour",
"     </b>",
"     (Duragesic-100 Transdermal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mcg/hr (5): $580.45",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Patch, 72-hour",
"     </b>",
"     (Duragesic-12 Transdermal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     12 mcg/hr (5): $129.89",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Patch, 72-hour",
"     </b>",
"     (Duragesic-25 Transdermal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mcg/hr (5): $156.83",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Patch, 72-hour",
"     </b>",
"     (Duragesic-50 Transdermal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mcg/hr (5): $286.73",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Patch, 72-hour",
"     </b>",
"     (Duragesic-75 Transdermal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     75 mcg/hr (5): $437.34",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Patch, 72-hour",
"     </b>",
"     (FentaNYL Transdermal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     12 mcg/hr (5): $69.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mcg/hr (5): $72.17",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mcg/hr (5): $131.92",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     75 mcg/hr (5): $201.23",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mcg/hr (5): $267.07",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (FentaNYL Citrate Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.05 mg/mL (5 mL): $0.53",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Lazanda Nasal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mcg/ACT (1): $336.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     400 mcg/ACT (1): $480.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Sublimaze Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.05 mg/mL (5 mL): $3.04",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Sublingual",
"     </b>",
"     (Abstral Sublingual)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mcg (4): $67.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mcg (4): $76.80",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     300 mcg (4): $91.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     400 mcg (4): $115.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     600 mcg (4): $153.60",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     800 mcg (4): $192.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Fentora Buccal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mcg (28): $967.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mcg (28): $1221.60",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     400 mcg (28): $1773.60",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     600 mcg (28): $2302.80",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     800 mcg (28): $2836.80",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F170580\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Respiratory and cardiovascular status, blood pressure, heart rate; signs of misuse, abuse, or addiction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Transdermal patch: Monitor for 24 hours after application of first dose",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F170596\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Abstral (GB);",
"     </li>",
"     <li>",
"      Actiq (AU, CH, DE, DK, ES, FI, FR, GB, IE, IL, KP, NO, PT, SE);",
"     </li>",
"     <li>",
"      Dolforin (BG);",
"     </li>",
"     <li>",
"      Durogesic (CL, CO, ID, IN, MX, NZ, PK, SG, TH);",
"     </li>",
"     <li>",
"      Durogesic D Trans (HK, KP, PE, TW);",
"     </li>",
"     <li>",
"      Effentora (EE, GB);",
"     </li>",
"     <li>",
"      Fantamax (SG);",
"     </li>",
"     <li>",
"      Fencino (GB);",
"     </li>",
"     <li>",
"      Fenta (IL);",
"     </li>",
"     <li>",
"      Fentabbott (BR);",
"     </li>",
"     <li>",
"      Fentalis (GB, IE);",
"     </li>",
"     <li>",
"      Fentamax Mat Patch (KP);",
"     </li>",
"     <li>",
"      Fentanest (IT, MX, UY);",
"     </li>",
"     <li>",
"      Fentanila (CN);",
"     </li>",
"     <li>",
"      Fentanilo (VE);",
"     </li>",
"     <li>",
"      Fentanyl (CR, DO, GT, NI, PA, SV);",
"     </li>",
"     <li>",
"      Fentax (PY);",
"     </li>",
"     <li>",
"      Instanyl (AT, BE, CZ, DE, DK, EE, FR, NL, SE);",
"     </li>",
"     <li>",
"      Instanyl Nasal (GB, NO);",
"     </li>",
"     <li>",
"      Ionsys (AT, BE, BG, CH, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HN, IE, IT, MT, NL, NO, PL, PT, RU, SE, SK, TR);",
"     </li>",
"     <li>",
"      Leptanal (NO, SE);",
"     </li>",
"     <li>",
"      Matrifen (BE, DK, EE, GB);",
"     </li>",
"     <li>",
"      Mezolar Matrix (GB);",
"     </li>",
"     <li>",
"      Osmanil (GB);",
"     </li>",
"     <li>",
"      PecFent (GB);",
"     </li>",
"     <li>",
"      Sublimaze (AR, AU, GB, IE, NZ, PH, ZA);",
"     </li>",
"     <li>",
"      Tanyl (IL);",
"     </li>",
"     <li>",
"      Trofentyl (IN, PH);",
"     </li>",
"     <li>",
"      Victanyl (GB)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F170570\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Binds with stereospecific receptors at many sites within the CNS, increases pain threshold, alters pain reception, inhibits ascending pain pathways",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F170589\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Analgesic: I.M.: 7-8 minutes; I.V.: Almost immediate; Transdermal (initial placement): 6 hours; Transmucosal: 5-15 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: I.M.: 1-2 hours; I.V.: 0.5-1 hour; Transdermal (removal of patch/no replacement): Related to blood level; some effects may last 72-96 hours due to extended half-life and absorption from the skin, fentanyl concentrations decrease by ~50% in 20-27 hours; Transmucosal: Related to blood level; respiratory depressant effect may last longer than analgesic effect",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Transdermal: Initial application: Drug is released at a nearly constant rate from the transdermal matrix system into the skin, where it accumulates; this results in a depot of fentanyl in the outer layer of skin. Fentanyl is absorbed into systemic circulation from the depot. This results in a gradual increase in serum concentration over the first 12-24 hours, followed by fairly constant concentrations for the remainder of the dosing interval. Absorption is decreased in cachectic patients (compared to normal size patients). Exposure to external heat increases drug absorption from patch.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Transmucosal, buccal tablet and buccal film: Rapid, ~50% from the buccal mucosa; remaining 50% swallowed with saliva and slowly absorbed from GI tract.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Transmucosal, lozenge: Rapid, ~25% from the buccal mucosa; 75% swallowed with saliva and slowly absorbed from GI tract",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: 4-6 L/kg; Highly lipophilic, redistributes into muscle and fat",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 80% to 85%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic, primarily via CYP3A4",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Buccal film: 71% (mucositis did not have a clinically significant effect on C",
"     <sub>",
"      max",
"     </sub>",
"     and AUC; however, bioavailability is expected to decrease if film is inappropriately chewed and swallowed)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Buccal tablet: 65%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lozenge: ~50%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sublingual spray: 76%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sublingual tablet: 54%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: 2-4 hours; when administered as a continuous infusion, the half-life prolongs with infusion duration due to the large volume of distribution (Sessler, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Transdermal patch: 20-27 hours (apparent half-life is influenced by continued fentanyl absorption from skin)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Transmucosal products: 3-14 hours (dose dependent);  Nasal spray: 15-25 hours (based on a multiple-dose pharmacokinetic study when doses are administered in the same nostril and separated by a 1-, 2-, or 4-hour time lapse)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Buccal film: 0.75-4 hours (median: 1 hour)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Buccal tablet: 20-240 minutes (median: 47 minutes)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lozenge: 20-480 minutes (median: 20-40 minutes)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nasal spray: Median: 15-21 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sublingual spray: 10-120 minutes (median: 90 minutes)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sublingual tablet: 15-240 minutes (median: 30-60 minutes)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Transdermal patch: 20-72 hours; steady state serum concentrations are reached after two sequential 72-hour applications",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine 75% (primarily as metabolites, &lt;7% to 10% as unchanged drug); feces ~9%",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/52/38730/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Anwar M, Garrettson L, Huddleston K, et al, &ldquo;Withdrawal Seizures in a Neonate Following Prolonged Fentanyl Use,&rdquo;",
"      <i>",
"       Clin Toxicol",
"      </i>",
"      , 1995, 33(5):493.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bailey PL, Pace NL, Ashburn MA, et al, &ldquo;Frequent Hypoxemia and Apnea After Sedation With Midazolam and Fentanyl,&rdquo;",
"      <i>",
"       Anesthesiology",
"      </i>",
"      , 1990, 73(5):826-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/52/38730/abstract-text/2122773/pubmed\" id=\"2122773\" target=\"_blank\">",
"        2122773",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Baraka A, &ldquo;Fentanyl-Induced Laryngospasm Following Tracheal Extubation in a Child,&rdquo;",
"      <i>",
"       Anaesthesia",
"      </i>",
"      , 1995, 50(4):375.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/52/38730/abstract-text/7747873/pubmed\" id=\"7747873\" target=\"_blank\">",
"        7747873",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Barr J, Fraser GL, Puntillo K, et al, &ldquo;Clinical Practice Guidelines for the Management of Pain, Agitation, and Delirium in Adult Patients in the Intensive Care Unit,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2013, 41(1):263-306.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/52/38730/abstract-text/23269131/pubmed\" id=\"23269131\" target=\"_blank\">",
"        23269131",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bedforth NM and Lockey DJ, &ldquo;Raynaud's Syndrome Following Intravenous Induction of Anaesthesia,&rdquo;",
"      <i>",
"       Anaesthesia",
"      </i>",
"      , 1995, 50(3):248-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/52/38730/abstract-text/7717494/pubmed\" id=\"7717494\" target=\"_blank\">",
"        7717494",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bennett MR and Adams AP, &ldquo;Postoperative Respiratory Complications of Opiates,&rdquo;",
"      <i>",
"       Clin Anaesthesiol",
"      </i>",
"      , 1983, 1:41-56.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Berde C, Ablin A, Glazer J, et al, &ldquo;Report of the Subcommittee on Disease-Related Pain in Childhood Cancer,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1990, 86(5 Pt 2):818-85.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/52/38730/abstract-text/2216644/pubmed\" id=\"2216644\" target=\"_blank\">",
"        2216644",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Billmire DA, Neale HW, and Gregory RO, &ldquo;Use of I.V. Fentanyl in the Outpatient Treatment of Pediatric Facial Trauma,&rdquo;",
"      <i>",
"       J Trauma",
"      </i>",
"      , 1985, 25(11):1079-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/52/38730/abstract-text/4057297/pubmed\" id=\"4057297\" target=\"_blank\">",
"        4057297",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chaturvedi AK, Rao NG, and Baird JR, &ldquo;A Death Due to Self-Administered Fentanyl,&rdquo;",
"      <i>",
"       J Anal Toxicol",
"      </i>",
"      , 1990, 14(6):385-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/52/38730/abstract-text/2087101/pubmed\" id=\"2087101\" target=\"_blank\">",
"        2087101",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Drugs for Pain,&rdquo;",
"      <i>",
"       Med Lett Drugs Ther",
"      </i>",
"      , 2000, 42(1085):73-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/52/38730/abstract-text/10951654/pubmed\" id=\"10951654\" target=\"_blank\">",
"        10951654",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fine PG, &ldquo;Fentanyl in the Treatment of Cancer Pain,&rdquo;",
"      <i>",
"       Semin Oncol",
"      </i>",
"      , 1997, 24(5 Suppl 16):16-20-7.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Friedrichsdorf SJ amd Kand TI, &ldquo;The Management of Pain in Children With Life-Limiting Illnesses,&rdquo;",
"      <i>",
"       Pediatr Clin North Am",
"      </i>",
"      , 2007, 54(5):645-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/52/38730/abstract-text/7933616/pubmed\" id=\"7933616\" target=\"_blank\">",
"        7933616",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Furuya H and Okumura F, &ldquo;Hemolysis After Administration of High Dose Fentanyl,&rdquo;",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 1986, 65(2):207-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/52/38730/abstract-text/3942312/pubmed\" id=\"3942312\" target=\"_blank\">",
"        3942312",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gomar C and Fernandez C, &ldquo;Epidural Analgesia-Anaesthesia in Obstetrics,&rdquo;",
"      <i>",
"       Eur J Anaesthesiol",
"      </i>",
"      , 2000, 17(9):542-58.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/52/38730/abstract-text/11029122/pubmed\" id=\"11029122\" target=\"_blank\">",
"        11029122",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Greco C and Berde C, &ldquo;Pain Management for the Hospitalized Pediatric Patient,&rdquo;",
"      <i>",
"       Pediat Clin North Am",
"      </i>",
"      , 2005, 52(4):995-1027.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/52/38730/abstract-text/16009254/pubmed\" id=\"16009254\" target=\"_blank\">",
"        16009254",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hegenbarth MA and the American Academy of Pediatrics Committee on Drugs, &ldquo;Preparing for Pediatric Emergencies: Drugs to Consider,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2008, 121(2):433-443.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/52/38730/abstract-text/18245435/pubmed\" id=\"18245435\" target=\"_blank\">",
"        18245435",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Heiskanen T, Matzke S, Haakana S, et al, &ldquo;Transdermal Fentanyl in Cachetic Cancer Patients,&rdquo;",
"      <i>",
"       Pain",
"      </i>",
"      , 2009, 144(1-2):218-22.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/52/38730/abstract-text/19442446/pubmed\" id=\"19442446\" target=\"_blank\">",
"        19442446",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Institute for Safe Medication Practice (ISMP) and Vermont Oxford Network, &ldquo;Standard Concentrations of Neonatal Drug Infusions,&rdquo; 2011.  Available at https://www.ismp.org/Tools/PediatricConcentrations.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jeal W and Benfield P, &ldquo;Transdermal Fentanyl. A Review of Its Pharmacological Properties and Therapeutic Efficacy in Pain Control,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 1997, 53(1):109-38.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/52/38730/abstract-text/9010652/pubmed\" id=\"9010652\" target=\"_blank\">",
"        9010652",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Katz R, Kelly HW, and Hsi A, &ldquo;Prospective Study on the Occurrence of Withdrawal in Critically Ill Children Who Receive Fentanyl by Continuous Infusion,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 1994, 22(5):763-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/52/38730/abstract-text/8181283/pubmed\" id=\"8181283\" target=\"_blank\">",
"        8181283",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kornick CA, Santiago-Palma J, Khojainova N, et al, &ldquo;A Safe and Effective Method for Converting Cancer Patients from Intravenous to Transdermal Fentanyl,&rdquo;",
"      <i>",
"       Cancer",
"      </i>",
"      , 2001, 92(12):3056-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/52/38730/abstract-text/11753984/pubmed\" id=\"11753984\" target=\"_blank\">",
"        11753984",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Leuschen MP, Willett LD, Hoie EB, et al, &ldquo;Plasma Fentanyl Levels in Infants Undergoing Extracorporeal Membrane Oxygenation,&rdquo;",
"      <i>",
"       J Thorac Cardiovasc Surg",
"      </i>",
"      , 1993, 105(5):885-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/52/38730/abstract-text/8487566/pubmed\" id=\"8487566\" target=\"_blank\">",
"        8487566",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Liu LL and Gropper MA, &ldquo;Postoperative Analgesia and Sedation in the Adult Intensive Care Unit,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 2003, 63(8):755-67.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/52/38730/abstract-text/12662124/pubmed\" id=\"12662124\" target=\"_blank\">",
"        12662124",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Maurer PM and Bartkowski RR, &ldquo;Drug Interactions of Clinical Significance With Opiad Analgesics,&rdquo;",
"      <i>",
"       Drug Saf",
"      </i>",
"      , 1993, 8(1):30-48.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/52/38730/abstract-text/8471186/pubmed\" id=\"8471186\" target=\"_blank\">",
"        8471186",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mokhlesi B, Leikin JB, Murray P, et al, &ldquo;Adult Toxicology in Critical Care: Part II: Specific Poisonings,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2003, 123(3):897-922.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/52/38730/abstract-text/12628894/pubmed\" id=\"12628894\" target=\"_blank\">",
"        12628894",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Momeni M, Crucitti M, and De Kock M, &ldquo;Patient Controlled Analgesia in the Management of Postoperative Pain,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 2006, 66(18):2321-37.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/52/38730/abstract-text/17181375/pubmed\" id=\"17181375\" target=\"_blank\">",
"        17181375",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pang WW, Huang S, Chung YT, et al, &ldquo;Comparison of Intravenous Retention of Fentanyl and Lidocaine on Local Analgesia in Propofol Injection Pain,&rdquo;",
"      <i>",
"       Acta Anaesthesiol Sin",
"      </i>",
"      , 1997, 35(4):217-21.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/52/38730/abstract-text/9553237/pubmed\" id=\"9553237\" target=\"_blank\">",
"        9553237",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Peng PW and Sandler AN, &ldquo;A Review of the Use of Fentanyl Analgesia in the Management of Acute Pain in Adults,&rdquo;",
"      <i>",
"       Anesthesiology",
"      </i>",
"      , 1999, 90(2):576-99.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/52/38730/abstract-text/9952166/pubmed\" id=\"9952166\" target=\"_blank\">",
"        9952166",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Phillips MS, &ldquo;Standardizing I.V. Infusion Concentrations: National Survey Results,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2011, 68(22):2176-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/52/38730/abstract-text/22058104/pubmed\" id=\"22058104\" target=\"_blank\">",
"        22058104",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Poklis A, &ldquo;Fentanyl: A Review for Clinical and Analytical Toxicologists,&rdquo;",
"      <i>",
"       J Toxicol Clin Toxicol",
"      </i>",
"      , 1995, 33(5):439-47.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/52/38730/abstract-text/7650768/pubmed\" id=\"7650768\" target=\"_blank\">",
"        7650768",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Principles of Analgesic Use in the Treatment of Acute Pain and Cancer Pain,&rdquo; 6th ed, Glenview, IL: American Pain Society, 2008.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Roth B, Schlunder C, Houben F, et al, &ldquo;Analgesia and Sedation in Neonatal Intensive Care Using Fentanyl by Continuous Infusion,&rdquo;",
"      <i>",
"       Dev Pharmacol Ther",
"      </i>",
"      , 1991, 17(3-4):121-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/52/38730/abstract-text/1841826/pubmed\" id=\"1841826\" target=\"_blank\">",
"        1841826",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schechter NL, Weisman SJ, Rosenblum M, et al, &ldquo;The Use of Oral Transmucosal Fentanyl Citrate for Painful Procedures in Children,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1995, 95(3):335-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/52/38730/abstract-text/7862469/pubmed\" id=\"7862469\" target=\"_blank\">",
"        7862469",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Scholz J, Steinfath M, and Schulz M, &ldquo;Clinical Pharmacokinetics of Alfentanil, Fentanyl, and Sufentanil. An Update,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1996, 31(4):275-92.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/52/38730/abstract-text/8896944/pubmed\" id=\"8896944\" target=\"_blank\">",
"        8896944",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sessler CN and Varney K, &ldquo;Patient-Focused Sedation and Analgesia in the ICU,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2008, 133(2):552-65.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/52/38730/abstract-text/18252923/pubmed\" id=\"18252923\" target=\"_blank\">",
"        18252923",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Spigset O and Hagg S, &ldquo;Analgesics and Breast-feeding: Safety Considerations,&rdquo;",
"      <i>",
"       Paediatr Drugs",
"      </i>",
"      , 2000, 2(3):223-38.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/52/38730/abstract-text/10937472/pubmed\" id=\"10937472\" target=\"_blank\">",
"        10937472",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stoukides CA and Stegman M, &ldquo;Diffuse Rash Associated With Transdermal Fentanyl,&rdquo;",
"      <i>",
"       Clin Pharm",
"      </i>",
"      , 1992, 11(3):222.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/52/38730/abstract-text/1535304/pubmed\" id=\"1535304\" target=\"_blank\">",
"        1535304",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Zeltzer LK, Altman A, Cohen D, et al, &ldquo;Report of the Subcommittee on the Management of Pain Associated With Procedures in Children With Cancer,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1990, 86(5 Pt 2):826-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/52/38730/abstract-text/2216645/pubmed\" id=\"2216645\" target=\"_blank\">",
"        2216645",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8441 Version 58.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-0C172D990F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_52_38730=[""].join("\n");
var outline_f37_52_38730=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708780\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170610\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170611\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170659\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170615\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170639\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170616\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14936198\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170617\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170583\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10461326\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170567\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170661\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11233769\">",
"      Prescribing and Access Restrictions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874432\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170587\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14472636\">",
"      Usual Infusion Concentrations: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14472637\">",
"      Usual Infusion Concentrations: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170668\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170586\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170670\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170657\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170590\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170571\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170653\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170576\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170606\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170578\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170593\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170621\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170594\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170595\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5989383\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170580\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170596\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170570\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170589\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8441\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8441|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?0/29/472?source=related_link\">",
"      Fentanyl: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/45/35546?source=related_link\">",
"      Fentanyl: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_52_38731="Findings neonatal sepsis";
var content_f37_52_38731=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F72985&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F72985&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical findings in neonatal sepsis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Finding",
"       </td>",
"       <td class=\"subtitle1\">",
"        Frequency*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hyperthermia",
"       </td>",
"       <td>",
"        +++",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Respiratory distress",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anorexia",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vomiting",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Jaundice",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hepatomegaly",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lethargy",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cyanosis",
"       </td>",
"       <td>",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypothermia",
"       </td>",
"       <td>",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Irritability",
"       </td>",
"       <td>",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Apnea",
"       </td>",
"       <td>",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Abdominal distension",
"       </td>",
"       <td>",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diarrhea",
"       </td>",
"       <td>",
"        +",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * +++: commonly associated (&ge;50 percent of cases); ++: frequently associated (25-50 percent); +: occasionally associated (&lt;25 percent).",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Nizet V, Klein JO. Bacterial sepsis and meningitis. In: Infectious Diseases of the Fetus and Newborn Infant, 7th ed, Remington JS, et al (Eds), Elsevier Saunders, Philadelphia 2010. p.244.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_52_38731=[""].join("\n");
var outline_f37_52_38731=null;
var title_f37_52_38732="Maternal serum marker pattern in selected fetal syndromes";
var content_f37_52_38732=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F71552&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F71552&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Maternal serum marker pattern in selected fetal syndromes",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       &nbsp;",
"      </td>",
"      <td class=\"subtitle1\" colspan=\"4\">",
"       Second trimester markers",
"      </td>",
"      <td class=\"subtitle1\" colspan=\"4\">",
"       First trimester markers",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2\">",
"       Genetic disorder",
"      </td>",
"      <td class=\"subtitle2\">",
"       AFP",
"      </td>",
"      <td class=\"subtitle2\">",
"       uE3",
"      </td>",
"      <td class=\"subtitle2\">",
"       hCG",
"      </td>",
"      <td class=\"subtitle2\">",
"       Inh A",
"      </td>",
"      <td class=\"subtitle2\">",
"       PAPP-A",
"      </td>",
"      <td class=\"subtitle2\">",
"       beta hCG",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Down syndrome",
"      </td>",
"      <td>",
"       &darr;",
"      </td>",
"      <td>",
"       &darr;",
"      </td>",
"      <td>",
"       &uarr;",
"      </td>",
"      <td>",
"       &uarr;",
"      </td>",
"      <td>",
"       &darr;",
"      </td>",
"      <td>",
"       &uarr;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Trisomy 18",
"      </td>",
"      <td>",
"       &darr;",
"      </td>",
"      <td>",
"       &darr; &darr;",
"      </td>",
"      <td>",
"       &darr; &darr;",
"      </td>",
"      <td>",
"       &harr;",
"      </td>",
"      <td>",
"       &darr; &darr;",
"      </td>",
"      <td>",
"       &darr; &darr;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Trisomy 13",
"      </td>",
"      <td>",
"       &harr;",
"      </td>",
"      <td>",
"       &harr;",
"      </td>",
"      <td>",
"       &harr;",
"      </td>",
"      <td>",
"       &harr;",
"      </td>",
"      <td>",
"       &darr; &darr;",
"      </td>",
"      <td>",
"       &darr;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Turner syndrome with hydrops",
"      </td>",
"      <td>",
"       &darr;",
"      </td>",
"      <td>",
"       &darr;",
"      </td>",
"      <td>",
"       &uarr;",
"      </td>",
"      <td>",
"       &uarr;",
"      </td>",
"      <td>",
"       &darr; &uarr;",
"      </td>",
"      <td>",
"       &darr; &uarr;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Turner syndrome without hydrops",
"      </td>",
"      <td>",
"       &darr;",
"      </td>",
"      <td>",
"       &darr;",
"      </td>",
"      <td>",
"       &darr;",
"      </td>",
"      <td>",
"       &darr;",
"      </td>",
"      <td>",
"       &darr; &uarr;",
"      </td>",
"      <td>",
"       &darr; &uarr;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Triploidy (paternal)",
"      </td>",
"      <td>",
"       &harr;",
"      </td>",
"      <td>",
"       &darr;",
"      </td>",
"      <td>",
"       &uarr;",
"      </td>",
"      <td>",
"       &uarr;",
"      </td>",
"      <td>",
"       &darr; &uarr;",
"      </td>",
"      <td>",
"       &uarr; &uarr;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Triploidy (maternal)",
"      </td>",
"      <td>",
"       &harr;",
"      </td>",
"      <td>",
"       &darr;",
"      </td>",
"      <td>",
"       &darr;",
"      </td>",
"      <td>",
"       &darr;",
"      </td>",
"      <td>",
"       &darr; &uarr;",
"      </td>",
"      <td>",
"       &darr; &darr;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Smith-Lemli-Opitz syndrome",
"      </td>",
"      <td>",
"       &darr;",
"      </td>",
"      <td>",
"       &darr; &darr;",
"      </td>",
"      <td>",
"       &darr;",
"      </td>",
"      <td>",
"       NR",
"      </td>",
"      <td>",
"       NR",
"      </td>",
"      <td>",
"       NR",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Second trimester markers: AFP (alpha-fetoprotein); uE3 (unconjugated estriol); hCG (human chorionic gonadotropin); inh A (inhibin A).",
"    <br>",
"     First trimester marker: PAPP-A (pregnancy-associate plasma protein A); beta hCG (beta human chorionic gonadotropin).",
"     <div class=\"footnotes\">",
"      &uarr;: increased; &darr;: decreased; &harr;: unaffected; &darr; &uarr;: variable; NR: not reported.",
"     </div>",
"     <div class=\"reference\">",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_52_38732=[""].join("\n");
var outline_f37_52_38732=null;
var title_f37_52_38733="Pathogens following BMT-I";
var content_f37_52_38733=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F74989%7EID%2F54989%7EID%2F67849&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=12\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F74989%7EID%2F54989%7EID%2F67849&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=12\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Pathogens likely to cause infections in bone marrow/stem cell transplant recipients not receiving standard prophylaxis-I",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Pre-engraftment (&lt;3 weeks)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       Bacteria",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2_start\">",
"       Gram-positive cocci",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Coagulase-negative staphylococci",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Staphylococcus aureus",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Viridans streptococci",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Streptococcus pneumoniae",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Enterococcus (including vancomycin-resistant)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2_start\">",
"       Gram negative bacilli",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Enterobacteriaceae",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist3\">",
"       Escherichia coli",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist3\">",
"       Enterobacter spp.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist3\">",
"       Klebsiella spp.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Pseudomonas aeruginosa",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Stenotrophomonas maltophilia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Legionella pneumophilia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2_start\">",
"       Anaerobes",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Clostridium spp.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist3\">",
"       C. difficile",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist3\">",
"       C. septicum",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       Fungi",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2_start\">",
"       Candida spp.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       C. albicans",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       C. parapsilosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       C. tropicalis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2_start\">",
"       Aspergillus spp.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       A. fumigatus",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       A. flavus",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       A. terreus",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       Viruses",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Herpes simplex virus (HSV)-1, -2",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2_start\">",
"       Respiratory viruses",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Respiratory syncytial virus",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Influenza",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Parainfluenza",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Adenovirus",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Pathogens likely to cause infections in bone marrow/stem cell transplant recipients not receiving standard prophylaxis-II",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Immediate post-engraftment (3 weeks to 3 months)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       Bacteria",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Same as for the pre-engraftment period",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       Fungi",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Aspergillus spp.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       Viruses",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Cytomegalovirus",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       HHV-6",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Respiratory viruses (Same as for the pre-engraftment period) &gt;3 mos",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Protozoa",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Pneumocystis carinii",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Pathogens likely to cause infections in bone marrow/stem cell transplant recipients not receiving standard prophylaxis-III",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Late postengraftment (allogeneic BMT)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Bacteria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        Encapsulated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        S. pneumoniae",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Haemophilus influenzae",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Neisseria meningitidis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Klebsiella spp.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        S. aureus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        P. aeruginosa",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Fungi",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Same as for the preengraftment period",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Viruses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Varicella zoster virus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Epstein Barr virus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Respiratory viruses (Same as for the preengraftment period)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Protozoa",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        P. carinii",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_52_38733=[""].join("\n");
var outline_f37_52_38733=null;
var title_f37_52_38734="ACC AHA choice imaging risk I";
var content_f37_52_38734=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F74428%7ECARD%2F61603%7ECARD%2F52995&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F74428%7ECARD%2F61603%7ECARD%2F52995&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    ACC/AHA guideline summary: Cardiac stress imaging as the initial test for risk stratification of patients with chronic stable angina who are able to exercise",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Class I - There is evidence and/or general agreement that cardiac stress imaging as the initial test for risk stratification of patients with chronic stable angina who are able to exercise should be performed in the following manner:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &bull; Among patients who do not have left bundle branch block or an electronically paced ventricular rhythm but have either an abnormal ECG or are taking digoxin, exercise myocardial perfusion imaging (MPI) or exercise echocardiography to identify the extent, severity, and location of ischemia.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &bull; Among patients with left bundle branch block or an electronically paced ventricular rhythm, dipyridamole or adenosine MPI.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &bull; Among patients with left bundle branch block, dobutamine stress echocardiography.*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &bull; When assessing the functional significance of coronary lesions, exercise MPI or exercise echocardiography.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Class IIb - The weight of evidence or opinion is less well established for the usefulness of cardiac stress imaging as the initial test for risk stratification of patients with chronic stable angina who are able to exercise in the following setting:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &bull; Exercise echocardiography in the presence of left bundle branch block.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &bull; Exercise, dipyridamole, or adenosis MPI or exercise or dobutamine echocardiography in patients who have a normal rest ECG and are not taking digoxin.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Class III - There is evidence and/or general agreement that cardiac stress imaging as the initial test for risk stratification of patients with chronic stable angina who are able to exercise is not useful in in the following settings:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &bull; Exercise MPI in the presence of left bundle branch block.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &bull; Severe comorbidity that is likely to limit life expectation or prevent revascularization.",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Modified from: Fleisher, LA, Beckman, JA, Brown, KA, et al. ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery): developed in collaboration with the American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, and Society for Vascular Surgery. Circulation 2007; 116:e418.",
"    </div>",
"    <div class=\"reference\">",
"     Data from Gibbons, RJ, Abrams, J, Chatterjee, K, et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina--summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Chronic Stable Angina). Circulation 2003; 107:149. Copyright 2003 by the American College of Cardiology and American Heart Association, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Recommendations for cardiac stress imaging as the initial test for diagnosis of coronary heart disease (CHD) in patients with chronic stable angina who are unable to exercise",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       Class I",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       1. Adenosine or dipyridamole myocardial perfusion imaging or dobutamine echocardiography in patients with an intermediate pretest probability of CAD.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       2. Adenosine or dipyridamole stress myocardial perfusion imaging or dobutamine echocardiography in patients with prior revascularization (either PTCA or CABG).",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       Class IIb",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       1. Adenosine or dipyridamole stress myocardial perfusion imaging or dobutamine echocardiography in patients with a low or high probability of CAD in the absence of electronically paced ventricular rhythm or left bundle-branch block.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2_start\">",
"       2. Adenosine or dipyridamole myocardial perfusion imaging in patients with a low or a high probability of CAD and one of the following baseline ECG abnormalities",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       a. Electronically paced ventricular rhythm",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       b. Left bundle-branch block",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       ACC/AHA classification",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        Class I:",
"       </strong>",
"       Conditions for which there is evidence and/or general agreement that a given procedure or treatment is useful and effective.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       <strong>",
"        Class II:",
"       </strong>",
"       Conditions for which there is conflicting evidence and/or a divergence of opinion about the usefulness/efficacy of a procedure or treatment.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       <strong>",
"        Class IIa:",
"       </strong>",
"       Weight of evidence/opinion is in favor of usefulness/efficacy.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       <strong>",
"        Class IIb:",
"       </strong>",
"       Usefulness/efficacy less well established by evidence/opinion.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        Class III:",
"       </strong>",
"       Conditions for which there is evidence and/or general agreement that the procedure/treatment is not useful and in some cases may be harmful.",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data modified from: Gibbons RJ, Abrams J, Chatterjee K, et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina--summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Chronic Stable Angina). Circulation 2003; 107:149.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Recommendations for cardiac stress imaging as the initial test for diagnosis of coronary heart disease (CHD) in patients with chronic stable angina who are able to exercise",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       Class I",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2_start\">",
"       1. Exercise myocardial perfusion imaging or exercise echocardiography in patients with an intermediate pretest probability of CAD who have one of the following baseline ECG abnormalities:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       a. Pre-excitation (Wolff-Parkinson-White) syndrome",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       b. More than 1 mm of ST depression at rest",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       2. Exercise myocardial perfusion imaging or exercise echocardiography in patients with prior revascularization (either PTCA or CABG).",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2_start\">",
"       3. Adenosine or dipyridamole myocardial perfusion imaging in patients with an intermediate pretest probability of CAD and one of the following baseline ECG abnormalities:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       a. Electronically paced ventricular rhythm",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       b. Left bundle-branch block",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       4. Dobutamine stress echocardiography in patients with an intermediate pretest probability of CAD and left bundle branch block.*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       Class IIb",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2_start\">",
"       1. Exercise myocardial perfusion imaging and exercise echocardiography in patients with a low or high probability of CAD who have one of the following baseline ECG abnormalities:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       a. Pre-excitation (Wolff-Parkinson-White) syndrome",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       b. More than 1 mm of ST depression",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2_start\">",
"       2. Adenosine or dipyridamole myocardial perfusion imaging in patients with a low or high probability of CAD and one of the following baseline ECG abnormalities:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       a. Electronically paced ventricular rhythm b. Left bundle-branch block",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2_start\">",
"       3. Exercise myocardial perfusion imaging or exercise echocardiography in patients with an intermediate probability of CAD who have one of the following:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       a. Digoxin use with &lt;1 mm ST depression on the baseline ECG",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       b. LVH with &lt;1 mm ST depression on the baseline ECG",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       4. Exercise myocardial perfusion imaging, exercise echocardiography, adenosine or dipyridamole myocardial perfusion imaging or dobutamine echocardiography as the initial stress test in a patient with a normal rest ECG who is not taking digoxin.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       5. Exercise in patients with left bundle-branch block.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       ACC/AHA classification",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        Class I:",
"       </strong>",
"       Conditions for which there is evidence and/or general agreement that a given procedure or treatment is useful and effective.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       <strong>",
"        Class II:",
"       </strong>",
"       Conditions for which there is conflicting evidence and/or a divergence of opinion about the usefulness/efficacy of a procedure or treatment.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       <strong>",
"        Class IIa:",
"       </strong>",
"       Weight of evidence/opinion is in favor of usefulness/efficacy.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       <strong>",
"        Class IIb:",
"       </strong>",
"       Usefulness/efficacy less well established by evidence/opinion.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        Class III:",
"       </strong>",
"       Conditions for which there is evidence and/or general agreement that the procedure/treatment is not useful and in some cases may be harmful.",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Modified from: Fleisher LA, Beckman JA, Brown KA, et al. ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery): developed in collaboration with the American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, and Society for Vascular Surgery. Circulation 2007; 116:e418.",
"    </div>",
"    <div class=\"reference\">",
"     Data modified from: Gibbons RJ, Abrams J, Chatterjee K, et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina--summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Chronic Stable Angina). Circulation 2003; 107:149.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_52_38734=[""].join("\n");
var outline_f37_52_38734=null;
var title_f37_52_38735="Two day method chart";
var content_f37_52_38735=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F60185&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F60185&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cervical secretion variations during a menstrual cycle",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 295px; height: 586px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: The Institute for Reproductive Health, Georgetown University.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_52_38735=[""].join("\n");
var outline_f37_52_38735=null;
